[ADDRESS_725002]:  MK-3475 (SCH 900475), INCB024360 
Protocol/Amendment No.:
 252-10 (INCB 
[ZIP_CODE]-3 01 -10) / [STUDY_ID_REMOVED]
MK-3475-252-10 (INCB [ZIP_CODE]-301-10) Final Protocol 18-May-2018
ConfidentialTHIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., 
WHITEHOUSE STATION, NJ, U.S.A.
This study is co -funded by [CONTACT_398821]. 
Execution of Trial :
[COMPANY_006] Sharp & Dohme Corp., a subsidiary  of [COMPANY_006] & Co., Inc. 
One [COMPANY_006] Drive
P.O. Box [ADDRESS_725003] information can be found in the Investigator Trial File Binder (or 
equivalent) .
Global Sponsor of the Study:
Incyte Corporation (Referenced 
herein as Sponsor)
1801 Augustine Cut -Off
Wilmington, Delaware, [ZIP_CODE], U.S.A
TITLE:
A Phase 3 Randomized, Double- Blind, Placebo- Controlled Study  of Pembrolizumab (MK -
3475) in Combination With Epacadostat or Placebo in Subjects with Unresectable or 
Metastatic Melanoma (KEYNOTE -252 / ECHO -301)
IND NUMBER:   
121,[ADDRESS_725004] NUMBER:   2015-004991-[ADDRESS_725005]:   MK-3475 (SCH 900475), INCB 024360 2
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
ConfidentialTABLE OF CONTENTS
SUMMARY OF CHANGES ................................................................................................ .14
1.0 TRIAL SUMMARY ................................................................................................... 29
2.0 TRIAL DESIGN ......................................................................................................... 30
Trial Design ............................................................................................................ 30 2.1
Trial Diagram ......................................................................................................... 31 2.2
3.0 OBJECTIVE(S) & HYPOTHESIS(ES) ................................................................... 32
Primary Objective(s) & Hypothesis(es) ............................................................... 32 3.1
Secondary Objective(s) & Hypothesis(es) ............................................................ 32 3.2
33
4.0 BACKGROUND & RATIONALE ........................................................................... 34
Background ................................................................
............................................ 34 4.1
Pharmaceutical and Therapeutic Background ..................................................... 34 4.1.1
[IP_ADDRESS] Inhibition of PD -1 as a Target for Cancer .................................................... 35
[IP_ADDRESS] Inhibition of Indoleamine 2,3 –Dioxy genase as a Target for Cancer ............ 35
[IP_ADDRESS] Combined I mmune Checkpoint I nhibition ................................................... 37
[IP_ADDRESS] Overview of Metastatic Melanoma ............................................................... 38
[IP_ADDRESS] Treatment for Advanced or Metastatic Melanoma ....................................... [ADDRESS_725006] Population ..................................... 41 4.2.1
[IP_ADDRESS] Rationale for Combining PD-[ADDRESS_725007]:   MK-3475 (SCH 900475), INCB 024360 3
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
ConfidentialRationale for Dose Selection/Regimen/Modification .......................................... 42 4.2.2
[IP_ADDRESS] Justification for Treatment Regimen ............................................................ 42
[IP_ADDRESS] Rationale for a Fixed Dose of Pembrolizumab ............................................. 43
Rationale for Endpoints ....................................................................................... 44 4.2.3
[IP_ADDRESS] Efficacy  Endpoints ........................................................................................ 44
[IP_ADDRESS].1 Primary  Efficacy  Endpoints ................................................................... 44
[IP_ADDRESS].2 Secondary  Efficacy  Endpoints ............................................................... 44
45
[IP_ADDRESS] Immune -related RECI ST (irRECI ST).......................................................... 45
[IP_ADDRESS] Patient Reported Outcomes ........................................................................... 46
[IP_ADDRESS] Safety  Endpoints ........................................................................................... 46
[IP_ADDRESS] Pharmacokinetic Endpoints .......................................................................... 46
[IP_ADDRESS] Pharmacod ynamic Endpoints ........................................................................ 46
46
47
47
47
48
48
49
Benefit/Risk ............................................................................................................ [ADDRESS_725008]:   MK-3475 (SCH 900475), INCB 024360 4
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
Confidential5.0 METHODOLOGY .................................................................................................... 52
Entry Criteria ......................................................................................................... 52 5.1
Diagnosis/Condition for Entry  into the Trial ....................................................... [ADDRESS_725009] Exclusion Criteria ................................................................................... 55 5.1.3
Trial Treatment(s) ................................................................................................ .58 5.2
Dose Selection/Modification ............................................................................... 58 5.2.1
[IP_ADDRESS] Dose Selection (Preparation) ........................................................................ 58
[IP_ADDRESS] Dose Modification (Escalation/Titration/Other) ........................................... 58
[IP_ADDRESS] Dose Modification and Toxicity  Management of Infusion -reactions 
Related to Pembrolizumab ............................................................................ 63
[IP_ADDRESS] Procedures for Subjects Exhibiting Serotonin Sy ndrome (SS) ..................... 65
[IP_ADDRESS] Dose Interruptions Unrelated to Adverse Events .......................................... 66
Timing of Dose Administration ........................................................................... 66 5.2.2
[IP_ADDRESS] Timing of Dose Administration of Pembrolizumab ..................................... 66
Trial Blinding....................................................................................................... 67 5.2.3
Randomization or Treatment Allocation ............................................................. 67 5.3
Stratification ........................................................................................................... 67 5.4
Concomitant Medications/Vaccinations (Allowed & Prohibited) ..................... 68 5.5
Acceptable Concomitant Medications ................................................................ .68 5.5.1
Prohibited Medications and Measures ................................................................ .68 5.5.2
Rescue Medications & Supportive Care .............................................................. 69 5.6
Supportive Care Guidelines for Pembrolizumab ................................................. 69 5.6.1
Diet/Activity/Other Considerations ...................................................................... [ADDRESS_725010]:   MK-3475 (SCH 900475), INCB 024360 5
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-[ADDRESS_725011] Withdrawal/Discontinuation Criteria .................................................... [ADDRESS_725012] Replacement Strategy .............................................................................. 75 5.9
Beginning and End of the Trial ............................................................................ 75 5.10
Clinical Criteria for Early Trial Termination .................................................... 75 5.11
6.0 TRIAL FLOW CHART ............................................................................................ 77
Trial Flow Chart .................................................................................................... 77 6.1
7.0 TRIAL PROCEDURES ............................................................................................ 81
Trial Procedures .................................................................................................... 81 7.1
Administrative Procedures ................................................................................... 81 7.1.1
[IP_ADDRESS] Informed Consent .......................................................................................... 81
[IP_ADDRESS].1 General Informed Consent ..................................................................... 81
82
[IP_ADDRESS] Inclusion/Exclusion Criteria ......................................................................... 82
[IP_ADDRESS] Subject I dentification Card ........................................................................... 82
[IP_ADDRESS] Medical History ............................................................................................ 82
[IP_ADDRESS] Prior and Concomitant Medications Review ................................................ 82
[IP_ADDRESS].1 Prior Medications ................................................................................... 82
[IP_ADDRESS].2 Concomitant M edications ...................................................................... 82
[IP_ADDRESS] Assignment of Screening Number ................................................................ [ADDRESS_725013]:   MK-3475 (SCH 900475), INCB 024360 6
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
Confidential7.1.1.7 Assignment of Treatment/Randomization Number ...................................... 83
[IP_ADDRESS] Trial Compliance (Medication) ..................................................................... 83
[IP_ADDRESS].1 Administration of Pembrolizumab and Compliance ............................. 84
[IP_ADDRESS].2 Dispensing of Pembrolizumab ............................................................... 84
[IP_ADDRESS].[ADDRESS_725014] Reminder Cards and Serotonin Syndrome 
(SS) I nformation Sheet .......................................................................... 84
[IP_ADDRESS] Poststudy  Anticancer Therap y Status ........................................................... 84
Clinical Procedures/Assessments ......................................................................... 84 7.1.2
[IP_ADDRESS] Adverse Events ............................................................................................. 84
[IP_ADDRESS] Full Phy sical Examination ............................................................................ 85
[IP_ADDRESS] Directed Ph ysical Examination ..................................................................... 85
[IP_ADDRESS] Vital Signs..................................................................................................... 85
[IP_ADDRESS] Twelve- Lead Electrocardiograms................................................................ .85
[IP_ADDRESS] Performance and Quality of L ife Assessments ............................................. 85
[IP_ADDRESS].1 Eastern Cooperative Oncology  Group Performance Status ................... 85
86
86
86
87
Tumor Biops y/Archival Tissue Collection .......................................................... 87 7.1.3
Tumor Biops y...................................................................................................... 87 7.1.4
Tumor I maging and Assessment of Disease ........................................................ 87 7.1.5
[IP_ADDRESS] Initial Tumor Imaging ................................................................................... 87
[IP_ADDRESS] Tumor Imaging During the Study ................................................................ .88
[IP_ADDRESS].[ADDRESS_725015]:   MK-3475 (SCH 900475), INCB 024360 7
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-[ADDRESS_725016] 1.1 ............... 89
[IP_ADDRESS] Photograph y for Cutaneous L esions ............................................................. 91
Laboratory  Procedures/Assessments ................................................................... 91 7.1.6
[IP_ADDRESS] Hematology , Hemostatic Panel, Serology , Urinaly sis and Endocrine 
Function Testing ........................................................................................... 91
[IP_ADDRESS] Serum Chemistry  and Liver Function Tests ................................................. 91
[IP_ADDRESS] Pregnancy  Testing ......................................................................................... 92
[IP_ADDRESS] Laboratory  Safet y Evaluations (Hemato logy, Chemistry  and Urinaly sis)...92
[IP_ADDRESS] Pharmacokinetic/Pharmacody namic Evaluations ......................................... 93
[IP_ADDRESS].1 Blood Sample Collection for PK of Pembrolizumab ............................. 94
[IP_ADDRESS].2 Blood Sample Collection for Anti -pembrolizumab Antibodies ............ 94
[IP_ADDRESS].3 Blood Sample Collection for PK of Epacadostat ................................... 94
[IP_ADDRESS].4 Pharmacod ynamic Assessments ............................................................ 95
95
Other Procedures .................................................................................................. 96 7.1.7
[IP_ADDRESS] Withdrawal/Discontinuation ......................................................................... 96
96
[IP_ADDRESS].[ADDRESS_725017] to Follow -up................................................................................... 96
[IP_ADDRESS] Blinding/Unblinding ..................................................................................... 97
[IP_ADDRESS] Calibration of Equipment .............................................................................. 97
Visit Requirements ............................................................................................... 98 7.1.8
[IP_ADDRESS] Screening Visit .............................................................................................. 98
[IP_ADDRESS] Treatment Period Visit.................................................................................. 98
[IP_ADDRESS] End of Treatment .......................................................................................... 98
[IP_ADDRESS] Post-Treatment Visits .................................................................................... [ADDRESS_725018]:   MK-3475 (SCH 900475), INCB 024360 8
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
Confidential7.[IP_ADDRESS] Safety  Follo w-Up Visit .......................................................................... 99
[IP_ADDRESS].2 Follow -Up Visits .................................................................................... 99
[IP_ADDRESS].3 Survival Follow -Up............................................................................. 100
[IP_ADDRESS] Unscheduled Visits ..................................................................................... 100
[IP_ADDRESS] Survival Status ............................................................................................ 100
Assessing and Recording Adverse Events ......................................................... 100 7.2
Definition of an Overdose for This Protocol and Reporting of Overdose ......... 101 7.2.1
Reporting of Pregnancy  and Lactation ............................................................... 102 7.2.2
Immediate Reporting of Adverse Events ........................................................... 102 7.2.3
[IP_ADDRESS] Serious Adverse Events .............................................................................. 102
[IP_ADDRESS] Events of Clinical I nterest ........................................................................... 103
[IP_ADDRESS] Protocol -Specific Exceptions to Serious Adverse Event Reporting ........... 104
Evaluating Adverse Events ................................................................................ 104 7.2.4
Responsibility  for Reporting Adverse Events .................................................... 107 7.2.5
TRIAL GOVERNANCE AND OVERSIGHT .................................................. 107 7.3
Scientific Advisory  Committee .......................................................................... 107 7.3.1
Executive Oversight Committee ........................................................................ 107 7.3.2
Data Monitoring Committee .............................................................................. 107 7.3.3
8.0 STATISTICAL ANALYSIS PLAN ....................................................................... 108
Statistical Analysis Plan Summary .................................................................... 108 8.1
Responsibility for Analyses/In -House Blinding ................................................ 110 8.2
Hypotheses/Estimation ........................................................................................ [ADDRESS_725019]:   MK-3475 (SCH 900475), INCB 024360 9
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
ConfidentialSafety  Endpoints ................................................................................................ 111 8.4.2
Analysis Population ............................................................................................. 112 8.5
Efficacy  Anal ysis Population ............................................................................. 112 8.5.1
Safety Anal ysis Populations .............................................................................. 112 8.5.2
Statistical Methods ............................................................................................... 112 8.6
Statistical Methods for Efficacy  Anal yses......................................................... 112 8.6.1
[IP_ADDRESS] Progression -Free Survival (PFS) ................................................................ 112
[IP_ADDRESS] Overall Survival (OS) ................................................................................. 114
[IP_ADDRESS] Objective Response Rate (ORR) ................................................................ [ADDRESS_725020] of Baseline Factors .......................................... 122 8.10
Compliance (Medication Adherence) ................................................................ .[ADDRESS_725021]:   MK-3475 (SCH 900475), INCB 024360 10
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-[ADDRESS_725022]/Destruction/Returns and Reconciliation ............................................. [ADDRESS_725023] Records .................................................................... 125 10.1.2
Confidentiality  of Investigator Information ....................................................... 126 10.1.3
Confidentiality  of IRB/IEC I nformation ............................................................ [ADDRESS_725024]:   MK-3475 (SCH 900475), INCB 024360 11
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
ConfidentialResponse Evaluation Criteria in Solid Tumors (RECIST) 1.[ADDRESS_725025] of Abbreviations ........................................................................................... 165 12.9
R Code for Calculations of Sample Size and Monitoring Boundaries for 12.10
Progression- Free Survival ................................................................................... 168
13.0 SIGNATURES .......................................................................................................... 170
Sponsor's Representative .................................................................................... [ADDRESS_725026]:   MK -3475 (SCH 900475), INCB 024360 12
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-[ADDRESS_725027]:   MK -3475 (SCH 900475), INCB 024360 13
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-[ADDRESS_725028]:   MK -3475 (SCH 900475), INCB 024360 14
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
ConfidentialSUMMARY OF CHANGES
PRIMARY REASON(S) FOR THIS AMENDMENT:
Section 
Number (s)Section Title (s) Description of Change (s) Rationale
1.0 Trial S ummary Addition of notes to clarify  the removal of 
epacadostat and placebo from the trial and that all 
subjects remaining in the trial will receive open -
label pembrolizumab only  as of Amendment 10.An interim review of the data 
indicated no benefit of epacadostat 
over placebo when combined with 
pembrolizumab. The external Data 
Monitoring Committee (DMC ) 
recommended that all subjects be 
unblinded and all epacadostat and 
placebo administration stop. The 
study  willremain open so that 
subjects still on study willhave 
continued access to 
pembrolizumab.
All references to epacadostat and 
placebo, as well as assessments/ 
procedures specific to these 
treatments, are removed from the 
protocol. Where deletion of text 
could cause confusion, due to the 
design of the study  to date, the text 
has been left unchanged and a note 
has been added.2.1 Trial Design Addition of a note to describe the removal of 
epacadostat and placebo and that all subjects 
remaining in the trial will receive open -label 
pembrolizumab only  as of Amendment 10.
Addition of text summarizing the DMC 
recommendations.
2.2 Trial Diagram
Figure 2  Study  Design as 
of Amendment 10NewFigure2 showing the 
updated stud y design.
4.1
4.2
4.3Background
Rationale
Benefit/RiskAddition of notes to clarify  which sections and text 
are no longer applicable due to removal of 
epacadostat and placebo.
5.2 Trial Treatment(s) Addition of note that only pembrolizumab will be 
administered. Other treatments (prior to this 
amendment) aredeleted .
5.2 Trial Treatment(s)
Table [ADDRESS_725029]:   MK -3475 (SCH 900475), INCB 024360 15
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
ConfidentialSection 
Number (s)Section Title (s) Description of Change (s) Rationale
[IP_ADDRESS] Dose Modification 
(Escalation/Titration/Other )Deletion of textrelating to dose modification of 
epacadostat .
[IP_ADDRESS] Dose Modification 
(Escalation/Titration/Other)
Table [ADDRESS_725030] table for pembrolizumab alone.
5.2.1. 2 Dose Modification 
(Escalation/Titration/Other)
Table 3  Dose Level 
Adjustment of Epacadostat 
or Matching PlaceboDeletion of t able.
[IP_ADDRESS] Timing of Dose 
Administration of 
EpacadostatDeletion of section.
5.6.[ADDRESS_725031].
[IP_ADDRESS] Trial Compliance 
(Medication)Deletion of text and subsections relating to 
epacadostat/placebo compliance. 
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 16
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
ConfidentialSection 
Number (s)Section Title (s) Description of Change (s) Rationale
7.2.[ADDRESS_725032] Deletion of information relating to 
epacadostat/placebo.
9.2 Packaging and Labeling 
InformationDeletion of information relating to 
epacadostat/placebo.
1.0 Trial Summary Deletion of text relating to Second Course. Given the finding sof the study , 
subjects will be provided 
pembrolizumab monotherap y up to 
a total of 35 cycles, the Second 
Course of treatment will not be 
offered ,and data collection will be 
limited.5.2.2 Second Course Phase 
(Retreatment Period)Deletion of section.
5.[ADDRESS_725033] Withdrawal/ 
Discontinuation criteriaDeletion of text relating to retreatment.
5.8.1 Discontinuation of 
TreatmentDeletion of text relating to Second Course 
(retreatment).
6.2 Trial Flow Chart –Second 
Course Phase 
(Retreatment)Deletion of Flow Chart.
[IP_ADDRESS].2 Concomitant Medications Deletion of t ext relating to Second Course.
[IP_ADDRESS].2 Second Course 
(Retreatment) Tumor 
ImagingDeletion of section.
7.1.6 Laboratory  
Procedures/AssessmentsDeletion of text relating to laboratory  procedures 
for Second Course . 
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 17
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
ConfidentialSection 
Number (s)Section Title (s) Description of Change (s) Rationale
[IP_ADDRESS].1.1 
(now 
Section 
[IP_ADDRESS].1)Safety  Follow -
upVisit Deletion of text relating to eligibility  for Second 
Course treatment.
1.[ADDRESS_725034] trial visit is the Safety 
Follow -up Visit.Given the findings of the study , the
study  will close once all subjects 
complete treatment of
pembrolizumab (up to a total of 
35cycles). 
The final visit in the study  will be 
the Safety  Follow-up Visit. There 
will be no follow -up for survival 
status.  Subjects currentl y in 
follow -up or in survival follow -up 
are considered to have completed 
the study .  However, standard 
safety reporting should continue , as 
applicable .2.[ADDRESS_725035] Withdrawal/ 
Discontinuation criteriaDeletion of text relating to follow -up of subjects 
for survival data.
5.8.1 Discontinuation of 
TreatmentDeletion of text relating tofollow -up of subjects 
after treatment discontinuation .
6.1 Trial Flow Chart Deletion of columns for Follow -up and Survival 
Follow -up. Deletion of row for survival status 
assessment.
[IP_ADDRESS] Poststudy  A nticancer 
Therap y StatusAssessment of poststudy  anticancer therapy  will 
end at the Safet y Follow -up Visit.
[IP_ADDRESS].[ADDRESS_725036]:   MK -3475 (SCH 900475), INCB 024360 18
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
ConfidentialSection 
Number (s)Section Title (s) Description of Change (s) Rationale
[IP_ADDRESS] Withdrawal/ 
DiscontinuationDeletion of text indicating that subjects who 
discontinue/withdraw from treatment prior to 
completion of the treatment regime n should be 
encouraged to continue tobe followed for all 
remaining study  visits.  Subjects are considered to 
have completed the study  after attending the Safety  
Follow -up Visit.
[IP_ADDRESS].[ADDRESS_725037] to follow -up.
[IP_ADDRESS].1.1 
(now 
Section 
[IP_ADDRESS].1 )Safety  Follow -upVisit Addition of note that t he last trial visit is the Safety 
Follow -up Visit. Addition of clarification that 
subjects currently  in follow -up or in survival 
follow -up are considered to have completed the 
study ; these subjects are not required to attend any 
further visits.  Assessment and recording of AEs 
will be performed as per Section 7.2.
Deletion of text about follow -up of AEs that is 
covered in Section 7.2.
[IP_ADDRESS].1.2 
(now 
Section 
[IP_ADDRESS].2 )Follow -up Visits Addition of a note that this section is no longer 
applicable.   A subject will be considered to have 
completed this study  once they have attended the 
Safety  Follow -
up Visit.  Subjects currently  in 
follow -up are considered to have completed the 
study ; these subjects are not required to attend any 
further visits.   Asse ssment and recording of AEs 
will be performed as per Section 7.2. 
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 19
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
ConfidentialSection 
Number (s)Section Title (s) Description of Change (s) Rationale
[IP_ADDRESS].1.3 
(now 
Section 
[IP_ADDRESS].3)Survival Follow
-up Addition of a note that this section is no longer 
applicable. Subjec ts currentl y in survival 
follow -up are considered to have comple ted the 
study ; these subjects will no longer be contact[CONTACT_551678].   Assessment and 
recording of AEs will be performed as per 
Section
7.2.
[IP_ADDRESS] Survival Status Addition of a note that this section is no longer 
applicable.   Subjec ts currentl y in survival 
follow -
up are considered to have completed the 
study ; these subjects will no longer be contact[CONTACT_551678].   Assessment and 
recording of AEs will be performed as per 
Section
7.2.
3.2 Secondary  Objectives Addition of anote that pharmacokinetic (PK) and 
antidrug antibodies (ADA) samples will no longer 
be collected.Further collection of samples in 
subjects receiving pembrolizumab 
alone is not required. Blood 
samples for PK and ADA may be 
stored. Analy sis will be perfo rmed 
if required.[IP_ADDRESS] Pharmacokinetic Endpoints Addition of a note that PK and ADA samples will 
no longer be collected.
6.1 Trial Flow Chart Deletion of rows for samples collection for PK and 
ADA, and associated footnote .
[IP_ADDRESS] and 
subsectionsPharmacokinetic/
Pharmacod ynamic 
EvaluationsAddition of a note that this section (and 
subsections) is no longer applicable. 
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 20
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
ConfidentialSection 
Number (s)Section Title (s) Description of Change (s) Rationale
[IP_ADDRESS] Procedures for Subjects 
Exhibiting Serotonin 
Syndrome (SS)Addition of a note that this section is no longer 
applicable .Subjects will no longer be 
receiving epacadostat, so activities 
and procedures relating to serotonin 
syndrome (an expected adverse 
reaction for epacadostat, but not for 
pembrolizumab) management and 
reporting is no longer needed.6.1 Trial Flow Chart Deletion of row for serotonin syndrome 
information sheet.
[IP_ADDRESS] Events of Clinical I nterest Deletion of text for serotonin sy ndrome .
12.8 Publication on Serotonin 
SyndromeAddition of a note that this section is no longer 
applicable .
5.2.4(now 
Section 
5.2.3)Trial Blinding Addition of a note that blinding is no longer 
applicable –all subjects will receive open -label 
pembrolizumab alone .Based on DMC recommendation, 
all subjects stopped receiving 
blinded epacadostat/placebo. All 
subjects remaining in the trial will 
continue on open -label 
pembrolizumab alone.[IP_ADDRESS] Blinding/Unblinding Addition of a note that blinding is no longer 
applicable –all subjects will receive open -label 
pembrolizumab alone .
9.[ADDRESS_725038]:   MK -3475 (SCH 900475), INCB 024360 21
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
ConfidentialSection 
Number (s)Section Title (s) Description of Change (s) Rationale
5.5.2 Restricted Medications and 
MeasuresDeletion of section. Subjects will no longer be 
receiving epacadostat, so restricted 
concomitant medications and 
prohibited medications related to 
epacadostat are no longer needed.5.5.3 (now 
Section 
5.5.2)Prohibited Medications and 
MeasuresRemoval of bullets for monoamine oxidase 
inhibitors and UGT1A9 inhibitors (or analogs).
12.[ADDRESS_725039] of care for subjects 
receiving pembrolizumab .6.1 Trial Flow Chart Pregnancy  testing is changed to monthly  per local 
regulations, as applicable.
[IP_ADDRESS] Pregnancy  Testing Pregnancy  testing is changed to monthly  per local 
regulations, as applicable. 
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 22
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
ConfidentialSection 
Number (s)Section Title (s) Description of Change (s) Rationale
7.2 Assessing and Recording 
Adverse EventsAdverse events (AEs) will be reported from the 
time of treatment allocation/randomization through 
30days following cessation of treatment or if the 
subject initiates new anticance r therapy , whichever 
is earlier.By [CONTACT_527655] [ADDRESS_725040] been off of 
epacadostat for >~[ADDRESS_725041].[IP_ADDRESS] Serious Adverse Events Serious adverse events (SAEs) will be reported 
from treatment allocation/randomization through 
90days following cessation of treatment, or 
30days following cessation of trial treatment if the 
subject initiates new anticancer therapy , whichever 
is earlier.
7.2.4 Evaluating Adverse Events Deletion of text stating that, for studies in which 
multiple agents are administered as part of a 
combination regimen, the investigator may 
attribute each adverse event causality  to the 
combination regimen or to a single agent of the 
combination.As pembrolizumab is now 
administered as single agent (ie, not 
in combination), this text is no 
longer applicable.
[IP_ADDRESS].[ADDRESS_725042] assessment 
burden.[IP_ADDRESS] Patient Reported Outcomes Addition of a note that ePRO assessments are no 
longer being collected.
6.1 Trial Flow Chart (including 
footnotes)Change offull physical exam ination to directed 
physical exam ination, per standard of care or as 
clinically  indicated, at End of Treatment (EOT) 
and Safet y Follow -up Visit.
Change of ECG at EOT visit to be per standard of 
care or as clinically indicated. 
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 23
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301-10) Final Protocol 18-May- 2018
ConfidentialSection 
Number (s)Section Title (s) Description of Change (s) Rationale
Deletion of patient reported outcome (PRO) 
assessments and associated footnote.
Change of laboratory assessments (including 
thyroid function and coagulation factors) from 
Cycle4 onwards to be per standard of care or as 
clinically  indicated.
Deletion of the optional request for tumor biopsy 
at Weeks 12, 24, and disease progression.
Change of tumor imaging timing to standard of 
care.  Removal of the requirement to send tumor 
imaging to the central imaging vendor.  A  repeat 
scan is not required if the investigator opts to 
discontinue the subject at the initial PD.
Deletion of digital photograph y assessment and 
associated footnote.
Addition of poststudy  anticancer therap y status 
assessment at EOT and at Safety  Follow -up Vis it. 
  04XN7M

Product:   MK -3475 (SCH 900475), INCB 024360 24
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
ConfidentialSection 
Number (s)Section Title (s) Description of Change (s) Rationale
[IP_ADDRESS]
7.1.2.3Full Physical Examination
Directed Physical 
ExaminationUpdate to reflect the change from full physical 
examination to directed physical examination , per 
standard of care or as clinically  indicated, at EOT 
and Safet y Follow -up Visit.Study procedures are reduced to the 
minimum requirement for 
investigational pembrolizumab 
administration to minimize subject 
assessment burden.[IP_ADDRESS].2 Patient Reported Outcomes Addition of a note that this section (and 
subsections) is no longer applicable.
7.1.4 Tumor Biops y Deletion of optional tumor biopsy  collection at 
Week 12, Week 24, and at disease progression.
7.1.5 Tumor Imaging and 
Assessment of DiseaseAddition of a note that central imaging vendor 
assessment is no longer required.  Disease 
assessments will be performed by [CONTACT_133052]/radiology  assessment ,perstandard of 
care.
Amendment of subsections to remove specific 
timing of assessments; timing should follow the 
site’s standard of care for oncologic tumor 
assessment until initial PD per RECI ST 1.1.  A 
repeat scan is not required if the investigator opts 
to discontinue the subject at the initial PD.  
Removal of text regarding repeat imagin g to 
confirm PR and CR.
[IP_ADDRESS] Photograph y for Cutaneous 
LesionsAddition of a note that this section is no longer 
applicable. 
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 25
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301-10) Final Protocol 18-May- 2018
ConfidentialSection 
Number (s)Section Title (s) Description of Change (s) Rationale
After their review of the second 
interim analy sis (IA)results, the 
DMC indicated that the comparison 
of PFS by [CONTACT_551679]-primary  endpoint OS was 
unlikely  to reach statistical 
significance for the study .  
Therefore, the DMC recommended 
that the study  willstop further 
efficacy  analyses.  Due to the 
current status of the study ,the 
statistical analy sis may be modified 
and will be reported in the CSR .8.1 Statistical Analy sis Plan 
SummaryAddition of a note that, based on recommendation 
from DMC at IA2, all subjects stopped oraltherapy  
(epacadostat/placebo )and only selected analyses 
will be performed a fterstudy  completion . 
  04XN7M

Product:   MK -3475 (SCH 900475), INCB 024360 26
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
ConfidentialADDITIONAL CHANGE (S)FOR THIS AMENDMENT:
Section 
Number (s)Section Title (s) Description of Change (s) Rationale
[IP_ADDRESS] Dose Modification 
(Escalation/Titration/Other)Minor language change in paragraph 2. To clarify  the language.
[IP_ADDRESS] Dose Modification 
(Escalation/Titration/Other)
Table 2  Dose Modification 
and Toxicity  Management 
Guidelines for Immune -
related AEs Associated 
with PembrolizumabAdded that, in case ofrecurrent Grade 3 colitis, 
subjects will pe rmanently  discontinue treatment .To align with KEYTRUDA® 
Summary  of Product Characteristics
and the Company  Core Data Sheet .
[IP_ADDRESS] Dose Interruptions 
Unrelated to Adverse 
EventsNew text added. To clarify  the language.
5.5.3 (now 
Section 
5.5.2)Prohibited Medications and 
MeasuresBullet 2 split out into 3 separate bullets. To clarify  the language.
5.8.1 Discontinuation of 
TreatmentAddition of a note to bullet “Any progression or 
recurrence of any malignancy , or any occurrence 
of another malignancy  that requires active 
treatment” that, for Franc e only, a subject 
experiencing this condition must be discontinued 
from the trial.French Health Authority  (ANSM) 
requested to clarify  that in the case 
of occurrence of another 
malignancy  during the trial, the 
subject must discontinue the trial.
5.8.[ADDRESS_725043]:   MK -3475 (SCH 900475), INCB 024360 27
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
ConfidentialSection 
Number (s)Section Title (s) Description of Change (s) Rationale
5.8.2 Withdrawal from the Trial Added:  For [LOCATION_009] only: A subject must be 
discontinued from the trial for the following 
reason:
-Any progression or recurrence of another 
malignancy , or any occurrence of another 
malignancy  that requires active treatment.ANSM requested to clarify  that in 
the case of occurrence of another 
malignancy  during the trial, the 
subject must discontinue th e trial.
[IP_ADDRESS] Serum Chemistry  and Liver 
Function Test sDeletion of duplicated sentence about liver 
function tests being done by  [CONTACT_28130].Correction.
Deletion of text relating to the frequency / duration 
of liver function monitoring in case of persistent 
low-grade abnormalities.Instructions for monitoring of liver 
function abnormalities are included 
in Table 2 in Section [IP_ADDRESS].
[IP_ADDRESS].1.1 
(now 
Section 
[IP_ADDRESS].1)Safety  Follow -up Visit Heading level changed from L evel 6 to Level 5 Correction.
[IP_ADDRESS].1.2 
(now 
Section 
[IP_ADDRESS].2)Follow -up Visits
[IP_ADDRESS].1.3 
(now 
Section 
[IP_ADDRESS].3)Survival Follow-up 
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 28
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
ConfidentialSection 
Number (s)Section Title (s) Description of Change (s) Rationale
8.6.2 Statistical Methods for 
Safety  Anal ysesDeletion of phrase for clarification, “ Continuous 
measures such as changes …and ECG parameters 
that are pre-specified as Tier-1 endpoints will be 
…” Clarification.
Throughout Minor typographical and formatting errors were 
corrected. 
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 29
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-[ADDRESS_725044] Identifiers MK-3475, INCB 024360
Pembrolizumab , epacadostat
NOTE: As of Amendment 10, epacadostat is rem oved .
Trial Phase Phase III
Clinical Indication Unresectable or metastatic m elanom a
Trial Type Interventional
Type of control Placebo
NOTE: As of Amendment 10, placebo is rem oved.
Route of administration Intravenous, Oral
NOTE: As of Amendment 10, epacadostat (oral adm inistration) 
is rem oved.
Trial Blinding Unblinded Open -label
Treatment Groups pembrolizumab +  epacadostat, pembrolizumab   +  placebo
NOTE: As of Amendment 10, epacadostat and placebo are 
removed. All subjects remaining in the trial 
receive open -label 
pembrolizumab only .
Number of trial subjects Approx imately 700subjects will be enrolled.
Estimated duration of trial The Trial is estimated torequire approximately 48months from the 
time the first subject signs the inform ed consent until the last 
subject’s last study -related phone call or visit.
Duration of Participation Each subject will participate in the trial from the time the subject 
signs the informed consent form (ICF) through the final protocol -
specified contact.  
After a screening phase of [ADDRESS_725045] will be assigned to 
receive trial treatment until radiographically confirmed disease 
progression is confirm ed by [CONTACT_551680] (irRECIST), unacceptable adverse 
event(s), intercurrent illness that prevents further administration of 
treatment, investi gator’s decision to withdraw  the subject, 
noncompliance with trial treatm ent or procedures requirements or 
administrative reasons requiring cessation of treatment, or until the 
subject has received 35 administrations of pembrolizumab 
(approximately 2 years ). 
After the end of treatment, each subject will be follow ed for the 
occurrence of adverse events and spontaneously reported pregnancy 
as described under S ection 7.[ADDRESS_725046] of abbreviations used in this document can be found in Section 12. 9.Randomization Ratio 1:[ADDRESS_725047]:   MK-3475 (SCH 900475), INCB 024360 30
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
Confidential2.0TRIAL DESIGN
Trial Design 2.1
NOTE: As ofAmendment 10,the epacadostat /placebo combination therap y is removed 
from both treatment groups . All subjects remaining in the trial continue on 
pembrolizumab alone in an open -label fashion . The Second Course retreatment phase 
is removed .The last trial visit is the Safety Follow -up Visit.
This is a randomized, placebo -controlled, parallel-group, multi -site, double-blind trial of 
pembrolizumab and epacadostat in subjects with unresectable or metastatic melanoma to be 
conducted in conformance with Good Clinical Practices .  This Phase 3 study  will be 
conducted in subjects with unresectable or metastatic melanoma . Subjects will be stratified 
by [CONTACT_551681] 1 (PD-L1)expression (positive versus 
negative /indeterminate ) and BRAF mutation status (BRAF mutant and received prior BRAF 
directed treatment, BRAF mutant with no prior BRAF directed treatment and BRAF wild 
type)and then be randomized 1:1 (active:placebo) toTreatment A (pembrolizumab + 
epacadostat ) or Treatment B ( pembrolizumab + placebo ).  No treatment crossover is planned. 
The treatment period with the combination therapy  will continue every 21 days for up to 
35cycles (approximately  2 years) as long as subjects are receiving benefit from treatment 
and have not had disease progression or met an y criteria for stud y withdrawal. 
Specific procedures to be performed during the trial, as well as their prescribed times and 
associated visit windows, are outlined in the Trial Flow Chart -Section 6.0. Details of each 
procedure are provided in Section 7 .0–Trial Procedures.
This trial will use an adaptive design based on pre-specified criteria, using an independent, 
external Data Monitoring Committee (DMC) to monitor safety  and efficacy .There will be [ADDRESS_725048]:   MK-3475 (SCH 900475), INCB 024360 31
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-[ADDRESS_725049]:   MK-3475 (SCH 900475), INCB 024360 32
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
Confidential3.0OBJECTIVE(S) & HYPOT HESIS(ES)
Primary Objective(s) & Hypothesis (es) 3.1
In all randomized male/female subjects with histologicall y confirmed diagnosis of melanoma 
with unresectable or metastatic melanoma of at least 18 y ears of age:
1)Objective: To compare the progression -free survival (PFS ) of the combination of 
pembrolizumab and epacadostat versus pembrolizumab and placebo (i.e. 2 treatment 
groups) based on Response Evaluation Criteria in Solid Tumors (RECIST )1.1by 
[CONTACT_69795].
Hypothesis (H1): The combination of pembrolizumab and epacadostat prolongs PFS 
based on RECI ST 1.1 by  [CONTACT_551682]. 
2)Objective: To compare overall survival (OS) of the 2 treatment groups.
Hypothesis (H2): The combination of pembrolizumab and epacadostat prolongs OS 
compared to pembrolizumab and placebo. 
This study  is considered to have met its study  objective if pembrolizumab and epacadostat is 
superior to pembrolizumab and placebo in either PFS or OS .
Secondary Objective(s) & Hyp othesis(es) 3.2
In all randomized male/female subjects with histologicall y confirmed diagnosis of melanoma 
with unresectable or metastatic melanoma of at least 18 y ears of age:
1)Objective : To compare the objective response rate (ORR) of the [ADDRESS_725050] 1.1 by [CONTACT_69795].
Hypothesis (H1): The combination of pembrolizumab and epacadostat increases 
ORR based on RECIST 1.1 by [CONTACT_551683].
2)Objective : To evaluate the safet y and tolerab ility of the 2 treatment groups .
3)Objective : To evaluate the duration of response (DOR) of the [ADDRESS_725051] 1.1 by [CONTACT_69795].
4)Objective :To evaluate the pharmacokinetics (PK)and anti-pembrolizumab 
antibodies of pembrolizumab and epacadostat administered concomitantly .
NOTE : As of Amendment 10, samples for PKand antidrug antibod y(ADA)
assessments are no longer being collected. 
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 33
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-[ADDRESS_725052]:   MK-3475 (SCH 900475), INCB 024360 34
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
Confidential4.0BACKGROUND & RATIONA LE
Background 4.1
NOTE: As of Amendment 10, all text in this section relating to epacadostat is no longer 
applicable.
Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibod y 
(mAb) with high specificity  of binding to the programmed cell death 1 (PD-1) receptor, thus 
inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programm ed cell 
death ligand 2 (PD-L2).  Based on preclinical in vitro data, pembrolizumab has high affinit y 
and potent receptor blocking activity  for PD -1.  Pembrolizumab has an acceptable preclinical 
safet y profile and is in clinical development as an intravenou s (IV) immunotherapy  for 
advanced malignancies.  KEYTRUDA ™ (pembrolizumab) is indicated for the treatment of 
patients across a number of indications.  For more details on specific indications refer to the 
Investigator brochure.
Epacadostat (formerl y INCB02 4360) represents a novel, potent, and selective inhibitor of the 
enzy me indoleamine 2,3 dioxy genase -1 (IDO1) in both human tumor cells and human 
dendritic cells (DCs).  Pembrolizumab is a potent and highl y selective humanized 
monoclonal antibody  of the imm unoglobulin (Ig) G4/kappa isotype directed against 
programmed death receptor 1 (PD -1).
Refer to the respective Investigator’s Brochure (IB) for detailed background information on
pembrolizumab and epacadostat.
Pharmaceutical and Therapeutic Background 4.1.[ADDRESS_725053] immune surveillance in controlling outgrowth of neoplastic 
transformation has been known for decades [1].  Theinability  of the immune system to 
control tumor growth does not appear to result from an inability  to recognize the tumor as
foreign.  Tumor cells have been shown to evade immune destruction despi[INVESTIGATOR_551651]  T cells that are 
specific for these antigens [2], [3].  Histologic evaluation of many  human cancers show s
extensive infiltration by [CONTACT_551684] [4], suggesting that the immune 
system responds less effectivel y to malignancy .  These observations have led to the 
hypothesis that dominant mechanisms of immune tolerance or immune suppression are 
responsible for the immune system's inability to effectivel y respond in a way that 
consistently  results in rejection.
There are a number of inhibitory  mechanisms that have been identified to be involved in 
tumor -mediated immune suppression and include expression of the programmed death ligand 
1 (PD-L1), which can engage the inhibitory  receptor PD-1 on activated T cells; the presence 
of the tryptophan -catabolizing enzyme IDO1, which exposes the exquisite sensitivity  of T 
cells to tryptophan depletion and tryptophan metabolites; and infiltration with FoxP3+
regulatory  T cells (Treg), which can mediate extrinsic suppression of effector T -cell function.  
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 35
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-[ADDRESS_725054] s and thereb y allow the 
expansion of effector T cells present in the tumor may  be beneficial in the clinic.
[IP_ADDRESS] Inhibition of PD -[ADDRESS_725055]  stimulated by [CONTACT_55548].  The normal function of PD-1, e xpressed on the cell surface of activated 
Tcells under healthy  conditions, is to down -modulate unwanted or excessive immune 
responses, including autoimmune reactions.  PD-1 (encoded by [CONTACT_13228]1) is an 
immunoglobulin (Ig) superfamil y member related to CD28 and cytotoxic T-lymphocy te-
associated antigen -4 (CTL A-4), which has been shown to negatively regulate antigen 
receptor signaling upon engagement of its ligands (PD-L1 and/or PD-L2) [5], [6].  The 
mechanism by [CONTACT_13209]-[ADDRESS_725056] from 
that of CTL A-4, as both molecules regulate an overlappi[INVESTIGATOR_77971] [7], [8] .  
PD-1 has been shown to be expressed on activated lymphocy tes including peripheral CD4+ 
and CD8+ T-cells, B-cells, Tregs, and natural killer cells [9], [10].  Expression has also been 
shown during thy mic development on CD4 -CD8
-(double negative) T cells as well as subsets 
of macrophages and dendritic cells [11].  The ligands for PD-1 (PD-L1 and PD-L2) are 
constitutively  expressed or can be induced in a variet y of cell types, including 
nonhematopoietic tissues as well as in various tumors [12], [13], [14], [8].  Binding of either 
PD-[ADDRESS_725057] notably  on vascular 
endothelium, whereas PD -L2 protein is onl y detectably  expressed on antigen -presenting cells 
found in ly mphoid tissue or chronic inflammatory environments.  PD -L2 is thought to control 
immune T -cell activation in lymphoid organs, whereas PD -L1 serves to dampen unwarranted 
T-cell function in peripheral tissues [8].  Although healthy  organs express little (if any) PD-
L1, a variet y of cancers were demonstrated to express abundant leve ls of this T -cell inhibitor.  
PD-1 has been suggested to regulate tumor -specific T- cell expansion in subjects with 
melanoma [15].  This suggests that the PD-1/PD -L1 pathway  plays a critical role in tumor 
immune evasion and should be considered as an attrac tive target for therapeutic intervention.
[IP_ADDRESS] Inhibition of Indoleamine 2,3 –Dioxygenase as a Target for Cancer
NOTE:  
As of Amendment 10, this section is no longer applicable.
Recent interest has focused on the role of indoleamine 2,3–dioxy genase (IDO1) as a 
mechanism of induction of tolerance to malignancy [16].  IDO1 is a heme -containing, 
monomeric oxidoreductase that catal yzes the degradation of the essential amino acid 
tryptophan to N-formy l-kynurenine.  Kynurenine can be subsequentl y metabolized through a 
series of enzymatic steps to nicotinamide adenine dinucleotide.  IDO1 is the first rate-
limiting enzyme in one of the breakdown pathway s of tryptophan.  In another pathway , 
tryptophan hydroxylase cataly sis of tryptophan leads to the formation of serotonin and 
melatonin.  
The expression and activity  profiles of IDO1 are distinct from those of tryptophan 
dioxy genase, an enzyme predominantly  expressed in liver that cataly zes the same enzy matic  
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 36
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-[ADDRESS_725058] with potential sources of immune challenge 
(e.g., gut, respi[INVESTIGATOR_53121], placenta, spleen), consistent with a role for regulating tryptophan 
metabolism in a local microenvironment [17].  Within the immune system, IDO1 activity  is 
specificall y induced in cells such as DCs and macrophages at localized sites of inflammation
[18].  
IDO1 driven oxidation of tryptophan results in a strong inhibitory  effect on the development 
of T-cell mediated responses by [CONTACT_47506] T- cell activation and inducing T- cell apoptosis
[19].  Both the reduction in local tryptophan levels and the production of tryptophan 
catabolites that are inhibitory  to cell proliferation contr ibute to the immunosuppressive 
effects [20].  IDO1 activity  also promotes the differentiation of naive T cells to cells with a 
regulatory  phenoty pe (Treg) [21].  Since increased Treg activity  has been shown to promote 
tumor growth and Treg depletion has be en shown to allow an otherwise ineffectual antitumor 
immune response to occur [22], IDO1 expansion of Tregs may provide an additional 
mechanism whereb y IDO1 could promote an immunosuppressive environment.
The biological relevance of IDO1 inhibition to immu ne tolerance was first demonstrated 
when it was shown that treating mice with a small molecule inhibitor of the IDO1 pathway , 
1-methy l - tryptophan, could break the tolerogenic state that protects allogeneic concepti from 
the maternal immune system [23].  A critical role for IDO1 in immunomodulation has been 
confirmed in numerous animal models, including models of allograft tolerance, 
inflammation, and cancer [17].  While IDO1 inhibition can exacerbate disease in models of 
autoimmune disorders [17], IDO1 null mice show no evidence of susceptibility  to developi[INVESTIGATOR_551652] [19], suggesting 
that IDO1 inhibition, in a therapeutic setting, may produce minimal side effects in subjects 
without pre -existing autoimmune conditions.
Within the context of cancer, there are several lines of evidence to suggest that IDO1 is a key  
regulator of the immunosuppressive mechanisms responsible for tumor escape from immune 
surveillance.  Several groups have demonstrated tha t blockade of IDO1 activity  can directly 
influence the ability  of tumor -bearing animals to reject tumors [24], [25 ].  In addition, studies 
with 1-methy l - tryptophan, demonstrate that IDO1 inhibition dramatically  increases the 
efficacy  of various chemotherapeutic agents (e.g., platinum compounds, taxane derivatives, 
cyclophosphamide) without increased toxicity [25].  Although the specific mechanisms 
responsible for this potentiation remain to be fully elucidated, the effects were not observed 
in T-celldefici ent animals, suggesting that the results may be the consequence of the 
disablement of immunosuppressive mechanisms that exist within the tumor 
microenvironment.
Based on studies examining serum levels of tryptophan and kynurenine, IDO1 appears to be 
chroni cally activated in subjects with cancer, and IDO1 activation correlates with more 
extensive disease [26], [27].  IDO1 has subsequently  been found to be overexpressed by a 
wide variet y of human tumor cell types as well as by [CONTACT_551685]  
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 37
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
Confidentialdraining lymph nodes [24].  Increased expression of IDO1 in tumor cells has been shown to 
be an independent prognostic variable for reduced overall survival (OS) in subjects with 
melanoma, ovarian, colorectal, and pancreatic cancers [28], [29], [30], [31], [32].  Together, 
these results suggest that the IDO1 pathway  is a key regulatory  element responsible for the 
induction and maintenance of tumor immune tolerance.  Small molecule inhibitors of IDO1 
may provide an innovative and tractable method to treat advanced malignancies either alone 
or in combination with chemotherapeutics and/or immunotherapy -based strate gies.
[IP_ADDRESS] Combined Immune Checkpoint Inhibition
NOTE:  
As of Amendment 10, this section is no longer applicable.
Blockade of immune inhibitory  pathway s is emerging as an important therapeutic modality 
for the treatment of cancer as evidenced by  [CONTACT_551686] A-4 and PD-1/PD -L1.  Ipi[INVESTIGATOR_125], a fully human, IgG1 monoclonal antibody  blocking 
CTL A-4, improved OS in patients with advanced melanoma [9], [33 ].  Nivolumab, a fully 
human IgG4 antibody  blocking PD-
1, produced durab le overall responses in patients with 
melanoma, renal cell cancer, and NSCL C[34], [35], [36] .  Although these single agents have 
antitumor activity , multiple immune inhibitory  mechanisms are present concurrently  within 
the tumor microenvironment, suggesti ng that combination therapi[INVESTIGATOR_551653] [37].
For example, CTL A-[ADDRESS_725059]  alone [38], [39] .
On the basis of these observations, a Phase 3 study  was conducted to investigate the safet y 
and efficacy  of combined CTLA -4 and PD-1 blockade (with the use of ipi[INVESTIGATOR_45767], respectivel y) in 
patients with advanced melanoma.  The objective response rate 
(ORR; according to modified World Health Organization criteria) for all patients in the 
concurrent -regimen group was 61% among subjects with BRAF wild-type tumors versus 
11% in the ipi[INVESTIGATOR_195664]. Median duration of response had not been reached in 
either group. Median PFS had not been reached with the combination therap y and was 4.4 
months for ipi[INVESTIGATOR_551654] y.  Grade 3 or 4 AEs occurred in 54% of subjects in the 
concurrent -regimen group and were 24% in the ipi[INVESTIGATOR_551654] y group [40]. 
Common Grade 3 or 4 selected AEs that were related to the combination therap y included 
colitis (17%), diarrhea (11%), and an elevated alanine aminotransferase level (11%).  
Diarrhea (11%) was the most frequentl y reported Grade 3 or 4 AE associated with 
ipi[INVESTIGATOR_79285], followed by [CONTACT_551687] (7%).  In both regimen groups, treatment -
related AEs were manageable and generally reversible with the use of immunosuppressants 
(or hormone -replacement therapy  for endocrinopathies) according to previously  established 
algorithms [40]. 
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 38
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
ConfidentialAs described previousl y, IDO1 is another negative regulatory  mechanism that contributes to 
tumor -deriv ed immune suppression.  In preclinical models, IDO1 inhibition has been shown 
to synergize with blockade of either antiCTLA -4 or antiPD-1/PD -L1 in delay ing tumor 
growth and increasing OS[41], [42].  This effect was shown to be T-cell dependent, leading 
to enhanced T-cell proliferation and interleukin -2 production within the tumor and to a 
marked increase in the effector -to-regulatory  T cell ratios in the tumors.
The IDO1 inhibitor epacadostat has completed a Phase 1 study  and has several ongoing 
Phase 1 and Phase 2 studies in combination with immune -targeted agents, such as anti –PD-1, 
anti–PD-L1, and anti –CTLA -4 antibodies.  I n a study  combining epacadostat and ipi[INVESTIGATOR_125] 
(INCB [ZIP_CODE]- 201) subjects received ipi[INVESTIGATOR_125] (3 mg/kg IV every  3  weeks for 4 cycles) 
with epacadostat at doses of 25 mg BID, 50 mg BID continuous, 50 mg BID intermittent 
(2 weeks on, 1 w eek off), and 75 mg (50 mg q AM/25 mg q PM). A total of 42 subjects were 
enrolled: 25 mg BID (n=8), 50 mg BID (continuous) (n=18), 50 mg BID ( intermittent) (n=9), 
and 75 mg (n=7). DLTs were: [ADDRESS_725060] (n=1); 50 mg BID 
(continuous), Grade 3 diarrhea, Grade 3 increased ALT/AST grade 3 colitis and grade 3 
pneumonitis (n=1 each); 50 mg BID (intermittent), Grade 3 colitis (n=1 ); 75 mg, Grade 3 
rash (n=1). The most common all Grade immune -related adverse events (irAEs) were rash 
(52%), pruritus (38%), diarrhea (33%), increased ALT (21%), increased AST (16%) 
hypothy roidism (12%) and colitis (10%). Grade ≥3 irAEs occurred in 23% of subjects. 
Grade ≥ [ADDRESS_725061] and colitis (n=4 
[9.5%] each). Among 32 immunotherapy -naïve subjects, ORR was 31% (10/32) per irRC 
and 28% (9/32) per RECI ST and the CR rate per both criteria was 9.4%. At data cutoff, 
responses were ongoing in 6 subjects. The disease control rate (DCR; CR+PR+SD) was 
62.5% per irRC and 53% per RECI ST. Median PFS was 8.[ADDRESS_725062]. Among 10 subjects previously  treated with immunotherapy, theDCR by [CONTACT_551688] 30% (all SDs).  In a study  combining pembrolizumab and epacadostat (INCB 
[ZIP_CODE]- 202) similar efficacy  and safet y were also demonstrated.
In summary , both IDO1 and PD-
[ADDRESS_725063] been shown to suppress T-cellmediated antitumor 
immunity ,and IDO1 and the PD-[ADDRESS_725064] s are important in 
melanoma as well as in other cancers, including NSCL C.
[IP_ADDRESS] Overview of Metastatic Melanoma
Melanoma is the most serious form of skin cancer and strikes adults of all ages. The 5-year 
prevalence of melanoma in the European Union (EU) is approximately  159,000 patients with 
an incidence of approximately  41,000 per year and approximately  11,000 deaths annually  as 
described in the World Health Organization (WHO) Europe region [43].  Melanoma accounts 
for approximately  5% of all new cases of cancer in the [LOCATION_002] (US). The incidence of 
melanoma continues to rise by [CONTACT_34120] 3% per year in the US. 
This translates to 76,[ADDRESS_725065]:   MK -3475 (SCH 900475), INCB 024360 39
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
Confidentialis 1.4:1, respectively [44].  The 5-year survival rate is 15% once patients have progressed to
late-stage disease [45].
[IP_ADDRESS] Treatment for Advanced or Metastatic Melanoma
Surgical excision with wide margins is the stand ard of care for early
-stage melanoma, and 
most patients with in situor early -stage melanoma will be cured by [CONTACT_551689].  
Metastatic melanoma, however, is very unlikely to be curable by [CONTACT_551690], MRI, or PET scans [46].  
National Comprehensive Cancer Network (NCCN) guidelines (Melanoma –Version 2.2016) 
endorse adjuvant treatment, including clinical study , observation, or high -dose interferon alfa 
for node- negative Stage IIB or IIC disease. For Stage III disease, ipi[INVESTIGATOR_551655].  R adiation therapy  may  have a role as adjuvant therapy  after surgery  for primary 
melanomas that are associated with a high rate of local recurrence despi[INVESTIGATOR_551656], and in those with positive margins after surgical excision [48].
High -dose interleukin -2 (IL-2) was the first treatment to modify  the natural history  of 
patients with metastatic melanoma and may be curative for a small fraction of patients.  
However , its severe toxicity  limits its application to carefull y selected patients treated at 
centers with experience in managing the side effects of treatment.  More recent research led 
to the development of immunotherapy  using checkpoint inhibitors such as anti-PD1 
antibodies, pembrolizumab and nivolumab, and the anti-CTLA4 antibody (ipi[INVESTIGATOR_125]) and 
to targeted therap y such as BRAF and/or MEK inhibition (dabrafenib and/or trametinib, 
respectivel y).  Both of these approaches prolong progression free and overall survival 
compared with chemotherap y [48].
Ipi[INVESTIGATOR_125], an anti-cytotoxic T lymphocy te associated antigen -4 (CTL A-4) blocking 
antibody , and vemurafenib, a BRAF inhibitor, were the only agents approved for advanced 
melanoma that have demonstrated overall survi val (OS) benefit in randomized, comparative 
Phase [ADDRESS_725066] ratio (HR) of 0.66 and a 4-month median OS benefit 
compared to gp100 in pretreated advanced melanoma subjects [58].  Grade 3 to 4 immune -
related adverse events (AEs) included colitis (5.3%), diarrhea (4.6%), endocrinopathies 
(3.8%), and rash (0.8%). In the US, 3 mg/kg of ipi[INVESTIGATOR_551657]010 -20 and without restriction to line of therap y, in part 
because of the results of an additional Phase 3 randomized ipi[INVESTIGATOR_551658] , 
CA184024. In the CA184024 study , treatment -naïve advanced melanoma subjects treated 
with 10 mg/kg ipi[INVESTIGATOR_551659] (DTIC) demonstrated an HR of 
0.72 and a 2 -month median OS benefit compared with monotherapy  dacarbazine [33].  In the 
EU, ipi[INVESTIGATOR_551660] (unresectable and 
metastatic) melanoma in adults who have received prior therap y.Approximately  50% of 
cutaneous melanoma cases are BRAF V600E mutation positive. Vemurafenib is approved in 
the US and in the EU for the treatment of BRAF V600E mutation -positive advanced 
melanoma subjects regar dless of line of therapy  [49].  In the BRIM -[ADDRESS_725067]:   MK -3475 (SCH 900475), INCB 024360 40
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
Confidentialvemurafenib demonstrated a 48% response rate and an increased OS benefit compared to 
dacarbazine with a HR of 0.37, but with inadequate follow-up.
First line data in advanced or metastatic melano ma with pembrolizumab versus ipi[INVESTIGATOR_551661] 2015 meeting with an estimated 46.4% 6-month PFS 
rate for pembrolizumab 10mg/kg every  3
 weeks versus 26.5% for ipi[INVESTIGATOR_125].  The ORR 
was 32.9% for pembrolizumab 2 mg/kg every  3 weeks (Q3W) versus 11.9% for ipi[INVESTIGATOR_125].  
Responses were ongoing in 96.7% of subjects after a median follow -
up of 7.[ADDRESS_725068] ratio for the disease progression for pemb rolizumab every  3weeks versus ipi[INVESTIGATOR_551662] 0.58 (95% CI, 0.47 to 0.72; p<0.001).  At the time of the data cut off for the second 
interim analy sis in this study , which was driven by a m inimum follow up of duration of 12 
months for all subjects, 289 death s occurred.  One-year estimates of survival for subjects 
receiving pembrolizumab every  3 w eeks were68.4% as compared with ipi[INVESTIGATOR_125] 58.2% 
(HR for death as compared with ipi[INVESTIGATOR_102315] 0.69; 95% CI, 0.52 to 0.90; p=0.0036).  
Because the OS results were superior to those for the ipi[INVESTIGATOR_551663] [50].  
Similarly , nivolumab was studied in subjects with previousl y untreated advanced melanoma 
compared to dacarbazine and reported a 5.1 month median PFS compared to 2.2 months for 
the dacarbazine. The objective response rates were 40% in the nivolumab group and 13.9% 
in the dacarbazine group.  At 1 year the overall rate of survival was 72.9% for the nivolumab 
group compared to 42.1% in the dacarbazine group. Nivolumab showed significant 
improvements in overall survival and PFS compared with dacarbazine among previousl y 
untreated patients who had metastatic melanoma without BRAF mutation [51].  
In 2014, the FDA approved both nivolumab and pembrolizumab, human programmed death 
receptor -1 (PD-1) blocking antibodies, for the treatment of patients with unresectable or 
metastatic melanoma and disease progression following ipi[INVESTIGATOR_164], if BRAF V600E 
mutation positive, a BRAF inhibitor.  This indication is approved under accelerated approval 
based on tumor response rate and durability  of response. Both pembrolizumab and 
nivolumab received NCCN compendia listing recommendations for use in the first line 
metastatic melanoma setting based on these data.   In November 2015, nivolumab received 
approval for first-line treatment of patients with BRAF V600 wild-type unresectable or 
metastatic melanoma.  In December 2015, the pembrolizumab label was expanded to include 
first-line treatment of patients with unresectable or metastatic mela noma regardless of BRAF 
status. The European Commission has also approved pembrolizumab and nivolumab, for 
both first -line and previously -treated patients with advance d melanoma. 
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 41
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
ConfidentialPre-clinical and Clinical Trials 4.1.2
NOTE:  As of Amendment 10, text in this section relating to epacadostat is no longer 
applicable.
Refer to the Investigator's Brochures (IBs)for pembrolizumab and epacadostat for preclinical 
and clinical study  data.
Ongoing Clinical Trials 4.1.3
NOTE:  As of Amendment 10, text in this section relating to epacadostat is no longer 
applicable.
Refer to the Investigator's Brochures (IB s) for pembrolizumab and epacadostat for preclinical 
and clinical study  data.
Rationale 4.[ADDRESS_725069] Population 4.2.1
[IP_ADDRESS] Rationale for Combining PD -1 Inhibitor and IDO1 Inhibitor in Melanoma
NOTE:  As of Amendment 10, this section is no longer applicable.
If the safet y profile is acceptable and this combination is shown to improve PFS and/or OS, 
this study  could support the regulatory approval of this combination in subjects with 
unresectable or metastatic melanoma.  
In an ongoing dose-escalation and expansion study  of pembrolizumab in combination with 
epacadostat subje cts with Stage IIIB, IV, or recurrent NSCLC, melanoma, transitional cell 
carcinoma (TCC), RCC, endometrial adenocarcinoma, or SCCHN are being enrolled.    
Subjects previously  treated with PD-1 or CTLA -4 targeted therapi[INVESTIGATOR_551664]. 
Enrollment is comp lete in the epacadostat 25 mg BID, 50 mg BID, and 100 mg BID cohorts 
with pemb rolizumab 2 mg/kg IV Q3W . Phase [ADDRESS_725070] frequently  reported (≥15%) adverse events (AEs) of any grade for 
the combined Phase 1 and Phase 2 treatment groups treated with epacados tat 100 mg BID 
were fatigue (35.0%), constipation (24.8%), diarrhea (20.5%), nausea (20.5%), vomiting 
(18.8%), pyrexia (16.2%) and dyspnea (15.4%). Fatigue (13.7%) and rash (11.1%)  
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 42
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
Confidential(including the preferred terms rash, rash maculopapular, rash generalized, and rash macular) 
were the only treatment -related AE reported in >10% of subjects. Treatment -related AEs of 
rash were onl y reported in the Phase 2 group.   
Treatment -related AEs ≥Grade [ADDRESS_725071] in the combined 
Phase 1 and Phase 2 epacadostat 100 mg BID treatment group included rash (5 subjects, 
4.3%) and deh ydration, lipase increased, AST increased and nausea (2 subjects [1.7%] each).
Based on the Phase 1 safety  data of epacadostat doses ranging from 25 mg BID up to 300 mg 
BID, a dose of 100 mg BID was selected for the Phase 2 portion of Study  202 and for this 
Phase 3 study of epacadostat to be combined with pembrolizumab 200 mg IV Q3W .
ORR in 19 evaluable subjects with treatment -naïve metastatic melanoma was 58% (11/19) 
with disease control rate of 74% (14/19). Median PFS has not been reached and all 
responses are ongoing with min follow up of 31.7 weeks.
Rationale for Dose Selection/Regimen /Modification 4.2.2
[IP_ADDRESS] Justification for Treatment Regimen
NOTE:  As of Amendment 10, this sec tion is no longer applicable.
The dose selected forepacadostat forthe current study  was formed on the basis of having a 
well-tolerated safet y profile as monotherapy  and in combination with pembrolizumab, a 
robust objective response rate, durable disease control rates, as well as providing optimal 
target inhibition of ID O1 based on nonclinical models. Doses of epacadostat of up to [ADDRESS_725072] been well tolerated and doses of 25 mg BID to 300 mg BID in 
combination with pembrolizumab, nivolumab, durvalumab and atezolizumab are currentl y 
being evaluated in several ongoing Phase 2 studies. Doses of pembrolizumab 2 mg/kg and 
[ADDRESS_725073] been studied in the ongoing Phase 1/2 study  of pembrolizumab in 
combination with epacadostat. Reductions in tumor burden were seen in 14of 19 evaluable 
subjects across doses of 25 mg BID to 100 mg BID in combination with pembrolizumab 
2mg/kg and 200 mg flat dosing. Objective responses were observed in all tumor types and 
all are ongoing and this combination has been well tolerated.
Based on a pharmacokinetic -pharmacod ynamic model for epacadostat, nearl y all patients’ 
Cavgexceeded the IC 50, the range of active drug exposure seen in non -clinical models ;further 
dose of 100 mg BID and above exceeded the IC 50at trough in nearl y all patients [52].
Based on observed systemic exposures and a pharmacokinetic -pharmacody namic model for 
epacadostat, all patients who received 100 mg BID epacadostat in combination with 
pembrolizumab had time-averaged inhibition of IDO1 activity  exceeding 50%, a level of PD 
activity  associated with inhibition of tumor growth seen in non-clinical models .  Dosingof 
100 mg BID and above exceeded the IC50at trough in nearl y all patients [52]; further, the 
majority  of patients had trough epacadostat exposures that were above the IC50of IDO1 
inhibition.   Therefore, [ADDRESS_725074]:   MK -3475 (SCH 900475), INCB 024360 43
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
Confidentialepacadostat in study  INCB [ZIP_CODE]-202 because this regimen had better tolerability  as 
demonstrated by [CONTACT_165894] 1 safet y data including fewer dose modifications (suspens ion and 
reductions) and resulted in consistent inhibition of IDO1. The overall experience of the 
epacadostat 100 mg BID dose in combination with pembrolizumab in study  INCB [ZIP_CODE]
-202 
supports this dose selected for the Phase 3 stud y INCB [ZIP_CODE] -301.
[IP_ADDRESS] Ration ale for a Fixed Dose of Pembrolizumab
The planned dose of pembrolizumab for this trial is 200 mg every  3 weeks (Q3W). Based on 
the totality  of data generated in the Keytruda development program, 200 mg Q3W is the 
appropriate dose of pembrolizumab across all indications and regardless of tumor type. As 
outlined below, this dose is justified by : 
•Clinical data from eight randomized studies demonstrating flat dose-and exposure -
efficacy  relationships from 2 mg/kg Q3W to 10 mg/kg every  2weeks (Q2W)
•Clinical data showing meaningful improvement in benefit -
risk including overall 
survival at 200 mg Q3W across multiple indications, and
•Pharmacology  data showing full target saturation in both systemic circulation 
(inferred from pharmacokinetic [PK] data) and tumor (inferred from physiologicall y 
based pharmacokinetic [PBPK] analy sis) at 200 mg Q3W
Among the eight randomized dose -comparison studies, a total of 2262 subjects were enrolled 
with melanoma and non-small cell lung cancer (NSCL C), covering different disease settings 
(treatment naïve, previously  treated, PD-L1 enriched and all-comers) and different treatment 
settings (monotherap y and in combination with chemotherap y). Five studies compared 
2mg/kg Q3W vs. 10 mg/kg Q3W ( KEYNOTE
-001 B2, KEYNOTE- 001 D, KEYNOTE -002, 
KEYNOTE -010 and KEYNOTE- 021), and three studies compared 10 mg/kg Q3W vs. 10 
mg/kg Q2W (KEYNOTE-001 B3, KEYNOTE- 001 F2 and KEYNOTE -006). All of these 
studies demonstrated flat dose-and exposure -response relationships across the doses studied 
represe nting an approximate 5 to 7.5 fold difference in exposure. The 2 mg/kg (or 200 mg 
fixed -dose) Q3W provided similar responses to the highest doses studied. Subsequently , flat 
dose-/exposure -response relationships were also observed in other tumor types including 
head and neck cancer, bladder cancer, gastric cancer and classical Hodgkin Lym phoma, 
confirming [ADDRESS_725075], PK 
data inKEYNOTE -001 evaluating target -mediated drug disposition (TMDD) conclusivel y 
demonstrated saturation of PD-[ADDRESS_725076]:   MK-3475 (SCH 900475), INCB 024360 44
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-[ADDRESS_725077] covariates on exposure, has shown that the fixed -dosing
provides similar control of PK variability  as weight based dosing, with considerable overlap 
in the distribution of exposures from the 200 mg Q3W fixed dose and 2 mg/kg Q3W dose.
Supported by [CONTACT_131877], and given that fixed -dose has advant ages of reduced 
dosing complexity  and reduced potential of dosing errors, the 200 mg Q3W fixed -dose was 
selected for evaluation across all pembrolizumab protocols .
Rationale for Endpoints 4.2.3
[IP_ADDRESS] Efficacy Endp oints
[IP_ADDRESS].1 Primary Efficacy Endpoints 
The dual primary  endp oints are PFS and OS.
Progression -free survival, defined as the time from date of randomization until the 
earliest date of disease progression, as determined by [CONTACT_551691] 1.1, or dea th from any  cause, 
whichever comes first.  
Overall survival, defined as the time from date of randomization to date of death due 
to any  cause.
The study  is considered to have met its study  objective if the combination is superior to 
pembrolizumab and plac ebo in either PFS or OS.
RECI ST 1.1(Section 12.7) as assessed by [CONTACT_551692]. 
Final determination of radiologic progressive diseas e (PD) will be based on the central 
imaging vendor assessment of progression, rather than local site investigator/radiology 
assessment.
NOTE:  As of Amendment 10, central imaging vendor assessment will no longer be 
required.
[IP_ADDRESS].2 Secondary Efficacy Endpoints
Objective response rate, defined as the proportion of subjects who have best response 
as complete response (CR) or partial response (PR). Responses are based on 
independent central review using RECI ST 1.1 .
Duration of response (DOR) determined by [CONTACT_551693], whichever comes first. Response will be determined by 
[CONTACT_551694]1.1. 
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 45
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301-10) Final Protocol 18-May- [ADDRESS_725078] (irRECIST)
RECI ST 1.[ADDRESS_725079] RECI ST1.1may, 
thus, not provide an accurate response assessment of immunotherapeutic agents such as 
pembrolizumab. Based on an analy sis of subjects with melanoma enrolled in 
KEYNOTE -
001, 7% of evaluable patients experienced delay ed or early  tumor 
pseudoprogression.  Of note, patients who had progressive disease by  [CONTACT_393] 1.[ADDRESS_725080] 1.1 may underestimate the benefit 
of pembrolizumab in approximately  15% of patients.  These findings support the need to 
apply  a modification to RECI ST 1.[ADDRESS_725081] (irRECIST) is RECI ST 1.[ADDRESS_725082]:   MK -3475 (SCH 900475), INCB 024360 46
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301-10) Final Protocol 18-May- 2018
Confidential4.2.3.4 Safety Endpoints
Safety  and tolerability  of the treatment regimens through assessment of AEs and 
changes in safet y assessments including laboratory parameters.
[IP_ADDRESS] Pharmacokinetic Endpoints
The PK parameters of epacadostat.  
The pharmacokinetics of pembrolizumab and formation of anti-pembrolizumab 
antibodies will be explored per existing modeling anal ysis plan (MAP) . 
NOTE: As of Amendment 10, samples for PK and ADA assessments are no longer 
being collected. 
  04XN7M

Product:   MK -3475 (SCH 900475), INCB 024360 47
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301-10) Final Protocol 18-May- [ADDRESS_725083]:   MK-3475 (SCH 900475), INCB 024360 48
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-[ADDRESS_725084]:   MK-3475 (SCH 900475), INCB 024360 49
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
ConfidentialBenefit/Risk 4.3
It cannot be guaranteed that subjects in clinical trials will directly  benefit from treatment 
during participation, as clinical trials are designed to provide information about the safety 
and effectiveness .
Risks from Epacadostat 4.3.1
NOTE:  As of Amendment 10, this section is no longer applicable.
In 28-day toxicology  studies, Cmaxvalues have exceeded the IC50for the IDO1 enzy me in 
cells (7nM) by [CONTACT_8622] 370-fold, and the IC50for the vasopressin 1a receptor by [CONTACT_8622] 40-fold 
(130-fold in single dose studies) in the absence of any toxicity , so the risk of unintended 
pharmacological activity  is expected to be low.  In the Phase 1 clinica l study  in subjects with 
refractory  solid tumors (INCB [ZIP_CODE] -101) doses up to [ADDRESS_725085]:   MK -3475 (SCH 900475), INCB 024360 50
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301-10) Final Protocol 18-May- 2018
ConfidentialAn uncommon risk of IDO1 inhibition is an increase in serotonin levels that could precipi[INVESTIGATOR_047] 
a cluster of AEs termed serotonin syndrome (SS) when administered in combination with 
other serotonergic agents.  This rare syndrome has been associated with some monoamine 
oxidase inhibitors (MAOI s) and combinations of serotonergic drugs [53].  The clinical 
manifestations of SS range from barely  perceptible to lethal; onset is rapid (within 12hours 
of drug(s) administration).  Based on preliminary  studies in the rat, concentrations of 
epacadostat in the cerebrospi[INVESTIGATOR_551665] (2 nM) 
after IV dosing, and total brain homogenate concentrations were approximately  15% of 
corresponding plasma concentrations.  In another preclinical study  in rats, the effect of 
epacadostat on the brain extracellular fluid concentration of serotonin was evaluated either 
alone or when co-administrated with the MAO inhibitor linezolid with or without the 
Serotonin reuptake inhibitors (SSRI )fluoxetine.  Both control conditions resulted in 2-6-fold 
increases in serotonin. In co ntrast, neither epacadostat alone or in combination with linezolid 
had an effect on the brain extracellular serotonin levels.  These preclinical data suggest that 
SS is unlikely  following treatment with either epacadostat alo
ne or with combination with 
MAO inhibitors such as linezolid [61]. Therefore, taken together, epacadostat exhibits 
apparent limited penetration across the blood -brain barrier and is likely not associated with 
significant effects on tryptophan metabolism in the brain that might impact brain serotonin 
levels.  
As of 27-F EB- 2017, 2 subjects across the epacadostat program (958 subjects treated) have 
reported serotonin syndrome or sy mptoms of serotonin sy ndrome and both were mild in their 
severit y and resolved.  One subject reported shivers , increased blood press ure and 
temperature (Grade 1).  The other subject reported Grade [ADDRESS_725086] from Study INCB [ZIP_CODE]-202 reported chills, increased blood pressure, and 
temperature (CTC Grade 1) on Cycle [ADDRESS_725087] was not on an SSRI  but on a medication for 
anxiety  (Alprazolam). The events resolved and the dosing with epacadostat was interrupted 
for one week.  Retreatment started with a lower dose of epacadostat of [ADDRESS_725088]:   MK-3475 (SCH 900475), INCB 024360 51
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
ConfidentialRisks from Pembrolizumab 4.3.2
An open -label Phase I study  (KEYNOTE --001) is being conducted to evaluate the safety  and 
clinical activit y of single agent pembrolizumab.  The dose -escalation portion of this study 
evaluated 3 dose levels, 1 mg/kg, 3 mg/kg, and 10 mg/kg, administered every  2 w eeks in 
subjects with advanced solid tumors.  All 3 dose levels were well tolerated and no DLTs 
were observed.  Based on pharmacokinetic (PK) data showing a half-life of [ADDRESS_725089] received pembrolizumab in KEYNOTE -001, 466 
(97.3%) experienced treatment -emergent AEs, of which 368 (76.8%) were conside red drug-
related.  Serious AEs were reported in 30.1% of subjects, but SAEs that were attributed as 
potentially  (possibly , probably , or definitel y) drug -related by [CONTACT_165892] 
6.7% of subjects overall.  Potential irAEs have been observed , including pneumonitis in both 
melanoma and NSCLC cohorts.  The most commonly  reported treatment -emergent AEs 
experienced have been fatigue, nausea, cough, pruritus, diarrhea, and rash.  Most subjects 
continued treatment despi[INVESTIGATOR_165826], and only 4.2% of subjects discontinued study  treatment 
because of an AE that was considered related to study  treatment by [CONTACT_431].  Thus, the 
overall AE summary  suggests that pembrolizumab is generall y tolerable, and AEs are 
generall y manageable in subjects.
Risks for the Combination of Pembrolizumab and Epacadostat 4.3.3
NOTE:  As of Amendment 10, this section is no longer applicable.
The combination of pembrolizumab and epacadostat has the potential to cause more frequent, 
more severe, and/or new immune -related toxicities as compared with each individually .
In the ongoing Phase 1/[ADDRESS_725090] that doses up to 300 mg BID of epacadostat are well tolerated with 200 mg IV of 
pembrolizumab. While 300 mg bid did not exceed the MTD, there were higher rates of dose 
holds and reductions compared to 100 mg bid supporting 100 mg bid as the Phase 2 dose (as 
is detailed later in this section). In the Phase 1 portion of the study , aDLT of Grade 3 rash 
and Grade 3 arthralgia wereseen in 2/19evaluable subjects with epacadostat 50 mg BID; 2
DLTsout of 15 evaluable subjects were seen with epacadostat 100 mgBID cohort (Grade [ADDRESS_725091] and Grade 2 nervous system disorder, other -ataxia), and 4 DLTs out of 19 evaluable 
subjects were seen at 300 mg BID (Grade 1 ery thema, 2 Grade 3 rashes and 1 nervous s ystem 
disorder –other –vomiting without nausea) . 
The most frequently  reported (≥15%) adverse events (AEs) of any grade for the combined 
Phase 1 and Phase 2 treatment groups (n=117) treated with epacadostat 100 mg BID were 
fatigue (35.0%), constipation (24.8%), diarrhea (20.5%), nausea (20.5%), vomiting (18.8%), 
pyrexia (16.2%) and dyspnea (15.4%). Fatigue (13.7%) and rash (11.1%) (including the 
preferred terms rash, rash maculopapular, rash generalized, and rash macular) were the only 
treatment -related AE reported in >10% of subjects. Treatment -related AEs of rash were 
only reported in the Phase [ADDRESS_725092]:   MK-3475 (SCH 900475), INCB 024360 52
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
ConfidentialAny Grade 3/4 AEs occurring in more than 1 subjects in the combined Phase 1 and Phase 2 
epacadostat 100 mg BID group include: rash (n=5, 4.3%), dehy dration (n=4 3.4%), naus ea, 
vomiting and AST increased, (n= 3 each, 2.6%), diarrhea, small intestine obstruction, fatigue, 
lipase increased, hypercalcemia, hyponatremia, tumor pain, and pneumonia aspi[INVESTIGATOR_1516] (n=2 
each, 1.7%).  Treatment -related AEs ≥Grade [ADDRESS_725093] included 
rash (5 subjects, 4.3%) and dehy dration, lipase increased, AST increased and nausea 
(2subjects [1.7%] each).
In subjects receiving epacadostat 300 mgBID, there was an observable trend in increased 
adverse events of rash (total events as well as severit y) and the number of required dose 
holds and dose reductions for epacadostat ,compared to subjects receiving 1 00 mg BID.  
Although the rashes observed at the 300 mg BID dose level were reversible with dose 
interruptions and medical treatment, total dose interruptions were higher in the 300 mg BID 
group with 5/[ADDRESS_725094] in 25 mg BID. Based on the risk for early progression during dose 
interruptions and dose reductions associated with epacadostat 300 mg BID in combination 
with pembrolizumab 200 mg IV Q3W , 100 mg BID was selected as the dose for use in the 
proposed Phase 3 stud y.
Additional details regarding specific benefits and risks for subjects participating in this 
clinical trial may be found in the accompany ing pembrolizumab and epacadostat
Investigators Brochure s(IBs) and Informed Consent documents.
5.0METHODOLOGY
Entry Criteria 5.1
Diagnosis/Condition for Entry into the Trial 5.1.1
Male/Female subjects with histologically  confirmed diagnosis of melanoma with 
unresectable or metastatic melanoma of at least [ADDRESS_725095]:
1.Have histologically  or cytologicall y confirmed melanoma .
2.Have unresectable Stage III or Stage IV melanoma, as per American Joint Committee 
on Cancer (AJCC )staging s ystem not amenable to local therap y. 
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 53
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-[ADDRESS_725096] of care targeted 
therap y (e.g.BRAF/MEK inhib itor, alone or in combination) and be eligible 
for this study
Note: T argeted therap y is not required for eligibility.
b.
Prior adjuvant or neoadjuvant melanoma therapy  is permitted if itwas 
completed at least [ADDRESS_725097] either returned to baseline or stabilized (resolution of toxic 
effect(s) of the most recent prior therap y to Grade 1 or less (except alopecia).
c.Prior adjuvant therap ycontaining immunotherapy  such as interferon or anti-
CTL A-[ADDRESS_725098] be ≤ 7 day s before treatment i nitiation.
a.Absolute neutrophil count ≥ 1.5 × 109/L.
b.Platelets ≥ 100 × 109/L.
c.Hemoglobin 
≥ 9 g/dL .
d.Serum creatinine ≤ 1.5 × institutional upper limit of normal (ULN) OR 
measured or calculated creatinine clearance (glomerular filtration rate can also 
be used in place of creatinine or CrCl) ≥ 50 mL/min for subjects with 
creatinine levels > 1.5 × institutional ULN.
e.Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and 
bilirubin, < 2.5 × ULN.
f.Conjugated bilirubin < 2.0 × ULN (need only be tested if total bilirubin 
exceeds ULN) .
g.International normalized ratio (INR) or prothrombin time (PT) ≤1.5 × ULN 
unless subject is receiving anticoagulant therapy  as long as PT or INR is 
within therapeutic range of intended use of anticoagulants. 
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 54
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301-10) Final Protocol 18-May- 2018
Confidentialh.Activated partia l thromboplastin time (aPTT) ≤1.5 × ULN unless subject is 
receiving anticoagulant therapy , as long as PTT is within therapeutic range of 
intended use of anticoagulants.
6.Have the presence of at least one measurable lesion by [CONTACT_551695] 1.1
criter iaas determined by [CONTACT_121159]/radiology  assessment .  Cutaneous 
lesions and other superficial lesions are not considered measurable lesions for the 
purposes of this protocol, but may  be considered as non -target lesions.
a.If subjects have only [ADDRESS_725099] 
been in the field of prior irradiation unless there is documented 
progression of the lesion(s).
7.Provide a baseline tumor biops y
a.Subjects must submit the tumor sample during screening for PD-L1 
expression testing at a central pathology  laboratory .  Subjects will be eligible 
to participate regardless of the level of PD -L1 expression, but will be stratified 
by [CONTACT_4002]-L1 expression level .Subjects who do not submit a sample adequate 
for PD-L1 determination will not be randomized. The biopsy  may not be 
obtained from a lone target lesion.    
b.Newl y
-obtained tissue is preferred (no intervening treatment [local or 
systemic] involving the site of tissue biopsy  once tissue biopsy  is obtained at 
time of study  enrollment). The only exception to this is a sample that was 
collected prior to BRAF +/-MEK targeted treatment, where the subject 
progressed on this targeted treatment, in cases where 1) fresh tissue or 2) 
archival tissue with no intervening local or systemic therap y is not possible to 
provide.
8. H ave resolution of toxic effect(s) of the most recent prior therapy to Grade 1 or less 
(except alopecia). If a subject received major surgery  or radiation therapy  of > [ADDRESS_725100] recovered from the toxicity  and/or complications from the 
intervention.
9.Be m ale or female subjects, age [ADDRESS_725101] an Eastern Cooperative Oncology Group ( ECOG )performance status [ADDRESS_725102]:   MK-3475 (SCH 900475), INCB 024360 55
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
Confidential12.If female of childbearing potential (Section 5.7.2 ),must have a negative urine or 
serum pregnancy  test within [ADDRESS_725103] will be required.  
13.If female of childbearing potential ( Section 5.7.2 ),must be willing to use an adequate 
method of contracep tion as outlined in Section 5.7.2 –Contraception, for the course 
of the study  through [ADDRESS_725104] dose of study  medication.
Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception 
for the subject.
14.If male of childbearing potential (Section5.7.2 ),must agree to use an adequate 
method of contraception as outlined in Section 5.7.[ADDRESS_725105] dose of study  therapy.
Note: Abstinence is acceptable if this is the usual lifesty le and preferred contraception 
for the subject.
Subject Exclusion Criteria 5.1.[ADDRESS_725106]:
1.Has received prior systemic treatment for unresectable or metasta tic melanoma 
(except BRAF directed therap y as noted in the third inclusion criteria ).
2.Has received p riortherapy  with an anti PD-1, anti PD-L1, antiPD-L2, antiCD137, 
or IDO1 inhibitor or any other antibod y or drug specifically  targeting checkpoint 
pathway s other than anti -CTL A-4 which is permitted in the adjuvant setting.
3.Has received p rior adjuvant therap y, monoclonal antibody ,chemotherapy ,or an 
investigational agent or device within 4 weeks or 5 half-lives (whichever is longer) 
before administra tion of study  drug or not recovered (≤ Grade 1 or at baseline) from 
AEs due to previously  administered agents. Exception to this rule would be use of 
denosumab, which is not excluded.
Note: Subjects with ≤ Grade 2 neuropath y are an exception and may enrol l.
4.Has a diagnosis of immunodeficiency  or is receiving chronic sy stemic steroid therapy  
(in dosing exceeding 10 mg daily  of prednisone equivalent) or any other form of 
immunosuppressive therapy within [ADDRESS_725107]:   MK -3475 (SCH 900475), INCB 024360 56
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
Confidential5.Has a known additional malignancy  that is progressing or requires active treatment. 
Exceptions include early stage cancers (carcinoma in situ or stage 1)
treated with 
curative intent, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, 
in situ cervical cancer, or in situ breast cancer that has undergone potentially  curative 
therap y. 
6.Has known active central nervous system (CNS) metastas es and/or carcinomatous 
meningitis. Subjects with previously  treated brain metastases may participate 
provided they are stable (without evidence of progression by [CONTACT_89181] [ADDRESS_725108] 
returned to baseline), have no evidence of new or enlarging brain metastases 
confirmed by [CONTACT_19406], and have not required steroids for at least [ADDRESS_725109] of excipi[INVESTIGATOR_840], refer to the respective Investigator 
Brochure (Section 3.3 )
.
9.Has an active autoimmune disease that has required sy stemic treatment in past 2 y ears 
(i.e. with use of disease modify ing agents, corticosteroids or immunosuppressive 
drugs). Replacement therapy  (e.g., thyroxine, insulin, or physiologic corticosteroid 
replacement thera py for adrenal or pi[INVESTIGATOR_90536] , etc.) is not considered a 
form of s ystemic treatment.
10.Has an a ctive infection requiring s ystemic therapy .
11.Has a known history  of human immunodeficiency  virus (HIV) (HIV 1/2 antibodies).
12.Has a known history  of or i s positive for Hepatitis B (HBsAg reactive) or Hepatitis C 
(HCV RNA [qualitative] is detected). Note: Without a know
nhistory , testing needs 
to be performed to determine eligibility .Hepatitis C Ab testing is allowed for 
screening purposes in countries where HCV RNA is not part of SOC.
13. H as a history  of (non-infectious) pneumonitis that required steroids or current 
pneumonitis.
14.Has received prior radiotherap y within [ADDRESS_725110] had radiation pneumonitis.  A
 1-week washout is permitted for palliative 
radiation (≤ 2 weeks of RT) to non -CNS disease. 
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 57
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-[ADDRESS_725111] dose of study treatment. 
Examples of live vaccines include, but are not limited to,the following: measles, 
mumps, rubella, chicken pox, yellow fever, rabies, Bacillus Calmette –Guérin (BCG), 
and typhoid vaccine.  Seasonal influenza vaccines for injection are generally  killed 
virus vaccines and are allowed; however, intranasal influenza 
vaccines (e.g., 
FluMist®) are live attenuated vaccines and are not allowed.
17.Has received monoamine oxidase inhibitors within [ADDRESS_725112] drug absorption.
20.Has a history or presence of an abnormal electrocardiogram (ECG) that, in the 
investigator's opi[INVESTIGATOR_1649], is clinically  meaningful.  Screening QTc interval > 480msec is 
excluded (corrected by [CONTACT_551696]).  In the event that a single QTc 
is > 480milliseconds, the subject may enroll if the average QTc for the 3 ECGs is < 
480milliseconds. 
21.Has c linicall ysignificant cardiac disease, including unstable angina, acute my ocardial 
infarction within [ADDRESS_725113]'s participation 
for the full duration of the study , or is not in the best interest of the subject to 
participate, in the opi[INVESTIGATOR_80021].
23.Has known psychiatric or substance abuse disorders that would interfere with 
cooperation with the requirements of the stud y.
24.Iscurrently  participating and receiving study  therapy or has participated in a study  of 
an investigational agent and received study therap yor used an investigation 
device within [ADDRESS_725114]:   MK-3475 (SCH 900475), INCB 024360 58
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
ConfidentialTrial Treatment(s) 5.2
The t reatments to be used i n this trial are outlined below in Table 1.
NOTE:  As of Amendment 10, only pembro lizumab will be administered. Other 
treatments (prior to this amendment) have been deleted.
Table 1 Trial Treatment
DrugDose/
PotencyDose 
FrequencyRoute of 
AdministrationRegimen/
Treatment Period Use
pembrolizumab 200 mg Every 3 weeks IV infusion Day 1 of each cycle 
for up to 35
pembrolizumab 
infusions 
(appr oximately 2
years)Experimental
Trial treatment for Cycle [ADDRESS_725115] y, storage, handling, distribution and usage of trial 
treatments in accordance with the protocol and an y applicable laws and regulations.
Dose Selection/Modification 5.2.1
[IP_ADDRESS] Dose Selection (Preparation)
The rationale for selection of doses to be used in this trial is provided in Section 4.0 –
Background & Rationale.  There are no specific calculations or evaluations required to be 
performed in order to administer the proper dose to each subject.
[IP_ADDRESS] Dose Modification (Escalation/Titration/Other)
NOTE:  As of Amendment 10, text in this section relating to dose modification of 
epacadostat is no longer applicable and has been deleted.
Dose mod ification and toxicity  management for immune -related AEs (irAEs) associated with 
pembrolizumab should be managed as follows.
Adverse events (both non -serious and serious) associated with pembrolizumab exposure may  
represent an immunologic etiology .  These irAEs may occur shortl y after the first dose or 
several months after the last dose of treatment and may affect more than one body  system 
simultaneously . Therefore, early recognition and initiation of treatment is critical to reduce  
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 59
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-[ADDRESS_725116] irAEs were reversible and could 
be managed with interruptions of pembrolizumab, administration of corticosteroids ,and/or 
other supportive care.  For suspected irAEs, ensure adequate evaluation to confirm etiology 
or exclude other causes.  Additional procedures or tests such as bronchoscopy , endoscop y, 
skin biopsy  may be included as part of the evaluation.  Based on the severit y of irAEs, 
withhold or permanentl y discontinue pembrolizumab and administer corticosteroids.
Table 2 summarize sthe irAE dose modification actions for pembrolizumab.
Except in cases of emergency , it is recommended that the investigator consult with the
medical monitor (or other representative of MSD ) before temporaril y interrupting therapy  for 
reasons other than protocol - mandated medication hold. 
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 60
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
ConfidentialTable 2 Dose Modification and Toxicity  Management Guidelines for Immune-related AEs Associated with Pembrolizumab 
NOTE:  As of Amendment 10, this table was replaced with the guidelines for pembrolizumab alone.
General instructions:
1.Corticosteroid taper should be initiated upon AE improving to Grade [ADDRESS_725117] dose or corticosteroids cannot be 
reduced to ≤[ADDRESS_725118] follow ed by  [CONTACT_44874]. Other immunosuppressive treatment should 
be initiated if irAEs cannot be controlled by [CONTACT_13216].
Immune -related 
AEsToxicity grade or 
conditions 
(CTCAEv4.0)Action taken to 
pembrolizumabirAE management with 
corticosteroid and/or other therapi[INVESTIGATOR_47418] -up 
Pneumonitis Grade 2 Withhold Administer corticosteroids (initial 
dose of 1 -2 mg/kg prednisone or 
equivalent) followed by [CONTACT_13217]Monitor participants for signs and 
symptoms of pneumonitis
Evaluate participants with suspected 
pneumonitis with radiographic imaging 
and initiate corticosteroid treatment
Add prophylactic antibiotics for 
opportunistic infectionsGrade 3 or 4, or 
recurrent Grade 2Perm anently discontinue
Diarrhea / Colitis Grade 2 or 3 Withhold Administer corticosteroids (initial 
dose of 1 -2 mg/kg prednisone or 
equivalent) followed by [CONTACT_13217]Monitor participants for signs and 
symptoms of enterocolitis (ie, diarrhea, 
abdominal pain, blood or mucus in stool 
with or without fever) and of bow el 
perforation (ie, peritoneal signs and ileus).
Participants with ≥ Grade 2 diarrhea 
suspecting colitis should consider GI 
consultation and performing endoscopy to 
rule out colitis. 
Participa nts with diarrhea/colitis should be 
advised to drink liberal quantities of clear 
fluids.  If sufficient oral fluid intake is not 
feasible, fluid and electrolytes should be 
substituted via IV infusion.Grade [ADDRESS_725119]:   MK -3475 (SCH 900475), INCB 024360 61
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
ConfidentialImmune -related 
AEsToxicity grade or 
conditions 
(CTCAEv4.0)Action taken to 
pembrolizumabirAE management with 
corticosteroid and/or other therapi[INVESTIGATOR_47418] -up 
AST / ALT 
elevation or 
Increased 
bilirubinGrade 2 Withhold Administer corticosteroids (initial 
dose of 0.5 -1 mg/kg prednisone or 
equivalent) followed by [CONTACT_13217]Monitor w ith liver function tests (consider 
weekly or more frequently until liver 
enzyme value returned to baseline or is 
stable ). Grade 3 or 4 Perm anently discontinue Administer corticosteroids (initial 
dose of 1 -2 mg/kg prednisone or 
equivalent) followed by [CONTACT_133390] 1 diabetes 
mellitus (T1DM) 
or 
HyperglycemiaNewly onset 
T1DM or 
Grade 3 or 4 
hyperglycemia 
associated with 
evidence of -cell 
failureWithhold Initiate insulin replacement therapy 
for participants with T1DM 
Administer anti -hyperglycemic in 
participants with hyperglycemia Monitor participants for hyperglycemia or 
other signs and symptoms of diabetes.
Hypophysitis Grade 2 Withhold Administer corticosteroids and 
initiate hormonal replacements as 
clinically indicated.  Monitor for signs and symptoms of 
hypophysitis (including hypopi[INVESTIGATOR_178870])
Grade 3 or 4 Withhold or permanently 
discontinue1
Hyperthyroidism Grade 2 Continue Treat w ith non -selective beta-
blockers (eg, propranolol) or 
thionamides as appropriate Monitor for signs and symptoms of thyroid 
disorders. 
Grade 3 or 4 Withhold or 
permanently 
discontinue1
Hypothyroidism Grade 2 -4 Continue Initiate thyroid replacement 
horm ones (eg, levothyroxine or 
liothyronine) per standard of careMonitor for signs and symptoms of thyroid 
disorders. 
Nephritis and 
Renal 
dysfunctionGrade 2 Withhold Administer corticosteroids 
(prednisone 1 -2 mg/kg or 
equivalent) followed by [CONTACT_13217].Monitor changes of renal function
Grade [ADDRESS_725120]:   MK -3475 (SCH 900475), INCB 024360 62
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
ConfidentialImmune -related 
AEsToxicity grade or 
conditions 
(CTCAEv4.0)Action taken to 
pembrolizumabirAE management with 
corticosteroid and/or other therapi[INVESTIGATOR_47418] -up 
Myocarditis Grade 1 or 2 Withhold Based on severity of AE administer 
corticosteroidsEnsure adequate evaluation to confirm 
etiology and/or exclude other causes
Grade 3 or 4 Perm anently discontinue
All other 
immune -related 
AEsIntolerable/ 
persistent Grade 2Withhold Based on type and severity of AE 
administer corticosteroids Ensure adequate evaluation to confirm 
etiology and/or exclude other causes
Grade 3 Withhold or discontinue 
based on the type of 
event.  Events that 
require discontinuation 
include and not limited 
to:  Guillain -Barre 
Syndrome, encephalitis
Grade 4 or 
recurrent Grade 3 Perm anently discontinue
1.Withhold or permanently discontinue pembrolizumab is at the discretion of the investigator or treating physician.  
NOTE: 
For participants with Grade 3 or 4 immune -related endocrinopathy where w ithhold of pembrolizumab is required, pembrolizumab may be resumed when 
AE resolves to ≤ Grade 2 and is controlled w ith hormonal replacement therapy or achieved metabolic control (in c ase of T1DM).   
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 63
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
Confidential5.2.1.3 Dose Modification and Toxicity Management of Infusion -reactions Related to 
Pembrolizumab
Pembrolizumab may cause severe or life threatening infusion- reactions including severe 
hypersensitivity  or anaphy laxis.  Signs and symptoms usually  develop during or shortly  after 
drug infusion and generally  resolve completel y within 24 h ours of completion of infusion.
Table 3shows treatment guidelines for subjects who experience an infusion reaction 
associated with administration of pembrolizumab (MK -3475).
Table 3 Infusion Reaction Treatment Guidelines
NCI CTCAE Grade TreatmentPremedication at 
subsequent dosing
Grade 1
Mild reaction; infusion 
interruption not indicated; 
intervention not indicatedIncrease monitoring of vital signs as 
medically indicated until the subject 
is deemed medically stable in the 
opi[INVESTIGATOR_871].None
Grade 2
Requires therapy or infusion 
interruption but responds 
promptly to symptomatic 
treatment (e.g., 
antihistamines, NSAIDS, 
narcotics, IV f luids); 
prophylactic medications 
indicated for ≤24 hrsStop Infusion and monitor 
symptoms.
Additional appropriate medical 
therapy may include but is not 
limited to:
IV fluids
Antihistamines
NSAIDS
Acetaminophen
Narcotics
Increase monitoring of vital signs as 
medically indicated until the subject 
isdeemed medically stable in the 
opi[INVESTIGATOR_871].
If symptoms resolve within one hour 
of stoppi[INVESTIGATOR_13056], the 
infusion may be restarted at 50% of 
the original infusion rate (e.g., from 
100 mL/hr to 50 mL/hr).  Otherwise 
dosing will be hel d until symptoms 
resolve and the subject should be 
premedicated for the next scheduled 
dose.
Subjects who develop Grade [ADDRESS_725121] may be 
premedicated 1.5h (± 30 
minutes) prior to infusion 
of pembrolizumab (MK -
3475) with:
Diphenhydramine 50 mg 
po (or equivalent dose of 
antihistamine).
Acetaminophen 500-1000 
mg po (or equivalent dose 
of antipyretic). 
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 64
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
ConfidentialNCI CTCAE Grade TreatmentPremedication at 
subsequent dosing
Grades 3 or 4
Grade 3:
Prolonged (i.e., not rapi[INVESTIGATOR_38194]/or brief 
interruption of infusion); 
recurrence of symptoms 
following initial 
improvement; hospi[INVESTIGATOR_260711] (e.g., renal 
impairment, pulmonary 
infiltrates)
Grade 4:
Life-threatening; pressor or 
ventilatory support indicatedStop Infusion.
Additional appropriate medical 
therapy may include but is not 
limited to:
Epi[INVESTIGATOR_238]**
IV fluids
Antihistamines
NSAIDS
Acetaminophen
Narcotics
Oxygen
Pressors
Corticosteroids
Increase monitoring of vital signs as 
medically indicated until the subject 
is deemed medically stable in the 
opi[INVESTIGATOR_871].
Hospi[INVESTIGATOR_13021].
**In cases of anaphylaxis, 
epi[INVESTIGATOR_13022].
Subject is permanently 
discontinued from further trial 
treatment administration.No subsequent dosing.
Appropriate resuscitation equipment should be available at the bedside and a physician readily 
available during the period of drug administration
For further information, please refer to the Common Term inology Criteria for Adverse Events v4.0 
(CTCAE) at http://ctep.cancer.gov
CTCAE=Common Term inology Criteria for Adverse Events, NCI=National Cancer Institute, 
NSAID=non -steroidal anti -inflammatory drug, po=oral  
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 65
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
Confidential5.2.1.4 Procedures for Subjects Exhibiting Serotonin Syndrome (SS)
NOTE: As of Amendment 10, this section is no longer applicable.
There is a rare chance that epacadostat could cause an increase in serotonin levels in the brain 
that might trigger serotonin syndrome [53], (Section 12.8) when administered in combination 
with other serotonergic agents.  This syndrome has been most closely  associated with use of 
MAOIs, meperidine , linezolid, or methy lene blue; all of these agents are prohibited during 
the study (Section 5.5.3).  Serotonin reuptake inhibitors (SSRI s )and 
serotonin/norepi[INVESTIGATOR_5608] (SNRI s) are permitted in the study .  Serotonin 
syndrome usually  manifests with autonomic changes, mental status changes, and 
neurological findings.  These mild, moderate, and severe signs and symptoms of SS 
(summarized inTable 4) should be evaluated in the context of possible comorbid conditions 
as well .
The following procedures will be implemented if subject s exhibit the signs/sy mptoms of SS
, 
includi ng tremor; hyperreflexia; spontaneous, ocular, or inducible clonus; together with 
agitation, fever, diaphoresis, or muscle rigidit y:
Immediately  interrupt epacadostat or matching placebo and pembrolizumab 
administration.  
Immediately  interrupt any  SSRI  orSNRI  administration.
Provide appropriate medical management of the subject until all signs/sy mptoms are 
resolved (e.g., IV fluids and/or sympathomimetic amines for hypotension, 
benzodiazepi[INVESTIGATOR_165836], administration of 5-hydroxy tryptamine antagonis ts such as 
cyproheptadine).
If etiologies other than SS are excluded, pembrolizumab administration may be resumed 
unless other AE management guidelines appl y for the specific event.
If subject chooses to remain in the study , restart treatment with epacados tator matching 
placebo after the SSRI  or SNRI  has been discontinued, no sooner than 5half-lives have 
elapsed for the specific SSRI  or SNRI in question, and after resolution of signs/s ymptoms 
of SS.  The SSRI  or SNRI dosing MAY NOT be restarted.
If subjec tchoo ses to withdraw from the study , ormust restart treatment with SSRI  or 
SNRI , the subject should be scheduled for a follow -up visit. .  Treatment with SSRI  or 
SNRI  may  be initiated 2 weeks after resolution of signs and s ymptoms of SS.
If a subject had experienced moderate or severe unconfounded SS in the opi[INVESTIGATOR_1070], without concomitant SSRI  or SNRI  usage, or serotonergic concomitant 
medications, only pembrolizumab administration may be resumed; epacadostat/placebo 
treatment should be pe rmanently  discontinued. 
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 66
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
ConfidentialTable 4 Sign and Sy mptoms of Serotonin Sy ndrome
Seriousness Autonomic signs                             Neurological signs                  Mental status                               Other
Mild Afebrile or low-grade 
fever
Tachycardia
Mydriasis
Diaphoresis or shiveringIntermittent tremor
Akathisia
Myoclonus
Mild hyperreflexiaRestlessness
Anxiety
Moderate Increased tachycardia
Fever (up to 41 °C)
Diarrhea with hyperactive 
bowel sounds
Diaphoresis with normal 
skin colorHyperreflexia
Inducible clonus
Ocular clonus (slow 
continuous lateral eye 
movements)
MyoclonusEasily startled
Increased 
confusion
Agitation and 
hypervigilanceRhabdomyolysis
Metabolic acidosis
Renal failure
Disseminated 
intravascular 
coagulopathy 
(secondary to 
hyperthermia)
Severe Temperature often more 
than 41°C (Secondary to 
increased tone)Increased muscle tone 
(lower limb > upper)
Spontaneous clonus
Substantial myoclonus 
or hyperreflexiaDelirium
Com aAs above
Source: [62]
[IP_ADDRESS] Dose Interruptions Unrelated to Adverse Events
Dosing interruptions are permitted for situations other than treatment -related AEs, such asin 
the case of medical / surgical events or logistical reasons (i.e., elective surgery , unrelated 
medical events, patient vacation, holiday s) not related to study  therap y.  Subjects should be 
placed back on study  therap y within 3weeks of the scheduled interruption , unless otherwise 
discussed with MSD .  The reason for interruption should be documented in the subject's 
study  record.
Timing of Dose Administration 5.2.2
[IP_ADDRESS] Timing of Dose Administration of Pembrolizumab
Study  treatment with pembrolizumab should be administered on Day  1 of each cycle after all 
procedures/assessments have been completed as detaile d in the Trial Flow Chart ( Section
6.0).  All study  treatments will be administered on an outpatient basis.
Study  treatment of pembrolizumab may be administered up to 3 days before or after the 
scheduled Day  1 of each cy cle due to administrative reasons except for Cycle 1 Day  1, whe re 
window is + [ADDRESS_725122]:   MK-3475 (SCH 900475), INCB 024360 67
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
ConfidentialPembrolizumab will be administered as a dose of 200 mg using a 30-minute IV infusion.  
Sites should make every effort to target infusion timing to be as close to 30 minutes as 
possible.  However, given the variabil ity of infusion pumps from site to site, a window of -5 
minutes and +10 minutes is permitted ( i.e., infusion time is 30 minutes -5 min/+10 min). 
The Pharmacy Manual contains specific instructions for pembrolizumab dose calculation, 
reconstitution, prepara tion of the infusion fluid, and administration.
Trial Blinding 5.2.3
NOTE:  As of Amendment 10, blinding is no longer applicable –all subjects will receive open -
label pembrolizumab alone.
A double -blinding technique with in-house blinding will be used.  Epacadostat and matching 
place bo will be packaged identicall y so that blind is maintained. The subject, the 
investigator , and Sponsor and MSD study  personnel or delegate(s) who are involved in the 
administration of epacadostat or matching placebo or clinical evaluation of the subjects are 
unaware of the group assignments.
Randomization or Treatment Allocation 5.3
Treatment allocation/r andomization will occur centrally  using aninteractive voice response 
system / integrated web response system (IVRS/I WRS). There are 2treatment arms.  
Subjects will be assigned randoml y in a1:1ratio to pembrolizumab + epacadostat or
pembrolizumab + matching placebo , respectivel y.  No treatment crossover is planned.  
Stratification 5.4
Subjects will be stratified by:  
[CONTACT_551697]-L1 expression
oPositive (≥1% of tumor and associated immune cells display ing PD-L1 
expression as determined by [CONTACT_9064] )
oNegative ( <1% expression /indeterminate )
oBRAF mutation status
oBRAF mutant and received prior BRAF directed treatment 
oBRAF mut ant and received no prior BRAF directed treatment
oBRAF wild t ype
Recently  acquired or archived tumor tissue (obtained since most recent therap y)from an 
unresectable or metastatic site must be analy zed and be evaluable for PD-L1 status during  
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 68
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-[ADDRESS_725123] of care.
Concomitant Medications /Vaccinations (Allowed & Prohibited ) 5.5
Medications or vaccinations specifically  prohibited in the exclusion criteria are not allowed 
during the ongoing trial.  If there is a clinical indication for any medication or vaccination 
specificall y prohibited during the trial, discontinuation from trial therapy  or vaccination may 
be required.  The investigator should discuss any questions regarding this with the MSD
Clinical Director.  The final decision on any supportive therap y or vaccination rests with the 
investigator and/or the subject's primary  physician.  However, the decision to continue the 
subject on trial therapy or vaccination schedule requires the mutual agreement of the 
investigator, the MSD Clinical Director and the subject.
Acceptable Concomitant Medications 5.5.[ADDRESS_725124]'s welfare may be 
administered at the discretion of the investigator in keepi[INVESTIGATOR_449676].  All concomitant medication will be recorded on the electronic Case Report 
Form (eCRF ), including all prescription, over-the-counter, herbal supplements, and IV 
medications and fluids.  If changes occur during the study  period, documentation of drug 
dosage, frequency , route, and date may  also be included on the eCRF.
All concomitant medications received within [ADDRESS_725125] dose of study  treatment should be 
recorded for SAEs and AEs as defined in Section 7.2.
Prohibited Medications and Measures 5.5.2
NOTE:  As of Amendment 10, prohibited concomitant medications that were specific to 
epacadostat administration were deleted.
Subjects are prohibited from receiving the following therapi[INVESTIGATOR_551666]:
Any investigational medication other than the study  drugs.
Antineoplastic sy stemic chemotherap y or biologic therap y.
Immunotherapy not specified in this protocol .
Chemotherap y not specified in this protocol. 
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 69
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
ConfidentialAny chronic immunological -suppressive treatment for any reason other than the 
management of adverse events, as described in Section 5.6.  (NOTE: Inhaled or 
topi[INVESTIGATOR_14271], and s ystemic steroids a t doses ≤ 10 mg/day  prednisone or 
equivalents are allowed, as described in Sectio n5.6, and immune suppressants are 
allowed as proph ylaxis for contrast allergy  for imaging procedures.)
Radiation therap y or surgery
Note: In the presence of a mixed response (some lesions improving or stable and 
other lesions progressing), radiation therapy  or surgery  to a symptomatic solitary 
lesion or to the brain is allowed , with MSD consultation . No pembrolizumab 
infusions are permitted during radiation therap y or procedure.  Study medications 
may be resumed as early  as [ADDRESS_725126]’s symptoms are 
improving and not requiring corticosteroids for management. If study  medicat ions 
are not resumed within [ADDRESS_725127] should 
discontinue study  treatment permanentl y.
Administration of a live attenuated vaccine within [ADDRESS_725128] dose of 
study  treatment and while participating in the study.  Examples of live vaccines 
include, but are not limited to, the following: measles, mumps, rubella, chicken pox, 
yellow fever, rabies, BCG, and typhoid vaccine.  Seasonal influenza vaccines for 
injection are generally  killed virus vaccines and are allow ed; however, intranasal 
influenza vaccines ( e.g., FluMist®) are live attenuated vaccines and are not allowed.
Subjects who, in the assessment by [CONTACT_093], require the use of any of the 
aforementioned treatments for clinical management should be removed from the study
treatment .  Subjects may receive other medications that the investigator deems to be 
medically  necessary .
The exclusion criteria (Section 5.1.3 ) describe other medications that are prohibited during 
this study .  There are no prohibited therapi[INVESTIGATOR_77983] -treatment follow -up phase.
Rescue Medications & Supportive Care 5.6
Supportive Care Guidelines for Pembrolizumab 5.6.1
Subjects should receive appropriate supportive care measures as deemed necessary  by [CONTACT_78017].  Suggested supportive care measures for the management of AEs with 
potential immunologic etiology  are outlined along with the dose modificatio n guidelines in 
Section [IP_ADDRESS] . Where appropriate, these guidelines include the use of oral or IVtreatment 
with corticosteroids as well as additional anti-inflammatory  agents if symptoms do not 
improve with admi nistration of corticosteroids. Note that several courses of steroid tapering 
may be necessary  as symptoms may worsen when the steroid dose is decreased. For each 
disorder, attempts should be made to rule out other causes such as metastatic disease or
bacterial or viral infection, which might require additional supportive care. The treatment  
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 70
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
Confidentialguidelines are intended to be applied when the investigator determi nes the events to be 
related to pembrolizumab. 
Note: if after the evaluation the event is determined not to be related to pembrolizumab , the 
investigator does not need to follow the treatment guidance. Refer to Table 2and Table 3in 
Section [IP_ADDRESS] for guidelines regarding dose modification and supportive care. 
It may be necessary  to perform conditional procedures such as bronchoscopy , endoscop y, or 
skin photograph y as part of evaluation of the event. 
Diet/Activity/Other Considerations 5.7
Diet 5.7.1
Subjects should maintain a normal diet unless modifications are required to manage an AE 
such as diarrhea, nausea, or vomiting.
Contraception 5.7.2
Pembrolizumab may haveadverse effects on a fetus (unborn baby ) in utero .  Furthermore, it 
is not known if pembrolizumab ha s transient adverse effects on the composition of sperm.  
For this trial, male subjects will be considered to be of non-reproductive potential if they 
have azoospermia (whether due to having had a vasectom y or due to an underly ing medical 
condition).  
Female subjects will be considered of non -reproductive potential if they  are either: 
1)postmenopausal (defined as at least 12 months with no menses without an alternative 
medical cause; in women < 45 y ears of age a high follicle stimulating hormone (FSH) 
level in the postmenopausal range may be used to confirm a post-menopausal state in 
women not using hormonal contraception or hormonal replacement therapy . In the 
absence of 12 months of amenorrhea, a single FSH measurement is insufficient.); 
OR 
2)have had a hysterectomy  and/or bilateral oophorectom y, bilateral salpi[INVESTIGATOR_551667]/occlusion, at least 6 weeks prior to screening; 
OR 
3)has a congenital or acquired condition that prevents childbearing. 
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 71
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-[ADDRESS_725129] ying with one of the following:  
1) practice abstinence† from heterosexual activit y; 
OR 
2)use (or have their partner use) acceptable contraception during heterosexual activity .  
Acceptable methods of contraception are‡:
Single method (one of the following is acceptable):
• Intrauterine device (IUD)
• V asectom y of a female subject’s male partner 
• Contraceptive rod implanted into the skin
Combination method (requires use of two of the following):
• Diaphragm with spermicide (cannot be used in conjunction with cervical cap/spermicide)
• C ervical cap with spermicide (nulliparous women only )  
• C ontraceptive sponge (nulliparous women only ) 
• Male condom or female condom (cannot be used together)
• H ormonal contraceptive: oral contraceptive pi[INVESTIGATOR_4382] (estrogen/progestin pi[INVESTIGATOR_64870] -only 
pi[INVESTIGATOR_4382]), contraceptive skin patch, vaginal contraceptive ring, or subcutaneous contraceptive 
injection
†Abstinence (relative to heterosexual activity ) can be used as the sole method of 
contraception if it is consistently  employ ed as the subject’s preferred and usual lifesty le and 
if considered acceptable by [CONTACT_551698]/I RBs.  Periodic abstinence 
(e.g., calendar, ovulation, sympto -thermal, post-ovulation methods, etc.) and withdrawal are 
not acceptable methods of contraception. 
‡If a contraceptive method listed above is restricted by [CONTACT_427]/guidelines, then it 
does not qualify  as an acceptable method of contraception for subjects participating at sites in 
this country /region.
Subjects should be informed that taking the study  medication may involve unknown risks to 
the fetus (unborn baby) if pregnancy  were to occur during the study .  In order to participate 
in the study  subjects of childbearing potential must adhere to the contraception requirement 
(described above) from the day of study  medication initiation (or [ADDRESS_725130]:   MK-3475 (SCH 900475), INCB 024360 72
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
Confidentialinitiation of study  medication for oral contraception) throughout the study period up to [ADDRESS_725131] should 
not be entered into the study .
Below are the required contraceptions for countries where the health authority  requests 
compliance with the Clinical Trial Facilitation G roup (CTFG) Guidance:
Subjects should use birth control methods that can achieve a failure rate of less than 1% per 
year when used consistently  and correctl y and are considered as highly  effective birth control 
methods. Such methods include:
Combined (estrogen and progestogen containing) hormonal contraception associated 
with inhibition of ovulation:
oOral
oIntravaginal
oTransdermal
Progestogen -only hormonal contraception associated with inhibition of ovulation:
Oral
Injectable
Implantable
oIntrauterine device (IUD)
oIntrauterine hormone -releasing s ystem (IUS)
oBilateral tubal occlusion
oVasectomised partner
oSexual abstinence
Pregnancy 5.7.[ADDRESS_725132]’ s status until the pregnancy  has been completed or 
terminated. The outcome of the pregnancy  will be reported to MSD without delay  and within 
24 hours if the outco me is a serious adverse experience (e.g., death, abortion, congenital 
anomaly , or other disabling or life-threatening complication to the mother or newborn). The 
study  investigator will make every  effort to obtain permission to follow the outcome of the 
pregnancy  and report the condition of the fetus or newborn to MSD . If a male subject 
impregnates his female partner, the study  personnel at the site must be informed immediately 
and the pregnancy  must be reported to MSD and follow ed as described in Section 7.2. 
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 73
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-[ADDRESS_725133] Withdrawal/Discontinuation Criteria 5.[ADDRESS_725134] may  be 
withdrawn by [CONTACT_551699], the trial 
plan is violated, or for administrative and/or other safet y reasons.  Specific details regarding 
discontinuation or withdrawal procedures ;  
are provided in Section 7.1.7–Other Procedures.
Discontinuation of Treatment 5.8.[ADDRESS_725135]’s last scheduled follow -up, even if the 
subject has discontinued treatment .  Therefore, all subjects who discontinue trial treatment
prior to completion of the treatment period will still continue to participate in the trial as 
specified in Section 6.0 -Trial Flow Chart and Section [IP_ADDRESS] – Post-Trial .
Subjects may discontinue treatment at any time for any reason or be dropped from treatment
at the discretion of the investigator should any untoward effect occur.  In addition, a subject 
may be discontinued from treatment by [CONTACT_551700], 
the trial plan is violated, or for administrative and/or other safety reasons.  Specific details 
regarding procedures to be performed at treatment discontinuation are provided in Section 
7.1.7 –Other Procedures.
A subject must be discontinued from treatment but continue to be monitored in the trial for 
any of the follow ing reasons:
The subject or subject’s legally  acceptable representative requests to discontinue 
treatment .
oThe subject has a medical condition or personal circumstance which, in the opi[INVESTIGATOR_19348]/or MSD, placed the subject at unnecessary  risk from continued 
administration of study  drug/vaccine.
oThe subject has a confirmed positive serum pregnancy  test.
oConfirmed radiographic disease progression outlined in Section 7.1.5 (exception if 
MSD approves treatment continuation).
oUnacceptable adver se experiences as described in Section 7.[ADDRESS_725136]:   MK -3475 (SCH 900475), INCB 024360 74
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
ConfidentialoAny progression or recurrence of any malignancy , or any occurrence of another 
malignancy  that requires active treatment . Note: For [LOCATION_009] only, a subject 
experiencing this condition must be discontinued from the trial.
oIntercurrent illness other than another malignancy  as noted above that prevents 
further administration of treatment.
oRecurrent Grade 2 pneumonitis .
oAny toxicity  listed in Section [IP_ADDRESS], Table 2, with a requirement to permanentl y 
discontinue .
oNon-
compliance with trial treatment or procedure requirements .
oInvestigator’s decision to discontinue treatment .
oAdministrative reasons
.
oCompleted 35 treatments with pembrolizumab.
Note: 35 cy cles (approximately . 2 years) are calculated from the first dose.  
oDiscontinuation of treatment may be considered for subjects who have attained a 
confirmed CR and have been treated for at least 8 cycles (at least 24 weeks) and had 
at least 2 cycles of the combination (at least 2 doses of pembrolizumab) beyond the 
date when the initial CR was declared. 
The End of Treatment and Follow -up visit procedures are listed in Sections [IP_ADDRESS] and the 
Trial Flow Chart -Section 6.0.  
For subjects who are discontinued from treatment but continue to be monitored in the trial, 
see Section 6.0 – Trial Flow Chart, and Section [IP_ADDRESS] – Post-Trial for those procedures to 
be completed at each specified visit. 
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 75
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-[ADDRESS_725137]’s legally  acceptable 
representative withdraws consent from the trial.
For [LOCATION_009] only: A subject must be discontinued from the trial for the following reason:
Any progression or recurrence of another malig nancy , or any occurrence of another 
malignancy  that requires active treatment.
If a subject withdraws from the trial, they will no longer receive treatment or be followed at 
scheduled protocol visits.
Specific details regarding procedures to be performed a t the time of withdrawal from the trial 
including the procedures to be performed should a subject repeatedl y fail to return for 
scheduled visits and/or if the study  site is unable to contact [CONTACT_423],  
 are outlined in Section 7.1.7
–Other Procedures.
Subject Replacement Strategy 5.[ADDRESS_725138] to follow -up (i.e. the subject is unable to be contact[CONTACT_551701]).
Clinical Criteria for Early Trial Termination 5.11
The clinical trial may be terminated early if the extent (incidence and/or severity ) of 
emerging effects/clinical endpoints is such that the risk/benefit ratio to the trial population as 
a whole is unacceptable.  In addition, further recruitment in the trial or at (a) particular trial 
site(s) may be stopped due to insufficient compliance with the protocol, GCP and/or other 
applicable regulatory  requirements, procedure -related problems or the number of 
discontinuations fo r administrative reasons is too high.
Early trial termination will be the result of the criteria specified below:
The investigator retains the right to terminate study  participation at any  time, according to the 
terms specified in the study  contract.  The investigator is to notify  the IRB or independent 
ethics committee (IEC) in writing of the study 's completion or early  termination, and send a 
copy  of the notification to MSD or MSD designee and retain 1copy for the site study 
regulatory  file. 
  04XN7M

Product:   MK -3475 (SCH 900475), INCB 024360 76
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
ConfidentialMSD in collaboration with the Sponsor may terminate the study  electively , if required by 
[CONTACT_551702], or upon advice of the DMC.  If the study  is terminated prematurel y, the 
investigators, the IRBs and IECs, and regulatory  bodies will be notified of the decision and 
reason for termination of the study .  The DMC will recommend termination of the study  if 
warranted, as described in 
Section 8.2.
In addition, earl y stud y termination may occur based on clinical criteria specified below:
1.Quality  or quantity  of data recording is inaccurate or incomplete;
2.Poor adherence to Protocol and regulatory  requirements;
3.Incidence or severit y of adverse drug reaction in this or other studies indicates a 
potential health hazard to subjects;
4.Plans to modify  or discontinue the d
evelopment of the study  drug.
In the event of a decision to no longer supply  study  drug, ample notification will be provided 
so that appropriate adjustments to subject treatment can be made. 
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 77
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-[ADDRESS_725139] been deleted .
Screening 
Phase Treat ment CyclesEnd of Treatment 
(EOT) Post-treatment
Treat ment Cycle Screening 
(Visit 1) [ADDRESS_725140]-
discontinuation
Scheduling Window (Days)a-28 to -1 ± 3 ± 3 ± 3 ± 5 + 7
Administrative Procedures
Informed Consent X
Inclusion/Exclusion Criteria X
Subject Identification Card X
Demographics and Medical History X
Prior and Concomitant Medication Review X X X X X X X
Post-study Anticancer Therapy Status X X
Clinical Procedures/Assessments
Review Adverse Events X X X X X X X
Full Physical Examination X
Directed Physical Examination X X X X XkXk 
  04XN7M

Product:   MK -3475 (SCH 900475), INCB 024360 78
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301-10) Final Protocol 18-May- 2018
ConfidentialScreening 
Phase Treat ment CyclesEnd of Treatment 
(EOT) Post-treatment
Treat ment Cycle Screening 
(Visit 1) [ADDRESS_725141]-
discontinuation
Scheduling Window (Days)a-28 to -1 ± 3 ± 3 ± 3 ± 5 + 7
Height, Weight, and Vital Signs (T,P,RR,BP)bX X X X X X X
12-Lead Electrocardiogram (Local)iX X X Xk
BRAF Testing Xj
ECOG Performance Status XjX X X X X X
Trial Treat ment Administration
Pembrolizumab Administration XaX X X
Laboratory Procedures/Assessments:  Analysis 
performed by [CONTACT_551703] X X X Xk
PT/INR and aPTT XcXkXk
CBC with Differential XcX X Xk
Chemistry Panel XcX X Xk
Urinalysis XcX Xk
T3, FT4, and TSH XcX Xk
Hepatitis B and C TestinglX
Laboratory Procedures/Assessments: Analysis 
performed by [CONTACT_551704]/REFERAL laboratory 
  04XN7M

Product:   MK -3475 (SCH 900475), INCB 024360 79
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
ConfidentialScreening 
Phase Treat ment CyclesEnd of Treatment 
(EOT) Post-treatment
Treat ment Cycle Screening 
(Visit 1) [ADDRESS_725142]-
discontinuation
Scheduling Window (Days)a-28 to -1 ± 3 ± 3 ± 3 ± 5 + [ADDRESS_725143] be given within 3 days of allocation. The window for each visit is ± [ADDRESS_725144] be excluded/discontinued in the event of a positive test result.  
e. Newly -obtained tissue is preferred (no intervening treatment [local or systemic] involving the site of tissue biopsy once tissue biopsy is obtained at time of study 
enrollment). Formalin -fixed, paraffin -embedded (FFPE) block specimens are preferred to slides.
f. Archived tissue samples obtained since last treatment may be acceptable.  Refer to Section 7.1.[ADDRESS_725145] 
throughout the study.  Local reading (investigator assessment with site radiology reading) will be used to determine eligibil ity and for subject management.
h. Imaging timing should be performed according to the site’s standard of care for tumor assessment until initial PD per RECIST 1.1. A repeat scan at least 4weeks later per 
irRECIST is not required if the investigator opts to discontinue the subject at the initial PD.
i. Baseline ECGs will be obtained at screening, with additional ECGs obtained at EOT, and as clinically indicated for all subjects. At select centers, additional ECGs will 
also be obtained at Cycle [ADDRESS_725146]:   MK -3475 (SCH 900475), INCB 024360 80
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301-10) Final Protocol 18-May- 2018
ConfidentialScreening 
Phase Treat ment CyclesEnd of Treatment 
(EOT) Post-treatment
Treat ment Cycle Screening 
(Visit 1) [ADDRESS_725147]-
discontinuation
Scheduling Window (Days)a-28 to -1 ± 3 ± 3 ± 3 ± 5 + [ADDRESS_725148] of care or as clinically indicated .
l. Hepatitis B and C serologies should be obtained for subjects without a known history of Hepatitis B or C.  Those with a known history are ineligible. Include HCV RNA 
(qualitative), HBsAg.  See Table 6for list of laboratory tests.  Hepatitis C Ab testing is allowed for screening purposes in countries where HCV RNA is not part of SOC.  
Hepatitis B and C testing should be performed within the [ADDRESS_725149] of C/A/P with contrast are mandatory at baseline, and at minimum, CT of known sites of disease be performed at all follow -up assessments. 
  04XN7M

Product:   MK-3475 (SCH 900475), INCB 024360 81
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
Confidential7.0TRIAL PROCEDURES
Trial Procedures 7.1
The Trial Flow Chart -Section 6.0summarizes the trial procedures to be performed at each 
visit.  Individual trial procedures are described in detail below.  It may be necessary  to 
perform these procedures at unscheduled time points if deemed clinically necessary  by [CONTACT_31035].
Furthermore, additional evaluations/testing may  be deemed necessary  by [CONTACT_551705] y. In some cases, such evaluation/testing may be 
potentially  sensitive in nature (e.g., HIV, Hepatitis C, etc.), and thus local regulations may 
require that additional informed consent be obtained from the subject.  In these cases, such 
evaluations/testing will be performed in accordance with those regulations.
Administrative Procedures 7.1.1
[IP_ADDRESS] Informed Consent
The investigator or qualified designee must obtain documented consent from each potential 
subject or each subject’s legally  acceptable representative prior to participating in a clinical 
trial .If there are changes to the subject’s status during the 
trial (e.g. ,health or age of majority  requirements ), the investigator or qualified designee must 
ensure the ap propriate consent is in place. 
[IP_ADDRESS].[ADDRESS_725150]’s dated signature [INVESTIGATOR_4388] [CONTACT_423]’s legally 
acceptable representative’s dated signature [INVESTIGATOR_2394] a consent form along with the dated signature 
[CONTACT_63564]. 
A copy  of the signed and dated consent form should be given to the subject before 
participation in the trial.
The initial informed consent form, any subsequent revised written informed consent form 
and any written information provided to the subject must receive the IRB/ERC’s 
approval/favorable opi[INVESTIGATOR_19349].  The subject or his/her legally acceptable 
representative should be informed in a timel y manner if new information becomes available 
that may be relevant to the subject’s willingness to continue participation in the trial.  The 
communication of this information will be provided and documented via a revised consent 
form or addendum to the original consent form that captures the subject’s dated signature [CONTACT_90096] [CONTACT_423]’s legall y acceptable representative’s dated signature.
Specifics about a trial and the trial population will be adde d to the consent form template at 
the protocol level.   
  04XN7M

Product:   MK -3475 (SCH 900475), INCB 024360 82
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301-10) Final Protocol 18-May- 2018
ConfidentialThe informed consent will adhere to IRB/ERC requirements, applicable laws and regulations.
[IP_ADDRESS] Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by  [CONTACT_26358].
[IP_ADDRESS] Subject Identification Card
All subjects will be given a Subject Identification Card identify ing them as participants in a 
research trial. The card will contain trial site contact [CONTACT_3031] (including direct telephone 
numbers) to be utilized in the event of an emergency . The investigator or qualified designee 
will provide the subject with a Subject Identification Card immediately  after the subject 
provides written informed consent. At the time of treatment allocation/randomization, site 
personnel will add the treatment/randomization number to the Subject Identification Card.
The subject identification card also contains contact [CONTACT_75345] a health care provider can obtain information about trial 
medication/vaccination in emergency  situations where th e inves tigator is not available.
[IP_ADDRESS] Medical History
A medical history  will be obtained by  [CONTACT_27404]. Medical history
will include all active conditions, and any condition diagnosed within the prior [ADDRESS_725151]’s melanoma will be recorded separatel y and not listed as medical history.
[IP_ADDRESS] Prior and Concomitant Medications Review
[IP_ADDRESS].[ADDRESS_725152] dose of trial treatment.
[IP_ADDRESS].[ADDRESS_725153]:   MK -3475 (SCH 900475), INCB 024360 83
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
ConfidentialAll medications related to reportable SAEs and ECIs should berecorded as defined in 
Section 7.2.
[IP_ADDRESS]
Assignment of Sc reening Number
All consented subjects will be given a unique screening number that will be used to identify 
the subject for all procedures that occur prior to randomization or treatment allocation.  Each 
subject will be assigned only one screening number. Screening numbers must not be re -used 
for different subjects.
Any subject who is screened multiple times will retain the original screening number 
assigned at the initial screening visit.
Specific details on the screening visit requirements (screening/res creening) are provided in 
Section [IP_ADDRESS].  
[IP_ADDRESS] Assignment of Treatment/ Randomization Number
All eligible subjects will be randoml y allocated and will receive a treatment/
randomization 
number.  The treatment/randomization number identifies the subject for all procedures 
occurring after treatment allocation/ randomization.  Once a treatment/ randomization number 
is assigned to a subject, it can never be re -assigned to another subject.
A single subject cannot be assigned more than 1 treatment/randomization number.
The IVRS/I WRS will be contact[CONTACT_147101] a subject identification number when a subject 
enters the screening phase.  Upon determining that the subject is eligible for study  entry, the 
IVRS/I WRS will be contact[CONTACT_551706].  Additionally , the 
IVRS/I WRS will be contact[CONTACT_551707] y.
[IP_ADDRESS] Trial Compliance (Medicat ion)
Administration of trial medications and complian ce are provided in Sections [IP_ADDRESS].
NOTE:  As of Amendment 10, text in this section relating to epacadostat is no longer 
applicable and has been deleted.
Interruptions from the protocol specified treatment plan for > 12weeks between 
pembrolizumab doses due to toxicity require consultation between the investigator and MSD
and written documentation of the collaborative decision on subject management.
Administration of pembrolizumab will be witnessed by [CONTACT_1755]/or trial staff.    
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 84
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
Confidential7.[IP_ADDRESS] Administration of Pembrolizumab and Compliance
Administration of pembrolizumab (± 3 days) will be witnessed by [CONTACT_1755]/or 
study  staff.  The total volume of study  treatment infused will be compared to the total volume 
prepared to determine compliance with eac h dose administered.
The instructions for preparing and administering pembrolizumab will be provided in the 
Pharmacy Manual.
[IP_ADDRESS].[ADDRESS_725154] the assigned vials and dispense the medication.   At subsequent 
medication dispensing visits, the investigator or designee will follow the same procedures as 
described a bove.  Full details will be provid ed in the IVRS Manual.
[IP_ADDRESS].[ADDRESS_725155] Reminder Cards and Serotonin Syndrome (SS)
Information Sheet
NOTE:  As of Amendment 10, this section is no longer applicable.
Subjects will be provided with reminder cards to remind the subject when they should not 
take their morning dose of epacadostat or matching placebo .  On Cycle 1 Day 1,subjects will 
also be given aserotonin syndrome (SS) information sheet for signs and symptoms of SS.  
This information sheet also instru cts subjects to seek immediate medical care if any of these 
symptoms are observed.
[IP_ADDRESS] Poststudy Anticancer Therapy Status
The investigator or qualified designee will review all new antineoplastic therapy  initiated 
after the last dose of study  treatment until the Safety  Follow -up Visit . 
Clinical Procedures/Assessments 7.1.2
[IP_ADDRESS] Adverse Events
The investigator or qualified designee will assess each subject to evaluate for potential new
or worsening AEs as specified in the Trial Flow Chart (Section 6.0) and more freque ntly if 
clinically  indicated.  Adverse events will be graded and recorded throughout the trial and 
during the follow -up period according to NCI CTCAE Version 4.0 (see Section 12.6). 
Toxicities will be characterized in terms regarding seriousness, causalit y, toxicity  grading, 
and actio n taken with regard to trial treatment.
Please refer to Section 7.[ADDRESS_725156]:   MK -3475 (SCH 900475), INCB 024360 85
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-[ADDRESS_725157] dose of trial treatment new clinicall y significant abnormal findings 
should be recorded as AEs.
[IP_ADDRESS] Directed Physical Examination
For cycles that do not require a full phy sical exam per the Trial Flow Chart (Section 6.0) , the 
investigator or qualified designee will perform a directed physical exam as clinicall y 
indicated prior to dosing on Day [ADDRESS_725158] of care or as 
clinically  indicated at theEOT visit and 30-day Safet y Follow - up Visit .  New clinicall y 
significant abnormal findings should be recorded as AEs.  
[IP_ADDRESS] Vital Signs
Vital sign measurements include blood pressure, pulse, respi[INVESTIGATOR_2842], body  temperature, 
and weight. The investigator or qualified designee will take vital signs at screening, prior to 
the administration of each dose of trial treatment and during the follow -up period as specified 
in the Trial Flow Chart (Section 6.0).   Height will be measured at screening onl y.
[IP_ADDRESS] Twelve -Lead Electrocardiograms
Baseline ECGs will be obtained at screening, with additional ECGs obtained at EOT, and as 
clinically  indicated for all subjects. At select centers, additional ECGs willalso be obtained 
at Cycle [ADDRESS_725159] from the 
study  based on an ECG flagged as "Abnormal, Clinically  Significant" is the responsibility  of 
the investigator, in consultation with the MSD medical monitor, as appropriate. The 
correction method (Fredericia or Bazett) used for calculating QTc will need to be provided in 
the eCRF.
[IP_ADDRESS] Performance and Quality of Life Assessments
[IP_ADDRESS].1 Eastern Cooperative Oncology Group Performance Status
The investigator or qualified designee will assess ECOG performance status (Section 12.4) at 
screening 
and before the administration of each cycle of study  treatment and as specified in 
the Trial Flow Chart ( Section 6.0).   
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 86
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-[ADDRESS_725160]:   MK-3475 (SCH 900475), INCB 024360 87
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
ConfidentialTumor Biopsy/Archival Tissue Collection 7.1.3
Tumor Biopsy 7.1.4
NOTE:  As of Amendment 10, optional post-baseline tumor biopsy has been removed .
Fresh tumor biopsies or archived tumor sample will be required at baseline.  Newly -obtained 
tissue is preferred (no intervening treatment [local or systemic] involving the site of tissue 
biopsy  once tissue biopsy  is obtained a ttime of study  enrollment).
Note: Submission of formalin -fixed paraffin embedded tumor tissue sample blocks are 
preferred; if submitting unstained slides, the slides should be freshly  cut and submitted to the 
testing labo ratory  per the specifications in the procedures manual .     
Note: Subjects for whom newly  obtained samples cannot be obtained (e.g. inaccessible or 
subject safet y concern) may submit an archived specimen .
Detailed instructions for fresh tissue collection, as well as details for processing and shippi[INVESTIGATOR_551668].
Tumor Imaging and Assessment of Disease 7.1.5
NOTE:  As of Amendment 10, central imaging vendor assessment is no longer required.
Disease assessments will be performed by [CONTACT_6962]/radiology assessment ,per 
standard of care.
The process for image collection and transmission to the central imaging vendor can be 
found in the Site Imaging Manual (SIM).  Tumor imaging should be acquired by [CONTACT_551708] y (CT, strongly  preferred). M agnetic resonance imaging (MRI )shoul d be used 
when CT is contraindicated or for imaging in the brain. The same imaging technique 
regarding modalit y and use of contrast should be used in a subject throughout the trial to 
optimize the visualization of existing and new tumor burden .  
[IP_ADDRESS] Initial Tumor Imaging
Initial tumor imaging must be performed within 28days before the first date of 
randomization . The site study  team must review prestudy  images to confirm the subject has 
measurable disease per RECI ST 1.1.  The baseline imaging scan should be submitted to the 
central imaging vendor for a retrospective anal ysis of this eligibility  criterion. 
  04XN7M

Product:   MK -3475 (SCH 900475), INCB 024360 88
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-[ADDRESS_725161] component of a positron 
emission tomograph y (PET)/CT uses higher energy  and thinner slices, it may be acceptable 
(with medical monitor approval). A standard, full assessment for lesions should be 
conducted at baseline, including CT or MRI  scans of chest, abdomen, and pelvis. The same 
modality  (CT or MRI) should be used for follow -up assessments , and includ eradiological 
assessments of all sites of disease present at baseline.  Timing should follow the site’s 
standard of care for oncologic tumor assessment .  In addition to radiological monitoring, all 
other lesions observed at the screening visit should be followed.
For selection of target lesions, RECI ST 1.1should be followed.  For example, RECI ST 
discourages selection of target lesions ins ide the field of prior irradiation.  Lesions situated in 
a previously  irradiated area, or in an area subjected to other loco -regional therap y, are usually 
not considered measurable unless it is the solitary site of measurable disease AND there has 
been demonstrated progression in the lesion.  Also, if a subject has only  1measurable lesion, 
this lesion should not be biopsied.
Subjects with previously treated brain metastases may participate provided they have stable 
brain metastases, i.e.without evidence of progression by [CONTACT_9661] (confirmed by [CONTACT_551709], or confirmed by [CONTACT_551710] )for at least 4weeks prior to the first dose of trial treatment. Any neurologic 
symptoms must have returned to baseline and subjects must have no evidence of new or 
enlarging brain metastases, and have not used steroids for brain metastases for at least 14 
days prior to trial initiation as per local site assessment. This exception does not include 
carcinomatous meni ngitis, as subjects with carcinomatous meningitis are excluded regardless 
of clinical stability .
[IP_ADDRESS] Tumor Imaging During the Study
NOTE:  As of Amendment 10, central imaging vendor assessment is no longer required . 
Disease assessments will be performed by [CONTACT_3433] e site investigator/radiology assessment ,per 
standard of care .
Tumor imaging may  be performed by [CONTACT_462] , but the same imaging technique should be 
used in asubject throughout the study . Scans must be a contrast CT or MRI , except in 
circumstances where there is a contrast allergy  or with medical monitor approval.  When the 
CT component of a PET/CT uses higher energy  and thinner slices, it may  be acceptable (with 
medical monitor approval) if it was the same technique used for baseline. Imaging should 
include radiological assessments of all sites of disease present at baseline. In addition to 
radiological monitoring, all other lesions observed at the screening visit should be followed.   
Imaging should continue to be performed until documented disease progression, the start of 
new anticancer treatment, withdrawal of consent, death, or the end of the study , whichever  
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 89
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-[ADDRESS_725162] met the conditions detailed inSection [IP_ADDRESS] .  A repeat scan is not required if the 
investigator opts to discontinue the subject at the initial PD.
[IP_ADDRESS].1 End of Treatment and Follow -up Tumor Imaging
In subjects who discontinue trial treatment, tumor imaging should be performed at the time 
of treatment discontinuation (± 4 week window).  If a previous scan was obtained within 
4weeks prior to the date of discontinuation, then a scan at treatment discontinuation isnot 
mandatory .In subjects who discontinue trial treatment due to documented 
disease 
progr ession, this is the final required tumor imaging.
[IP_ADDRESS] Assessment of Disease According to irRECIST and RECIST 1.1
NOTE:  As of Amen dment 10, d isease assessments will be performed by [CONTACT_133052]/radiology using RECIST 1.[ADDRESS_725163]; centralized review per 
RECIST 1.[ADDRESS_725164] 1.1 Criteria (irRECI ST) will be used for assessment of tumor 
response for the purposes of managing subjects on protocol treatment and decision making 
for discontin uation of study  therap y due to disease progression. These disease assessments 
will be performed by [CONTACT_6962]/radiology  assessment. One exception is that for 
baseline tumor assessments, at least one measurable lesion according to RECI ST 1.[ADDRESS_725165] be present on a bi -dimensional imaging study  (CT or MRI) at baseline. 
For the purposes of the efficacy  endpoints of the study , response assessment based on 
RECI ST 1.1by [CONTACT_551711].
RECI ST 1.1will be adapted for defining PD as follows to account for the unique tumor 
response seen in this class of therapeutics.
If imaging shows PD, it is at the discretion of the investigator to keep a subject on study  
treatment or to stop study treatment until imaging is repeated approximately  [ADDRESS_725166]’s overall clinical condition, including performance status, clinical 
symptoms, and laboratory  data. At a minimum, subjects must meet the following criteria for 
continued treatment on study  after disease progression is identified at a tumor assessment:
Subjects may receive study  treatment while waiting for confirmation of PD if they are 
clinically  stable (see Table 5 ) as defined b y the following criteria: 
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 90
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
ConfidentialNo decline in ECOG performance status
Absence of new or worsening s ymptoms
Absence of rapid progression of disease
Absence of progressive tumor at critical anatomical sites (e.g., spi[INVESTIGATOR_6710]) requiring urgent alternative medical intervention.
Table [ADDRESS_725167] radiologic 
evidence of PD Option to repeat 
imaging at ≥4 
weeks to confirm 
PD May continue 
study treatment at 
the investigator's 
discretion while 
awaiting 
confirmatory 
imagingRepeat imaging at 
≥ [ADDRESS_725168] of care Continue study 
treatment at the 
investigator's 
discretion Continue regularly 
scheduled imaging 
assessments per 
standard of careMay restart 
study treatment 
if condition has 
improved and/or 
clinically stable 
per 
investigator's 
discretion 
CR=complete response; irRECIST=immune -related response evaluation criteria in solid tumors; 
PD=progressive disease; PFS=progression -free survival; PR=partial response; SD=stable disease
In determining whether the tumor burden has increased or decreased, investigators should 
consider all target lesions as well as non-target lesions (refer to the Site Imaging Manual). 
Subjects who are deemed clinicall y unstable are notrequired to have repeat imaging for 
confirmation.  If radiologic progression is confirmed, then the subject will be discontinued 
from study  treatment as specified in the protocol, and the first radiographic evidence of PD 
should be the date of progression
.  If radiologic progression is not confirmed, then the subject 
should resume/continue study  treatment and have their next scan according to the Protocol -
specified schedule.  Ifprogression is not confirmed and the subject continues on treatment,  
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 91
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
Confidentialthe next imaging that documents disease progression (and is confirmed by a second tumor 
imaging at least 4 weeks later), will be considered the date of disease progression.
NOTE: If a subject with confirmed radiographic progression (i.e., [ADDRESS_725169] 28 days 
apart demonstrating progressive disease) is clinically  stable or clinically  improved, and there 
is no further increase in the tumor dimensions at the confirmatory  imaging , an exception may 
be considered to continue treatment upon consultation with MSD .  Clinically  stable subjects 
should also have at the confirmatory  scan no further increase in the target lesions, no 
unequivocal increase in non-target lesions, and no additional new lesions develop 
(nonworsening PD) to continue study  treatment .
[IP_ADDRESS] Photography for Cutaneous Lesions
NOTE:  As of Amendment 10, this section is no longer applicable.
Digital photographs documenting measureable cutaneous lesions should be obtained ifthe 
cutaneous lesion is included as part of the non-target lesions for disease assessment
according to RECI ST 1.1. Copi[INVESTIGATOR_551669]. The timing for capturing cutaneous
lesion photographs should follow the same schedule as the imaging scan s.
Laboratory Procedures/Assessments 7.1.6
Details regarding specific laboratory  procedures/assessments to be performed in this trial 
follow . The total amount of blood/tissue to be drawn/collected over the course of the trial 
(from pre-trial to post-trial visits), including approximate blood/tissue volumes 
drawn/collected by [CONTACT_551712] .
After Cycle 1, predose laboratory  procedures can be conducted up to [ADDRESS_725170] be reviewed by [CONTACT_551713] y treatment.
[IP_ADDRESS] Hematology, Hemostatic Panel, Serology, Urinalysis and Endocrine Function 
Testing 
Hematology , hemostatic panel, urinalysis and endocrine function will all be analyzed by [CONTACT_394437] .
[IP_ADDRESS] Serum Chemistry and Liver Function Tests
All serum chemistry  testing and liver function testing as shown in the Trial Flow Chart 
(Section 6.0) will be performed by [CONTACT_779]'s local laboratory .  Throughout the protocol, LFT 
refers specificall y to liver chemistry  testing, and required analytes for LFTs are listed in
Table 6. 
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 92
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-[ADDRESS_725171] be excluded/discontinued from study  treatment in the event of apositive or borderline -
positive test result.
[IP_ADDRESS]
Laboratory Safety Evaluations (Hematology, Chemistry and Urinalysis)
Laboratory  tests for hematology , chemistry  and urinaly sis are specified in Table 6.
Table [ADDRESS_725172] (serum or 
urine)a
Hemoglobin Alkaline phosphatase Glucose Hepatitis
Hepatitis B surface 
antigen
Hepatitis B core 
antibody
HCV -RNAf
Platelet count Alanine 
aminotransferase 
(ALT)Protein Hemostatic:
PT 
aPTT
INR
WBC (total and 
differential)eAspartate 
aminotransferase 
(AST)Specific gravity Endocrine Monitoring:
Thyroid-stimulating 
hormone (TSH)
Free thyroxine (T4)
Total 
triiodothyronine 
(T3)d
Red blood cell count Amylase Microscopic exam, if 
abnormal results are 
notedLFT Monitoring: 
Alkaline phosphatase
ALT
AST
Total bilirubin
Differential count, 
including:
Basophils
Eosinophils
Lymphocytes
Monocytes
NeutrophilsBicarbonate or Carbon 
Dioxidec 
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 93
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
ConfidentialHematology Chemistry Urinalysis Other
Blood Urea 
Nitrogen/UreabIgG -Immunoglobulin G
Calcium C-reactive protein ( CRP) 
Chloride
Creatinine
Glucose
Lactate dehydrogenase 
(LDH)
Phosphorus
Potassium
Serum lipase
Sodium
Total Bilirubin  
Direct Bilirubin, if 
total bilirubin is 
elevated above the 
upper limit of normal
Total protein
aPerform on women of childbearing potential only, [ADDRESS_725173] treatment.
bBlood Urea Nitrogen is preferred; if not available urea may be tested.
cIfthese tests are not done as part of standard of care in your region then these tests do not need to 
be performed.
d T3 is preferred; if not available free T3 may be tested. If the local laboratory is unable to perform 
either of these tests the site should submit the sample to the central laboratory for testing.  Details 
are provided in the procedures manual.  Blood draws for thyroid function tests should be done 
prior to dosing at the scheduled time point; however results can be reviewed after dosing if they 
are not available at the time of the scheduled dosing.
eReport % or absolute results per standard of practice. Report the results in the same manner 
throughout the study.
fHepatitis C Ab testing is allowed for screening purposes in countries where HCV RNA is not part 
of SOC.
Pre-dose laboratory  proc edures can be conducted up to 72 hours prior to dosing.
[IP_ADDRESS] Pharmacokinetic/Pharmacodynamic Evaluations
NOTE:  As of Amendment 10, this section is no longer applicable.
The accumulation of robust PK and ADA data has allowed for the adequate characterization 
the clinical pharmacology  of pembrolizumab across indications.  Further collection of 
samples in subjects receiving pembro lizumab alone isnot required.  Blood samples for PK 
and ADA may  be stored.  Analy sis will be performed only  if required .
To evaluate the immunogenicity  and exposure of pembrolizumab and epacadostat in this 
indication, sample colle ctions for analysis ofPKand anti-pembrolizumab antibodies (ADA) 
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 94
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301-10) Final Protocol 18-May- 2018
Confidentialare currentl y planned as shown in the Trial Flowchart (Section 6.0) . Blood samples collected 
for PK and ADA may only be stored at this time. Further analy sis may be performed if 
required. If ongoing PK and/or ADA sampling is deemed to be unnecessary  by [CONTACT_1034], 
it may  be reduced or discontinued.
[IP_ADDRESS].1 Blood Sample Collection for PK of Pembrolizumab
NOTE:  As of Amendment 10, this section is no longer applicable.
Sample collection, storage and shipment instructions for serum samples will be provided in
the Procedures Manual. PK samples should be drawn accordi ng to the PK collection 
schedule .
[IP_ADDRESS].2 Blood Sample Collection for Anti -pembrolizu mab Antibodies
NOTE:  A s of Amendment 10, this section is no longer applicable.
Sample collection, storage and shipment instructions for serum samples will be provided in
the Procedure sManual. Anti- pembrolizumab antibody  samples should be drawn according 
to the ADA collection schedule .  Simultaneous PK sampling is required for interpretation of 
ADA anal ysis.
[IP_ADDRESS].3 Blood Sample Collection for PK of Epacadostat
NOTE:  As of Amendment 10, this section is no longer applicable.
Pharmacokinetics samples for epacadostat will be required for all subjects enrolled in this 
study  as noted inTable 8with sample collection times and windows shown. Subjects will 
arrive at clinic having withheld their morning dose of epacadostat or matching placebo.  
Pharmacokinetic samples will be obtained at the visits indicated in the Trial Flow Chart
(Section 6.0.)  Additional timed serial sample collection for epacadostat will be collected at 
SELECT centers for all subjects enrolled at those centers as indicated in Table 7. All sample 
times noted are required.  
After the predose (predose is defined as within 24 hours before administration of 
pembrolizumab and before administration of epacadostat ) PK sample is drawn, subjects will 
take epacadostat or matching placebo and then begin infusion of pembrolizumab .  The exact 
date and time of the PK blood draws will be recorded along with the date and time of the last 
dose of study  drug and last meal preceding the blood draw.  Instructions for sample 
preparation and shippi[INVESTIGATOR_551670].   
  04XN7M

Product:   MK -3475 (SCH 900475), INCB 024360 95
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301-10) Final Protocol 18-May- [ADDRESS_725174] Centers ONLY
Study VisitTiming of Sam ple Relative to E pacadostat
or Matching Placebo Administration
C1D1 Predose1 h
± 30 min2 h
± 30 min4-10 h
C2D1 Predose1 h
± 30 min2 h
± 30 min4-10 h
Table 8 Sample Collection Time Windows for Pharmacokinetic Assessments for 
Epacadostat or Matching Placebo at ALL Centers
Study VisitTiming of Sam ple Relative to Epacadostat 
or Matching Placebo Administration
C1D1 Predose 1 h ± 30 min
C2D1 Predose 1 h ± 30 min
[IP_ADDRESS].4 Pharmacodynamic Assessments
NOTE:  As of Amendment 10, this section is no longer applicable.
Plasma PD samples will be analyzed for changes in the levels of tryptophan and kynurenine 
by [CONTACT_551714]1 enzy me. Protein analytes such as relevant tumor markers and markers 
of immune function may be measured by [CONTACT_28745]-
linked immunosorbent assay , or other 
relevant methods, using these samples. 
Plasma samples will be obtained for pharmacod ynamic assessments at the visits designated 
in the Trial Flow Chart (Section 6.0) andTable 9and will be collected for subjects in the 
treatment phase only (not in Second Course Phase [Retreatment ]).  The plasma PD sample 
collection for epacadostat or matching placebo should occur in parallel with the predose PK 
sampling for epacadostat or matching placebo outlined in Table [ADDRESS_725175]:   MK-3475 (SCH 900475), INCB 024360 96
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
ConfidentialOther Procedures 7.1.7
[IP_ADDRESS] Withdr awal/Discontinuation
When a subject discontinues/withdraws from participation in the trial , all applicable activities 
scheduled for the final trial visit should be performed at the time of discontinuation.  Any 
adverse events which are present at the time of discontinuation/withdrawal should be 
followed in accordance with the safety  requirements outlined in Section 7.[ADDRESS_725176] completed the study .
[IP_ADDRESS].[ADDRESS_725177] to Follow -up
NOTE: As of Amendment 10, this section is no longer applicable. There will be no 
additional efforts to contact [CONTACT_63381] -up.
If a subject fails to return to the clinic for a required study  visit and/or if the site is unable to 
contact [CONTACT_423], the following procedures are to be performed:
The site must attempt to contact [CONTACT_75359].  If the 
subject is contact[INVESTIGATOR_530], the subject should be counseled on the importance of 
mainta ining the protocol- specified visit schedule. 
  04XN7M

Product:   MK -3475 (SCH 900475), INCB 024360 97
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
ConfidentialThe investigator or designee must make every  effort to regain contact [CONTACT_75360] (e.g. phone calls and/or a certified letter to the subject’s last 
known mailing address or locally  equivalent methods). These contact [CONTACT_131994]’s medical record.
Note:  A subject is not considered lost to follow up until the last scheduled visit for 
the individual subject.  The amount of missing data for the subject will be managed 
via the pre -specified data handling and anal ysis guidelines
[IP_ADDRESS] Blinding/Unblinding
NOTE:  As of Amendment 10, blinding is no longer applicable –all subjects will receive open -
label pembrolizumab alone.
When the investigator or sub -investigator nee ds to identify the drug used by  a subject and the 
dosage administered in case of emergency  e.g., the occurrence of serious adverse 
experiences, he/she will contact [CONTACT_75362] 
a request for emergency  unblindin g.  As requested by [CONTACT_9940]-investigator the 
emergency  unblinding call center will provide the information to him/her promptly  and 
report unblinding to MSD .  The emergency  unblinding call center will make a record 
promptly  however, the investigator or sub-investigator must enter the toxicity  grade of the 
adverse experiences observed, their relation to study  drug, the reason thereof, etc., in the 
medical chart etc., before unblinding is performed.
Additionally , the investigator must go into the I VRS system and perform the unblind in the 
IVRS system to update drug disposition. In the event that the emergency  unblinding call 
center is not available for a given site in this study , the IVRS/I WRS system should be used 
for emergency  unblinding in t he event that this is required for subject safety .
In the event that unblinding has occurred, the circumstances around the unblinding (e.g., 
date, reason and person performing the unblinding) must be documented promptly , and the 
MSD Clinical Director notif ied as soon as possible. Only  the principal investigator [INVESTIGATOR_75307]’s code should be unblinded. Trial site personnel and MSD
personnel directly  associated with the conduct of the trial should not be unblinded.
Section 
5.8 outlin es the criteria for allowing subjects who are discontinued from treatment to 
continue to be monitored in the trial.
At the end of the trial, random code/disclosure envelopes or lists and unblinding logs are to 
be returned to MSD or designee.
[IP_ADDRESS] Calibration of Equipment
The investigator or qualified designee has the responsibility  to ensure that any device or 
instrument used for a clinical evaluation/test during a clinical trial that provides information 
about inclusion/exclusion criteria and/or safet y or efficacy parameters shall be suitably   
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 98
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
Confidentialcalibrated and/or maintained to ensure that the data obtained is reliable and/or reproducible. 
Documentation of equipment calibration must be retained as source documentation at the 
trial site .
Laboratory equipment –as required for inclu sion labs and trial assessments
Imaging equipment –as required for stud y objectives
See protocol -specified guidance in the Administrative Binder, Procedures Manual and Site 
Imaging Manual.
Visit Requirements 7.1.8
Visit requirements are outlin ed in Section 6 .0-Trial Flow Chart.   Specific procedure -related 
details are provided above in Section 7.1 -Trial Procedures.
[IP_ADDRESS] Screening Visit
Approximately  28 day sprior to treatment allocation/ randomization, potential subjects will be 
evaluated to determine that they fulfill the entry requirements as set forth in Section 5.1.  
Screening procedures may be repeated after consultation with MSD .  
Screening is the interval between the signing of the inform consent form (ICF) and the day 
the subject received the first dose of treatment in the study  (Cycle 1 Day 1).  Informed 
consent must be obtained before performing any study-specific procedures.  However, 
assessments done as part of standard of care prior to informed consent may be used if they 
are within the required screening period.   Screening procedures may be repeated with MSD 
consultation .  Results from the screening visit evaluations will be reviewed to confirm 
subject eligibility  before randomization or the administration of study  drug.  Baseline 
radiographic imaging must be performed within 28days of study  start. Subjects may be 
rescreened after initially  failing to meet the inclusion/exclusion criteria.
Subjects who are rescre ened will retain their original screening number.
[IP_ADDRESS] Treatment Period Visit
Visit requirements are outlined in the Trial Flow Chart (Section 6).  Specific 
procedure -related details are provided in Section 7.1.
[IP_ADDRESS] End of Treatment
If a decision is made that the subject will permanently  discontinue study  drug, the EOT visit 
should beconducted.  If the EOT visit coincides with a regular study  visit, the EOT 
evaluations will supersede those of that scheduled visit.  The subject should be encouraged to 
return for the follow -up visit. 
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 99
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-[ADDRESS_725178]-Treatment Visits
[IP_ADDRESS].1 Safety Follow -UpVisit
NOTE: As of Amendment 10, the Safety Follow-up Visit will be the last visit in the 
study. This section has been amended as appropriate.
The Safet y Follow -Up phase is the interval between the EOT visit and the scheduled Safet y 
Follow -Up visit, which should occur 30days after the EOT visit (or after the last dose of 
study  drug if the EOT visit was not performed).  A subject will be considered to have 
completed this study  once they  have attended this visit.  Subjects currently in follow -up or in 
survival follow -up are considered to have completed the study ; these subjects are not 
required to attend any further visits . Assessment and recording of AEs will be performed as 
per Section 7.2.  If a subject initiates a new anticancer therapy  within [ADDRESS_725179] return for 
the follow -up visit and report any AEs that may occur prior to initiating new anticancer 
therap y. 
[IP_ADDRESS].2 Follow -UpVisits
NOTE:  As of Amendment 10, this section is no longer applicable.   A subject will be 
considered to have completed this study once they have attended the Safety Follow -up 
Visit.  Subjects currently in follow -up are considered to have completed the study; these 
subjects are not required to attend any further visits. Assessment and recording of AEs 
will be performed as per Section 7.2.
Subjects who discontinue study  treatment for a reason other than disease progression will 
move into the Follow -Up Phase and should be assessed every  9 w eeks (63  ± 7days) from 
Week 12 
up to Week 102 by [CONTACT_551715] 
12weeks (84 days ± 7 days) thereafter.  Every effort should be made to collect information 
regarding disease status until the start of new anti-cancer therapy , disease progression, death, 
and 
end of the study , or if the subject begins retreatment as detailed in Section [IP_ADDRESS].  
Information r egarding poststudy  antineoplastic treatment will be collected if new treatment is 
initiated.
Subjects who are eligible to receive retreatment according to the criteria in Section
5.2.2 will 
move from the Follow -Up Pha se to the Second Course Phase (Retreatment) when they 
experience disease progression.  Details are provided in Section 5.2.2. MSD consultation 
will be needed prior to starting Second Course R
etreatment. 
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 100
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
Confidential7.[IP_ADDRESS] Survival Follow -Up
NOTE: As of Amendment 10, this section is no longer applicable.   Subjects currently in 
survival follow -up are considered to have completed the study; these subjec ts will no 
longer be contact[CONTACT_398843].   Assessment and recording of AEs will be 
performed as per Section 7.2.
Subjects who experience disease progression by [CONTACT_551716] a new anti-cancer
therap ywill move into the Survival Follow -Up Phase andshould be contact[CONTACT_551717]  [ADDRESS_725180].   
[IP_ADDRESS] Unscheduled Visits
Unscheduled study  visits may occur at any time if medically  warranted.  Any assessments 
performed at those visits should be recorded in the eCRF .
[IP_ADDRESS] Survival Status
NOTE:  As of Amendment 10, this section is no longer applicable.   Subjects currently in 
survival follow -up are considered to have completed the study; these subjects will no 
longer be contact[CONTACT_398843].   Assessment and recording of AEs will be 
performed as per Section 7.2.
To ensure current and complete survival data is available at the time of database locks, 
updated s urvival status may be requested during the course of the study  by [CONTACT_19487].  For 
example, updated survival status may be requested prior to but not limited to an external Data 
Monitoring Committee (eDMC) review, interim and/or final analysis.  Upon MSD 
notifica tion, all subject s who do not/will not have a scheduled study  visit or study  contact 
[CONTACT_551718] (excluding 
subject s that have a previously  recorded death event in the collection tool).
Assessing and Recording Adverse Events 7.[ADDRESS_725181] a causal relationship with this treatment. An adverse event can therefore be any 
unfavourable and unintended sign (including an abnormal laboratory  finding, for example), 
symptom, or disease temporally  associated with the use of a medicinal product or protocol -
specified procedure, whether or not considered related to the medicinal product or protocol -
specified procedure.  Any worsening (i.e., any clinically  significant adverse change in 
frequency  and/or intensity ) of a preexisting condition that is temporally  associated with the 
use of MSD ’s product, is also an adverse event.
Changes resulting from normal growth and development that do not vary significantl y in 
frequency  or severit y from expected levels are not to be considered adverse events.   
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 101
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
ConfidentialExamples of this may include, but are not limited to, teething, typi[INVESTIGATOR_26336] a ph ysiologically  appropriate time.
MSD 's product includes any pharmaceutical product, biological product, device, diagnostic 
agent or protocol -specified procedure, whether investigational (including placebo or active 
comparator medication) or marketed, manufactured by, licensed by, provided by [CONTACT_551719].
Adverse events may occur during clinical trials, or as prescribed inclinical practice, from 
overdose (whether accidental or intentional), from abuse and from withdrawal.
A progression of the cancer under stud y is not considered an adverse event.
All adverse events that occur after the consent form is signed but before treatment
allocation/randomization must be reported by [CONTACT_551720], or are the result of a protocol -specified intervention, including but
not limited to washout or discontinuation of usual therap y, diet, placebo treatment or a
procedure. 
From the time of treatment allocation/randomization through 30days following cessation of 
treatment or if the subject initiates new anticance r therapy , whichever is earlier , all adverse 
events must be reported by [CONTACT_093]. Such events will be recorded at each 
examination on the Adverse Event case report forms/worksheets. The reporting timeframe 
for adverse events meeting any serious criteria is described insection [IP_ADDRESS]. The 
investigator will make every  attempt to follow all subjects with nonserious adverse events for 
outcome.
Definition of an Overdose for This Pro tocol and Reporting of Overdose 7.2.1
In this trial, an overdose is any dose higher than ≥1000 mg (5 times the dose) of 
pembrolizumab .  No specific information is available on the treatment of overdose of 
pembrolizumab. In the event of overdose, the subject should be observed closely  for signs of 
toxicity .  Appropriate supportive treatment should be provided if clinically indicated .
If an adverse even t(s) is associated with (“results from”) the overdose of MSD’s product or 
vaccine, the adverse event(s) is reported as a serious adverse event, even if no other 
seriousness criteria are met.
If a dose of MSD’s product or vaccine meeting the protocol defini tion of overdose is taken 
without any associated clinical symptoms or abnormal laboratory  results, the overdose is 
reported as a non-serious Event of Clinical Interest (ECI ), using the terminology  “accidental 
or intentional overdose without adverse effect. ”
All reports of overdose with and without an adverse event must be reported by [CONTACT_23514] [ADDRESS_725182]:   MK-3475 (SCH 900475), INCB 024360 102
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
Confidentialprocedures can be found in the EDC data entry  guidelines. Paper reporting procedures can be 
found in the Investigator Trial File Binder (or equivalent) .
Reporting of Pregnancy and Lactation 7.2.[ADDRESS_725183] 
(spontaneousl y reported to them) that occurs during the trial.
Pregnancies and lactations that occur after the consent form is signed butbefore treatment 
allocation/randomization must be reported by [CONTACT_105943], or are the result of a protocol -specified intervention, including but 
not limited to washout or discontinuation of usua l therap y, diet, placebo treatment or a 
procedure. Pregnancies and lactations that occur from the time of treatment 
allocation/randomization through 120 days following cessation of MSD’s product , or if the 
subject initiates new anticancer therapy , whicheve r is earlier, must be reported by [CONTACT_1275]. All reported pregnancies must be followed to the completion/termination of the 
pregnancy . Pregnancy outcomes of spontaneous abortion, missed abortion, benign 
hydatidiform mole, blighted ovum, fetal death, intrauterine death, miscarriage and stillbirth 
must be reported as serious events (Important Medical Events). If the pregnancy  continues to 
term, the outcome (health of infant) must also be reported.
Such events must be reported within 24 hours to MSD either by [CONTACT_26365]. 
Electronic reporting procedures can be found in the EDC data entry  guidelines. Paper 
reporting procedures can be found in the Investigator Trial File Binder (or equivalent).
Immediate Reporting of Adverse Events 7.2.3
[IP_ADDRESS] Serious Adverse Events
A serious adverse event is any adverse event occurring at any dose or during any use of 
MSD’s product that:
●Results in death;
●Is life threatening;
●Results in persistent or significant disability /incapacity ;
●Results in or prolongs an ex isting inpatient hospi[INVESTIGATOR_059];
●Is a congenital anomal y/birth defect;
●Is an other important medical event .
Note: In addition to the above criteria, adverse events meeting either of the below criteria, 
although not serious per ICH definition, are reportable to MSD in the same timeframe as 
SAEs to meet certain local requirements. Therefore, these events are considered serious by 
[CONTACT_398864].
●Is a new cancer (that is not a condition of the study); 
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 103
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
Confidential●Is associated with an overdose.
Refer to Table 10for additional details regarding each of the above criteria.
For the time period beginning when the conse nt form is signed until treatment 
allocation/ randomization, any serious adverse event, or follow up to a serious adverse event,
including death due to any  cause, other than progression of the cancer under study  (reference 
Section [IP_ADDRESS] for additional details) that occurs to any subject must be reported within [ADDRESS_725184] to be excluded from the trial, or is the result of a 
protocol -specified intervention, including but 
not limited to washout or discontinuation of 
usual therap y, diet, placebo treatment or a procedure.
For the time period beginning at treatment allocation/ randomization through 90days 
following cessation of treatment ,or [ADDRESS_725185] initiates new anticancer therap y, whichever is earlier, any serious adverse event, or 
follow up to a serious adverse event, including death due to any cause other than progression 
of the cancer under study  (reference Section [IP_ADDRESS] for additional details) whether or not 
related to MSD’s product , must be reported within 24 hours to MSD either by [CONTACT_26366]. Electronic reporting procedures can be found in the EDC data entry  
guidelines. Paper reporting procedures can be found inthe Investigator Trial File Binder (or 
equivalent).
Additionally , any serious adverse event, considered by [CONTACT_19427] a qualified 
physician to be related to MSD’s product that is brought to the attention of the investigator at 
any time followi ng consent through the end of the specified safet y follow -up period specified 
in the paragraph above, or at any time outside of the time period specified in the previous 
paragraph also must be reported immediatel y to MSD .  
All subjects with serious adverse events must be followed up for outcome.
[IP_ADDRESS] Events of Clinical Interest
Selected non-serious and serious adverse events are also known as Eve nts of Clinical I nterest 
(ECI) and must be reported to MSD .
For the time period beginning when the consent form is signed until treatment 
allocation/ randomization, any  ECI, or follow up to an ECI , that occurs to any  subject must be 
reported within [ADDRESS_725186] to be excluded from the trial, or is 
the result of a protocol -specified interv ention, including but 
not limited to washout or 
discontinuation of usual therap y, diet, placebo treatment or a procedure.
For the time period beginning at treatment allocation/ randomization through 30days 
following cessation of treatment, any ECI, or follow up to an ECI, whether or not related to 
MSD’s product , must be reported within 24 hours to MSD , either by [CONTACT_90079].  Electronic reporting procedures can be found in the EDC data en try guidelines.  Paper 
reporting procedures can be found in the Investigator Trial File Binder (or equivalent). 
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 104
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-[ADDRESS_725187] for this trial include:
1. an overdose of MSD’s product , as defined in Section 7.2.[ADDRESS_725188]  of protocol -specified laboratory  
testing or un schedule d laboratory  testing.*
*Note:  These criteria are based upon available regulatory  guidance documents. The 
purpose of the criteria is to specify  a threshold of abnormal hepatic tests that may  require 
an additional evaluation for an underl ying etiology. The trial site guidance for assessment 
and follow up of these criteria can be found in the Investigator Trial File Binder (or 
equivalent).
[IP_ADDRESS] Protocol -Specific Exceptions to Serious Adverse Event Reporting
Efficacy  endpoints as outlined in this section will not be reported to MSD as described in 
Section 7.2.3 . -Immediate Reporting of Adverse Events to MSD.
Specificall y, the suspected/actual events covered in this exception include any event that is 
disease progression of the cancer under stud y.
Unblinded aggregated efficacy  endpoint events and safet y data will be monitored to ensure 
the safet y of the subjects in the trial. Any suspected endpoint which upon review is not 
progression of the cancer under study  will be forwarded to global safet y as aSAE within 
24 hours of determination that the event is not progression of the cancer under study
Evaluating Adverse Events 7.2.4
An investigator who is a qualified physician will evaluate all adverse events according to the 
NCI Common Terminology  for Adverse Events (CTCAE), version v4.0. Any adverse event 
which changes CTCAE grade over the course of a given epi[INVESTIGATOR_110507]/worksheets.
All adverse events regardless of CTCAE grade must also be evaluated for seriousness. 
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 105
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
ConfidentialTable 10 Evaluating Adverse Events
An investigator who is a qualified physician, will evaluate all adverse events as to:
V4.0 CTCAE 
GradingGrade 1 Mild; asymptomatic or mi ld symptoms; clinical or diagnostic observations only; intervention not indicated.
Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age -appropriate instrumental ADL.
Grade 3 Severe or medically significant but not immediately life -threatening; hospi[INVESTIGATOR_3111]; disabling; 
limiting self -care ADL.
Grade 4 Life threatening consequences; urgent intervention indicated.
Grade 5 Death related to AE
Seriousness A serious adverse event is any adverse event occurring at any dose or during any use of MSD’s product that:
†Results in death ; or
†Is life threatening; orplaces the subject, in the view of the investigator, at immediate risk of death from the event as it occurred (Note: This does not include an 
adverse event that, had it occurred in a more severe form, might have caused death.); or
†Results in a persiste nt or significant disability/incapacity (substantial disruption of one’s ability to conduct normal life functions); or
†Results in or prolongs an existing inpatient hospi[INVESTIGATOR_059] (hospi[INVESTIGATOR_19357], regardless of length of stay, even if the 
hospi[INVESTIGATOR_2138] a precautionary measure for continued observation. (Note: Hospi[INVESTIGATOR_19358] a pre-existing condition that has not 
worsened is not a serious adverse event.  A pre -existing condition is a clinical condition that is diagnosed prior to the use of a [COMPANY_006] product and is documented in the 
patient’s medical history.); or
†Is a congenital anomaly/birth defect (in offspring of subject taking the product regardless of time to diagnosis);or
Is anew cancer (that is not a condition of the study) (although not serious per ICH definition, is reportable to MSD within 24 hours to meet certain local 
requirements); or
Is an overdose (whether accidental or intentional).  Any adverse event associated with an overdose is considered a serious adverse event for collection purposes . An 
overdose that is not associated with an adverse event is considered a non -serious event of clinical inter est and must be reported within [ADDRESS_725189] and may require medical or surgical intervention to prevent one of the outcomes listed 
previously (designated above by a †).
Duration Record the start and stop dates of the adverse event. If less than 1 day, indicate the appropriate length of time and units
Action taken Did the adverse event cause MSD’s product to be discontinued?
Relationship to 
MSD’s productDid MSD’s product cause the adverse event? The determination of the likelihood that MSD’s product caused the adverse event will be provided by [CONTACT_78031] a qualified physician. The investigator’s signed/dated initials on the source document or worksheet that supports the causality noted on the AE form, ensures 
that a medically qualified assessment of causality was done. This initialed document must be retained for the required regulatory time frame. The criteria below are 
intended as reference guidelines to assist the investigator in assessing the likelihood of a relationship between the test drug and the adverse event based upon the 
available information.
The following components are to be used to assess the relationship between MSD’s product and the AE; the greater the correlation with the components and 
their respective elements (in number and/or inte nsity), the more likely MSD’s product caused the adverse event (AE):
Exposure Is there evidence that the subject was actually exposed to MSD’s product such as: reliable history, acceptable compliance assessment (pi[INVESTIGATOR_692], 
diary, etc.), expected pharmacologic effect, or measurement of drug/metabolite in bodily specimen?
Time Course Did the AE follow in a reasonable temporal sequence from administration of MSD’s product ? 
Is the time of onset of the AE compatible with a drug -induced effect (applies to trials with investigational medicinal product)?
Likely Cause Is the AE not reasona bly explained by [CONTACT_26369], other drug(s)/vaccine(s), or other host or environmental factor s 
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 106
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-[ADDRESS_725190] drug and the AE: (continued)
to MSD’s 
product
(continued) Dechallenge Was MSD’s product discontinued or dose/exposure/frequency reduced?
If yes, did the AE resolve or improve?
If yes, this is a positive dechallenge. If no, this is a negative dechallenge.
(Note: This criterion is not applicable if: (1) the AE resulted in death or permanent disability; (2) the AE resolved/improve d despi[INVESTIGATOR_551671]’s product ; or (3) the trial is a single -dose drug trial); or (4) MSD’s product (s) is/are only used on e time.)
Rechallenge Was the subject re- exposed to MSD’s product in this study?
If yes, did the AE recur or worsen?
If yes, this is a positive rechallenge. If no, this is a negative rechallenge.
(Note: This criterion is not applicable if: (1) the initial AE resulted in death or permanent disability, or (2) the trial is a single -dose drug trial); or (3) 
MSD’s product (s) is/are used only one time).
NOTE: IF A RECHALLENGE IS PLANNED FOR AN ADVERSE EVENT WHICH WAS SERIOUS AND WHICH MAY HAVE BEEN 
CAUSED BY [CONTACT_19487]’S PRODUCT , OR IF REEXPOSURE TO MSD’S PRODUCT POSES ADDITIONAL POTENTIAL SIGNIFICANT RISK 
TO THE SUBJECT, THEN THE RECHALLENGE MUST BE APPROVED IN ADVANCE BY [CONTACT_551721] M ODIFICATION GUIDELINES IN THE PROTOCOL.
Consistency 
with Trial 
Treatment 
ProfileIs the clinical/pathological presentation of the AE consistent with previous knowledge regarding MSD’s product or drug class pharmacology or 
toxicology?
The assessment of relationship will be reported on the case report forms /worksheets by [CONTACT_19427] a qualified physician according to his/her best clinical judgment, including 
consideration of the above elements.
Record one of the following Use the following sc ale of criteria as guidance (not all criteria must be present to be indicative of a MSD’s product relationship).
Yes, there is a reasonable 
possibility of MSD’s product
relationship.There is evidence of exposure to MSD’s product .  The temporal sequence of the AE onset relative to the administration of MSD’s product is 
reasonable.  The AE is more likely explained by [CONTACT_19487]’s product than by [CONTACT_5748].
No, there is not a reasonable 
possibility of MSD’s product
relationshipSubjec t did not receive MSD’s product OR temporal sequence of the AE onset relative to administration of MSD’s product is not reasonable OR the 
AE is more likely explained by [CONTACT_551722]’s product .  (Also entered for a subject with overdose without an associated AE.) 
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 107
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
ConfidentialResponsibility for Reporting Adverse Events 7.2.5
AllAdverse Events will be reported to regulatory authorities, IRB/IECs and investigators in 
accordance with all applicable global laws and regulations , i.e., per ICH Topic E6 (R1) 
Guidelines for Good Clinical Practice .
TRIAL GOVERNANCE AND OVERSIGHT 7.3
Scientific Advisory Committee 7.3.1
The Scientific Advisory  Committee (SAC )comprises both Sponsor and non-Sponsor 
scientific experts who provide input with respect to trial design, interpretation of trial results 
and subsequent peer -reviewed scientif ic publications.
Executive Oversight Committee 7.3.2
The Executive Oversight Committee (EOC) comprises members of Sponsor and MSD Senior 
Management.  The EOC will receive and decide upon any recommendations made by [CONTACT_171613] (D MC) regarding the trial.
Data Monitoring Committee 7.3.3
To supplement the routine trial monitoring outlined in this protocol, an external Data 
Monitoring Committee (DMC) will monitor the interim data from this trial.  The voting 
members of the committee are extern al to the Sponsor.  The members of the DMC must not 
be involved with the trial in any other way (e.g., they cannot be trial investigators) and must 
have no competing interests that could affect their roles with respect to the trial. 
The DMC will make recommendations to the EOC regarding steps to ensure both subject 
safet y and the continued ethical integrity  of the trial.  Also, the DMC will review interim trial 
results, consider the overall risk and benefit to trial participants (see Section 8.7-Interim 
Analy ses) and recommend to the EOC if the trial should continue in accordance with the 
protocol.
Specific details regarding composition, responsibilities ,and governance, including the roles 
and responsibilities of the various members and the protocol team ; meeting facilitation; the 
trial governance structure; and requirements for and proper documentation of DMC reports, 
minutes, and recommendations will be described in a separate charter that is reviewed and 
approved by [CONTACT_1363].  The DMC will monitor the trial at an appropriate frequency , as 
described in the detailed DMC charter.
A DMC recommendation will be communicated to as agreed to in the DMC charter . 
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 108
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
Confidential8.0STATISTICAL ANALYSIS PLAN
This section outlines the statistical analysis strategy  and procedures for the study .  If, after 
the study  has begun, but prior to any unblinding/final database lock, changes are made to 
primary  and/or key secondary  hypotheses, or the statistical methods related to those 
hypotheses, then the protocol will be amended (consistent with ICH Guideline E-9).  
 
 
 
 
 
Statistical Analysis Plan Summary 8.1
Key elements of the statistical analy sis plan are summarized below; the comprehensive plan 
is provided in Sections 8.2 -8.12. 
Study Design Overview A Phase 3 Random ized, Double -Blind, Placebo -Controlled Study of 
Pembrolizumab in Com bination With Epacadostat or Placebo in 
Subjects with Unresectable or Metastatic Melanoma 
Treatm entAssignment Follow ing stratification by [CONTACT_4002]-L1 expression (Positive; 
Negative /indeterminate ) and BRAF mutation status (BRAF mutant 
and received prior BRAF directed treatm ent; BRAF mutant no prior 
BRAF directed treatment; BRAF wild type) patients will be 
randomized 1:1 to treatment with pembrolizumab in combination 
with eith er epacadostat or placebo
Analysis Populations Efficacy: Intent to Treat (ITT)
Safety: All Subjects as Treated (ASaT)
Prim ary Endpoint(s) 1.Progression -free survival (PFS)
2.Overall survival (OS)
Key Secondary Endpoints 1.Objective response rate (ORR)
Statistical Methods for 
Key 
Efficacy/Immunogenicity/ 
Pharm acokinetic AnalysesThe primary hypotheses will be evaluated by [CONTACT_551723] (1) PFS and (2) OS using a stratified 
log-rank test. Estimation of the hazard ratio will be done using a 
Cox regression model. Event rates over time will be estimated 
within each treatment group using the Kaplan -Meier method. 
Statistical Methods fo r 
Key Safety AnalysesThe analysis strategy for safety endpoints will depend upon the 
safety tier (see Section 8.6.2 ).  There are no Tier 1 safety endpoints.  
Descriptive statistic swill be provided for the rate of Tier 2 safety 
endpoints, as well as 95% confidence interval sfor the treatment 
comparison s.   
  04XN7M

Product:   MK -3475 (SCH 900475), INCB 024360 109
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
ConfidentialInterim Analyses Twointerim analyses will be performed in this study.  Results will 
be reviewed by [CONTACT_4617].  These 
interim analyses are summarized below .  Details are provided in 
Section 8.7.An analysis of ORR may be conducted using data from 
interim analysis 2 (IA2). 
IA 1:
oTiming: To be performed when approximately 331 
PFS events are observed. This analysis is expected to 
be performed about 12months after enrollm ent starts.
Approximately 1 00OS events are expected at IA 1.
oTesting: Inferential analyses for PFS and OS will be 
performed. 
IA 2:
oTiming: to be perform ed when approximately 420PFS 
events are observed.  This is the final PFS analysis and 
is expected to be performed about 24months after 
enrollment starts. Approximately 200OS events are 
expected at IA 2. 
oTesting: Inferential analyses for PFS and OS will be 
performed .  
Final analysis
oTiming: To be perform ed when approximately 293 OS 
events are observed.  This is the final OS analysis and 
is expected to be performed about 45months after 
enrollment starts. 
oTesting: Inferential analyses for OS w ill be p erformed .
Multiplicity The Type-I error rate over the multiple endpoints tested, as well as 
for the multi ple analyses  planned ,will be controlled by [CONTACT_551724] m ethods of Maurer and Bretz [ 59]
Sample Size and Power The planned sample size was initially approximately [ADDRESS_725191] 
meet a minimum enrollment regulatory requirement . Therefore 
enrollment from Japan may continue after enrollment inother 
countries ends. Total enrollment is now expected to be 
approximately 700 subjects. For PFS, the trial has ~98% power to 
demonstrate that pembrolizumab and epacadostat is superior to 
pembrolizumab and placebo at an overall 1 -sided 1.25% alpha -level.  
For OS, the trial has ~79% power to demonstrate that 
pembrolizumab and epacadostat is superior to pembrolizumab and 
placebo at an initial overall 1
-sided 1.25% alpha -level.   Should the 
PFS comparison be statistically significant, the 1.25% alpha will be 
re-assigned to OS.  Should the OScomparison be statistically 
significant, the 2.5% alpha will be re-assigned to ORR. Should the 
total alpha assigned to OS be 2.5%, the power to demonstrate 
improved OS with the combination will be about 86%.  The 
treatment effect (true hazard rate) is assumed to be 0.65 for PFS and 
0.70 for OS.
Based on review of IA2 data, the DMC recommended that all subjects stop oral therapy  
(epacadostat/placebo ).  After study  completion, only  selected analy ses will be perfor med. 
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 110
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
ConfidentialResponsibility for Analyses/In -House Blinding 8.2
The statistical analysis of the data obtained from this study  will be the responsibility  of the 
Clinical Biostatistics department of MSD.
This study  will be conducted as a double -blind study  under in-hous e blinding procedures.  
The official, final database will not be unblinded until medical/scientific review has been 
performed, protocol deviations have been identified, and data have been declared final and 
complete.
The Clinical Biostatistics department will generate the randomized allocation schedule(s) for 
study  treatment assignment.  Randomization will be implemented in an interactive voice 
response s ystem (IVRS).
Planned interim analyses are described in Section 8.7.  Study enrollment is expected to be 
completed at the time of any interim analyses.  Blinding to treatment assignment will be 
maintained at all investigational sites.  The results of interim analy ses will not be shared with 
the investigators prior to the completion of the study.  Subject -level unblinding will be 
restricted to an external unblinded statistician and scientific programmer performing the 
interim analysisfor the DMC , who will have no other responsibilities associated with the 
study .
The external Data Monitoring Committee (DMC )will serve as the primary  reviewer of the 
unblinded results of the interim analy ses and will make recommendations for discontinuation 
of the study  or modification to an Executive Oversight Committee (EOC) .Depending on t he 
recommendation of the DMC , aregulatory  submission may be prepared . If the DMC 
recommends modifications to the design of the protocol or discontinuation of the study , this 
EOC and limited additional personnel may be unblinded to results at the treatment level in 
order toact on these recommendations. The extent to which individuals are unblinded with 
respect to results of interim analyses will be documented. Additional logistical details, 
revisions to the above plan,and data monitoring guidance will be provided in the DMC 
Charter .
Prior to final study  unblinding, the external unblinded statistician will not be involved in any 
discussions regarding modifications to the protocol, statistical methods, identification of 
protocol deviations, or data validation efforts after the interim anal yses.
Hypotheses/Estimation 8.[ADDRESS_725192] met its primary  objective in the study  population if the combination of pembrolizumab 
and epacadostat is superior to the pembrolizumab and placebo in PFS atan interim PFS
analysis or at thefinal analy sis(i.e.,interim analysis 2)or in OS at an interim OS analy sis or
atthe final OS anal ysis. 
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 111
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
ConfidentialAnalysis Endpoints 8.4
Efficacy  and safet y endpoints that will be evaluated for between -treatment differences are 
listed below, followed b y the descriptions of the derivations of selected endpoints.
Efficacy Endpoints 8.4.1
Dual -Primary 
Progression- Free Survival –RECIST 1.1
Progression -free survival (PFS) is defined as the time from randomization to the first 
documented disease progression per RECI ST 1.[ADDRESS_725193].  See Section [IP_ADDRESS] fordefinition of 
censoring.
Overall Survival
Overall Survival (OS) is defined as the time from randomization to death due to any cause. 
Patients without documented death at the time of the final analy sis will be censored at the 
date of the last follow -up.
Secondary
Duration of response (DOR) determined by [CONTACT_551725], whichever comes first based upon blinded independent radiologists’ RECI ST 1.1 
assessment.
Objective response rate (ORR) is defined as the proportion of the subjects in the analy sis 
population who have a confirmed complete response (CR) or partial response (PR) based on 
RECI ST 1.[ADDRESS_725194]:   MK-3475 (SCH 900475), INCB 024360 112
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
ConfidentialAnalysis Population 8.5
Efficacy Analysis Population 8.5.1
The Intent to Treat (ITT) population will serve as the population for the analy sis of efficac y 
data in this study .  The ITTpopulation consists of all randomized subjects .
Subjects will be included in the treatment group to which they are randomized for the 
analysis of efficacy  data.  Details on the approach to handling missing data are provided in 
Section 8.6Statistical Methods.
Safety Analysis Populations 8.5.2
The All Subjects as Treated (ASaT) population will be used for the analy sis of safet y data in 
this study .  The ASaT population consists of all randomized subjects who received at least 
one dose of study  treatment. Subjects will be included in the treatmen t group corresponding 
to the study  treatment they actuall y received for the analysis of safet y data using the ASaT 
population.  For most subjects this will be the treatment group to which they  are randomized.  
Subjects who take incorrect study  treatment fo r the entire treatment period will be included in 
the treatment group corresponding to the study  treatment actuall y received 
At least one laboratory  or vital sign measurement obtained subsequent to at least one dose of 
study  treatment is required for incl usion in the analy sis of each specific parameter.  To assess 
change from baseline, a baseline measurement is also required.
Statistical Methods 8.6
Statistical testing and inference for efficacy analyses are described in 8.6.1 . Efficacy  results 
that will be deemed to be statistically  significant after consideration of the Type I error 
control strategy  are descri bed in Section 8.8, Multiplicity .Nominal p-values may be 
computed for other efficacy  analyses, but should be interpreted with caution due to potentia l 
issues of multiplicity , sample size, etc.  Unless otherwise stated, all statistical tests will be 
conducted at α=0.05 (2 -sided) level.
Statistical Methods for Efficacy Analyses 8.6.1
This section describes the statistical methods that address the primary  and secondary 
objectives.   
[IP_ADDRESS] Progression-Free Survival (PFS)
To address the primary  PFS hypothesis, the Kaplan -Meier method will be used to estimate 
the PFS curve in each treatm ent group. The treatment difference in PFS will be assessed by 
[CONTACT_113821]-rank test. A stratified Cox proportional hazard model with Efron's method 
of tie handling will be used to assess the magnitude of the treatment difference (i.e., hazard 
ratio) between the treatment groups .The hazard ratio and its 95% confidence interval from  
  04XN7M

Product:   MK -3475 (SCH 900475), INCB 024360 113
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
Confidentialthe stratified Cox model with Efron's method of tie handling and with a single treatment 
covariate will be reported. The same stratification factors used for randomiz ation (see 
Section 5.4) will be applied to both the stratified log -rank test and the stratified Cox model. 
Since disease progression is assessed periodically, progressive disease (PD) can occur any 
time in the time interval between the last assessment where PD was not documented and the 
assessment when PD is documented. In the primary  analysis, for the subjects who have PD, 
the true date of disease progression will be approximated by [CONTACT_551726] 1.[ADDRESS_725195] disease assessment without PD 
when PD or death is documented after more than one missed disease assessment. The second 
sensitivity  analysis is the same as the primary  analysis except that it considers 
discontinuation of treatment or initiation of new anticancer treatment, whicheve r occurs later, 
to be a PD event for subjects without documented PD or death. The censoring rules for 
primary  and sensitivity  anal yses are summarized in Table 11.
Table 11 Censoring Rules for Primary  and Sensitivity  Analy ses of PFS
SituationPrimary 
AnalysisSensitivity
Analysis 1Sensitivity
Analysis 2
No PD and no death; 
new anticancer 
treatment is not 
initiatedCensored at last 
disease 
assessment Censored at last 
disease assessment Censored at last disease 
assessment if still on 
study therapy; progressed 
at treatment 
discontinuation otherwise
No PD and no death; 
new anticancer 
treatment is initiatedCensored at last 
disease 
assessment before 
new anticancer 
treatmentCensored at last 
disease assessment 
before new 
anticancer treatmentProgressed at date of new 
anticancer treatment
PD or death 
documented after ≤ 1 
missed disease 
assessmentProgressed at date 
of documented 
PD or deathProgressed at date of 
documented PD or 
deathProgressed at date of 
documented PD or death
PD or death 
documented after ≥ [ADDRESS_725196] 
disease assessment 
prior to the  ≥ [ADDRESS_725197]:   MK -3475 (SCH 900475), INCB 024360 114
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
ConfidentialIn case there is an imbalanc e between the treatment groups on disease assessment schedules 
or censoring patterns, the following two additional PFS sensitivity  analyses may be 
performed: 1) a PFS analy sis using time to scheduled tumor assessment visit from 
randomization as opposed to actual tumor assessment time; 2) Finkelstein’s likelihood -
based score test for interval- censored data [54] which modifies the Cox proportional hazard 
model for interval censored data ,will be used as a supportive analy sis for the PFS endpoint. 
The interva l will be constructed so that the left endpoint is the date of the last disease 
assessment without documented PD and the right endpoint is the date of documented PD or 
death, whichever occurs earlier.
The proportional hazards assumption onPFS will be examined using both graphical and 
analytical methods if warranted. Th elog[-log] ofthesurvival function versus time forPFS 
will beplotted forthecomparison between pembrolizumab andthecontrol group . Ifthe
curves are not parallel, indicating that hazards are not proportional, supportive analyses 
maybe conducted to account for the possible non-proportional hazards effect associated 
with immunotherapi[INVESTIGATOR_014]: for example, using Restricted Mean Survival Time (RMST) method
[55], parametric method [56], comparison of PFS at fixed follow -up times (6 months; 1 
year) etc. Further details ofsensitivity anal yseswillbedescribed insupplemental SAP.
[IP_ADDRESS] Overall Survival (OS)
To address the primary  OS hypothesis, the Kaplan -Meier method will be used to estimate the 
OS curves. The treatment difference in survival will be assessed by [CONTACT_113821]-rank 
test. A stratified Cox proportional hazard model with Efron's method of tie handling will be 
used to assess the magnitude of the treatment difference (i.e., the hazard ratio). The hazard 
ratio and its 95% confidence interval from the stratified Cox model with a single treatment 
covariate will be reported. The same stratific ation factors used for randomization (see 
Section 5.4) will be applied to both the stratified log -rank test and the stratified Cox model.
[IP_ADDRESS] O bjective Response Rate (ORR)
To address the secondary  ORR hypothesis, stratified Miettinen and Nurminen’s method [57]
with weighting based on group size will be used for comparison of the objective response 
rates between the treatment groups. A 95% confidence interval for the difference in response 
rates between the pembrolizumab + epacadostat regimen and the pembrolizumab + placebo 
regimen will be provided. Sensitivity  analyses will be performed for ORR using Cochran-
Mantel -Haenszel test. Associated odds ratios and 95% CIs will be calculated . The same 
stratification factors used for randomization (see Secti on 5.4) will be applied to the analy sis. 
Table [ADDRESS_725198]:   MK-3475 (SCH 900475), INCB 024360 115
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
ConfidentialTable 12 Analy sis Strategy  for Key  Efficacy  Variables
Endpoint/Variable
(Description, Time Point) Statistical MethodAnalysis 
PopulationMissing Data 
Approach
Dual Prim ary Hypotheses #1 and #2
Progression free -survival (per 
independent central review as 
assessed by [CONTACT_393] 1.1 )Testing: Stratified Log -
rank test
Estimation: Stratified Cox 
model with Efron's tie 
handling methodITT Model based
Overall survival Testing: Stratified Log -
rank test
Estimation: Stratified Cox 
model with Efron's tie 
handling methodITT Model based
Secondary Objectives 
ORR (per independent central review 
as assessed by[CONTACT_393] 1.1)Testing andestimation: 
Stratified Miettinen and 
Nurminen’s methodITT Model based
DOR (per independent central review  
as assessed by [CONTACT_393] 1.1)Testing: Stratified Log -
rank test
Estimation: Stratified Cox 
model with Model based  
Efron's tie handling 
methodITT (responder 
subs Model 
based et)Model based
The strategy  to address multiplicity  issues with regard to multiple efficacy  endpoints and 
interim analyses is described in Section 8.7, Interim Anal yses and in Section 8.8, 
Multiplicity .
Statistical Methods for Safety Analyses 8.6.2
Safety  and tolerability  will be assessed by  [CONTACT_551727] (AEs), laboratory  tests, vital signs, and ECG measurements.
The analysis of safet y results will follow a tiered approach (Table 13).  The tiers differ with 
respect to the anal yses that will be performed.  Safety  parameters or adverse events of special 
interest that are identified a priori constitute “Tier 1”safety  endpoints that will be subject to 
inferential testing for statistical significance with p-values and 95% confidence intervals 
provided for between -group comparisons.  For this protocol, there are no Tier 1 events .  
Other safet y parameters will be considered Tier 2 or Tier 3.  Tier 2 parameters will be 
assessed via point estimates with 95% confidence intervals provided for between -group 
comparisons; only point estimates by [CONTACT_113825] [ADDRESS_725199]:   MK -3475 (SCH 900475), INCB 024360 116
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
ConfidentialTable 13 Analy sis Strategy for Safety  Parameters
Safety Tier Safety Endpoint†p-Value95%  CI for 
Treat ment 
ComparisonDescriptive 
Statistics
Tier 2 Any AE X X
Any Serious AE X X
Any Drug -Related AE X X
Any Serious and Drug -Related AE X X
Discontinuation due to AE X X
Specific AEs, SOCs, or PDLCs‡(incidence ≥4/1% of 
subjects in one of the treatment groups)X X
Tier 3 Specific AEs, SOCs or PDLCs‡(incidence <4/1% of 
subjects in all of the treatment groups)X
Change from Baseline Results (Labs, ECGs, Vital 
Signs)X
†Adverse Event references refer to both Clinical and Laboratory AEs.
‡Includes only those endpoints not pre -specified as Tier 1 or not already pre -specified as Tier -2 endpoints.
Note: SOC=System Organ Class; PDLC=Pre -Defined Limit of Change; X= results will be provided.
Adverse events (specific terms as well as system organ class terms) and predefined limits of 
change in laboratory , vital signs, and ECG parameters that are not pre-specified as Tier-1 
endpoints will be classified as belonging to "Tier 2" or "Tier 3", based on the number of 
events observed.  Membership in Tier [ADDRESS_725200] 4 subjects in any treatment 
group exhibit the event; all other adverse events and predefined limits of change will belong 
to Tier 3.
The threshold of at least 4 events was chosen because the95% confidence interval for the 
between -group difference in percent incidence will alway s include zero when treatment 
groups of equal size each have less than 4 events and thus would add little to the 
interpretation of potentially  meaningful differences. Because many  95% confidence intervals 
may be provided without adjustment for multiplicity , the confidence intervals should be 
regarded as a helpful descriptive measure to be used in review, not a formal method for 
assessing the statistical significance ofthe between- group differences in adverse events and 
predefined limits of change.
Continuous measures such as changes from baseline in laboratory , vital signs, and ECG 
parameters will be considered Tier [ADDRESS_725201] clinical and laboratory  AE categories consisting of the percentage of subjects with 
any AE, a drug related AE, a serious AE, an AE which is both drug-related and serious, and 
who discontinued due to an AE will be considered Tier 2 endpoints.  Ninety -five percent 
confidence intervals (Tier 2) will be provided for between- treatment differences in the  
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 117
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
Confidentialpercentage of subjects with events; these analy ses will be performed using the unstratified 
Miettinen and Nurminen method [57], an unconditional, asymptotic method.
Summaries of Baseline Characteristics, Demographics, and Other Analyses 8.6.3
The comparability  of the treatment groups for each relevant characteris tic will be assessed by 
[CONTACT_113827]/or graphs.  No statistical hypothesis tests will be performed on these 
characteristics.  The number and percentage of subjects screened, randomized, the primary 
reasons for screening failure, and the primary  reason for discontinuation will be display ed.  
Demographic variables, baseline characteristics, primary  and secondary  diagnoses, and prior 
and concomitant therapi[INVESTIGATOR_180575].
Inter im Analyses 8.7
If the statistical criterion for success for one or more of the primary  hypotheses is met at an 
interim analy sis, a regulatory  submission may be prepared while the trial continues, and the 
Clinical Study  Report (CSR) will comprise all available data used to draw the conclusion in 
the decisive interim analysis.  The remaining data obtained afterwards (from additional visits 
and close -out visits) will be reported in a subsequent CSR. 
Efficacy Interim Analyses 8.7.1
Three analyses (twointerim and one final) are planned in this trial.   Table 14provides the 
summary  of the strategy  and timing of the interim and final analy ses. Accrual is expected to 
be completed prior to the first interim analysis.  The final analysis of PFS will be performed 
at interim analysis 2(IA2) scheduled to be performed at abou t 420 PFS events (about 24
months following the start of enrollment ).The final analysis of OS will be performed at 
about 293 OS events (about 4 5months following the start of en rollment).   
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 118
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
ConfidentialTable 14 Summary of Interim Analy sis Strategy
AnalysisKey 
endpointsTargeted number of 
events at the time of 
analysisExpected 
approximate 
timing of analysis 
(from study start)Primary purpose of 
analysis
IA 1PFS
OSApproximately [ADDRESS_725202] interim analysis of 
PFS: dem onstrate superiority 
of combination in PFS. First
interim analysis of OS; 
Dem onstrate superiority of 
combination in OS .
IA 2PFS
OSApproximately 420 total 
PFS events.  This is the 
final PFS analysis.  About 
200 OS events are 
expected at IA2.About 24monthsFinal analysis of PFS:
demonstrate superiority of 
combination in PFS .  
Second interim look at OS; 
Dem onstrate superiority of 
combination in OS .  
Final OS Approximately 293 total 
OS events.  This is the 
final OS analysis.  About 45months Final OS analysis:
Dem onstrate superiority of 
combination in OS .
Table [ADDRESS_725203] 
ratio
IA 1 ~331 < 0.0053 < ~0.75 ~100 < 0.0001 < ~0.46
IA 2
(Final 
PFS 
analysis)~420 < 0.0108 < ~0.80 ~200 < 0.0029 < ~0.68
Final 
OS 
AnalysisTargeted 
for ~293< 0.0115 < ~0.[ADDRESS_725204] occurred between the 
pembrolizumab + epacadostat regimen and the pembrolizumab + placebo regimen, which is 
expected to occur ~45months after study  start.  According to Table 15the nominal alpha for 
the 
final OS testing is 0.0115 (one-sided) if no alpha r e-use occurs. A nominal alpha 
< 0.[ADDRESS_725205] ratio for OS superiority  < 0.77. 
The nominal alpha level for PFS and OS interim hypothesis testing will be re-calculated if 
the actual number of events available at the times of the interim analy ses is different from 
those specified above .The nominal alpha level for OS interim hypothesis testing will be re- 
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 119
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
Confidentialcalculated if alpha is transferred to the OS hypothesis testing following a significant 
difference seen in PFS. A 95% confidence interval will be provided for the hazard ratios to 
characteri ze the PFS and OS effect sin case the superiorit y of the combination is not 
demonstrated. 
ORR analysis: Should the definitive OS analysis be statistically  significant at any interim or 
final anal ysis, the definitive ORR anal ysis will be performed using the data available at IA 2.
Safety Interim Analyses 8.7.2
The external Data Monitoring Committee (DMC) will perform ongoing review of the interim 
safet y data from this trial , as described in Section 7.3. 3. 
Multiplicity 8.8
The multiplicity  strategy  specified in thi s section will be applied to the overall ITT 
population for the testing of primary  hypotheses. The overall type I error is strongl y 
controlled at 2.5% (one-sided) for the multiple endpoints tested, as well as for the multiple 
analyses of overall survival planned using the methods of Maurer and Bretz [ 59],with 1.25% 
allocated up front to the PFS hypothesis and 1.25% allocated up front to the OS hypotheses.  
The trial is considered statistically positive if either PFS or OS is positive.
The superiority  of PFS will be tested at 1.25% in this study . If the pembrolizumab + 
epacadostat combination regimen demonstrates superior PFS, the 0.[ADDRESS_725206]:   MK-3475 (SCH 900475), INCB 024360 120
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
ConfidentialFigure 3Graphical Display  of Testing Strategy  
For the PFS and OS hypothesis, anexponential alpha -spending function (see Anderson and 
Clark [60]) with nu=0.7 5 (approximating an O’Brien -Fleming boundary) will be used.  For 
PFS the cumulative alpha will be 1.25%unless OS and ORR are statistically  significant, in 
which case the 1.25% alpha associated with OS will be reallocated to PFS and testing will be 
done at 2.5% alpha.  For OS,the cumulative alpha will be1.25% (if PFS superiority  is not 
demonstrated) or 2.5% (if PFS superiority  is demonstrated) .  
Sample Size and Power Calculations 8.9
Sample Size and Power for Efficacy Analyses 8.9.1
The study  will randomize subjects in a 1:1 ratio into the pembrolizumab + epacadostat 
regimen and the pembrolizumab + placebo regimen. The overall sample size for this study
was projected to be ~600 subjects (maximum enrollment 660).  Enrollment, excluding Japan, 
was 662 subjects, and is expected to be a total of 700 subjects after enrollment in Japan is 
completed.
The study is event driven (i.e., number of subjects and follow -up time are subject to change 
but number of events is not) and will complete after approximately  [ADDRESS_725207]:   MK -3475 (SCH 900475), INCB 024360 121
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
ConfidentialPFS analysis :The primary  PFS analysis will be carried out at the second interim analy sis, 
which occurs after about [ADDRESS_725208] been observed, expected tooccur about 24
months from the start of enrollment. An initial alpha of 1.25% will be allocated to the PFS 
analysis. If the number of PFS events is ex actly  as specified in Table 15,the study  has about 
98% power to detect a 0.65:1.[ADDRESS_725209] rat io < 0.80.
OS analyses : OS efficacy  analyses will be performed at the first and second interim anal yses.  
The final analy sis will be conducted when about [ADDRESS_725210] been observed.  An initial 
alpha of 1.25% will be allocated to the OS analy sis. If the comparison of PFS is not 
statistically  significant, and the number of OS events is exactly  as specified in Table 15, the 
study  has about 79% power to detect a 0.[ADDRESS_725211].  Details 
on the nominal alpha and the 
approximate efficacy  boundary  at each interim analysis are summarized in Section 8.2.9.  
The nominal alpha levels will be re-calculated based upon the actual observed number of 
deaths at each interim analy sis using the alpha -spending function.  If the comparison of PFS 
is statistically  signific ant, the 1.25% allocated to the PFS comparison will be re-allocated to 
the OS comparison.  If superiority  of the combination is demonstrated for PFS, the OS 
comparison will be performed at an alpha of 2.5% and, if the final analy sis is done at [ADDRESS_725212] ratio of 0.70 will be approximately  86%. If the 
accumulation of the final number of OS events (293) is substantially  delayed from the 
estimated 45 months, an additional interim 
analy sis may  be added .
ORR analysis: Should the definitive OS analy sis be statistically  significant, the definitive 
ORR analy sis will be performed using the data available at IA2.  Assuming the available 
alpha for the ORR comparison is 2.5% and an ORR of 35% for the pembrolizumab + placebo 
regimen, the study  has ~97% power to detect an ORR rate for the combination regimen of 
50%.   
The 
above calculations are based on the following assumptions (in addition to the interim 
analysis plan in Section 8.7):  1)OS for the pembrolizumab + placebo regimen follows a 
distribution with a “cure” rate of 35%, with survival for the remaining 65% of patients 
following an exponential distribution with a median of 14months; 2) PFS follows a 
distribution with a “cure” rate of 30%, with PFS for the remaining 70% of patients following 
an exponential distribution with a median of 4.75 months in the 
pembrolizumab + placebo 
regimen; 3) the hazard ratio for OS between the pembrolizumab + epacadostat combination 
and pembrolizumab + placebo is 0.7; 4) hazard ratio for PFS between the pembrolizumab + 
epacadostat combination and pembrolizumab + placebo is 0.65 and 5) an enrollment period 
of approximately  12months. The sample size and power calculation were performed in the 
software R package gsDesign (see R code, Section 12.10) . 
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 122
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-[ADDRESS_725213] (with a nominal 95% CI) for the primary 
endpoint will be estimated and plotted within each category  of the following classification 
variables:
Age category  (<65 vs. ≥65 years)
Sex (female vs. male)
Race (white vs. non -white)
Disease stage (III vs. IVM1a vs. IVM1b vs .IVM1c)
ECOG status (0 vs. 1)
BRAF mutation status (wild type vs. mutant with prior BRAF directed therapy  vs. 
mutant with no prior BRAF directed therap y)
PD-L1 status (positive vs. negative [includes indeterminate ])
LDH ( ≤ ULN vs. > ULN but < 2X ULN vs. ≥ 2X ULN)
In addition, a Forest plot will be produced, which provides the estimated point estimates and 
confidence intervals for the treatment effect across the categories of subgroups listed above.
The consistency  of the treatment effect will be assessed descriptively  via summary  statistics 
by [CONTACT_126557].
Compliance (Medication Adherence) 8.11
Pembrolizumab: Drug accountability  data for pembrolizumab will be collected during the 
study . Compliance with protocol -directed pembrolizumab will be measured by [CONTACT_1766]: (1) 
receiving unscheduled study  agent infusions/injections, (2) missing an infusion/injection, (3) 
receiving incorrect study  agent dose, and (4) receiving an infusion at rate greater than 
10mL/min. Numbers and percentages of subjects and infusion/injection visits with any 
deviation in these measures will be reported for the ITT population.
Epacadostat: In this study , as part of the routine recording of the amount of study  treatm ent 
taken by [CONTACT_551728], reviewed, and recorded at regular intervals.  These 
results will be used to calculate subject compliance.
For a subject who is followed for the entire study period, the “Number of Epacadostat 
Doses Should be on Therapy” is the total number of protocol specified doses from 
first treatment day to the last scheduled day for treatment administration for that 
subject.  For a subject who discontinued from the study  permanently , the “Number of 
Epacadostat Doses Should be on Therap y” is the total number of doses from first 
treatment day  to the date the subject discontinued from the study . 
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 123
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
ConfidentialPercent compliance is defined as “the number of doses the patient received on therap y” 
divided by “the number of doses the patient should have received on therapy ” multiplied by 
100.
Summary  statistics will be provided on percent compliance by [CONTACT_115381].
Extent of Exposure 8.[ADDRESS_725214] Name & Potency Dosage Form
pembrolizumab 100 mg/4 mL Solution for I nfusion
Packaging and Labeling Information 9.2
Clinical supplies will be affixed with a clinical label in accordance with regulator y 
requirements.
Pembrolizumab (MK -3475) will be provided as a kitted supply .
Clinical Supplies Disclosure 9.3
NOTE:  As of Amendment 10, blinding is no longer applicable –all subjects will receive open -
label pembrolizumab alone.
This is a blinded trial in which the epacados tat or epacadostat placebo treatment is blinded.  
However, the pembrolizumab (MK- 3475) provided for the trial is open -label; therefore, the 
subject, the trial site personnel, the Sponsor , MSD and/or designee are not blinded to the  
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 124
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
ConfidentialMK- 3475 treatment . Treatment (name, strength or potency ) is included in the label text; 
random code/ disclosure envelopes or lists are not provided.
The emergency  unblinding call center will use the treatment/randomization schedule for the 
study  to unblind subjects and to unmask epacadostat or matching placebo treatment identity  
The emergency  unblinding call center should only be used in cases of emergency  (see 
Section [IP_ADDRESS] ). In the event that the emergency  unblinding call center is not available for a 
given site in this study, the central electronic treatment allocation/randomization system 
(IVRS/I WRS ) should be used in order to unblind subjects and to unmask study  treatment 
identity . MSD will not provide random code/disclosure envelopes or lists with the clinical 
supplies.
Treatment identification information is to be unmasked ONLY if necessary  for the welfare of 
the subject.  Every  effort should be made not to unblind the subject unless necessary . 
In the event that unblinding has occurred, the circumstances around the unblinding (e.g., 
date, reason and person performing the unblinding) must be documented promptly , and MSD
Clinical Director notified as soon as possible.  Only  the principal investigator [INVESTIGATOR_551672]’s code should be unblinded.  Trial site personnel ,MSD , and Sponsor
personnel directl y associated with the conduct of the trial should not be unblinded to 
treatment assignment.
Section 5.[ADDRESS_725215]/Destruction/ Returns and Reconciliation 9.[ADDRESS_725216]/destruction p rocedure is documented . 
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 125
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-[ADDRESS_725217] access to a central electronic treatment 
allocation/ randomization system (IVRS/I WRS system) to allocate subjects, to assign 
treatment to subjects and to manage the distribution of clinical supplies. Each person 
accessing the IVRS system must be assigned an individual unique PIN.  They must use only 
their assigned PIN to access the system, and they must not share their assigned PIN with 
anyone.
At the close of the trial after unblinding , a letter is to be sent by [CONTACT_551729]’s product to provide the following 
advice: 
“You have participated in a trial conducted by [CONTACT_551730]. This is 
to advise you that you were among those who received a look -alike tablet created by [CONTACT_551731]. You did not receive the active
drug epacadostat as manufactured b y Incyte.”
10.[ADDRESS_725218], ethics review committee (IRB/ERC) or similar or expert 
committee; affiliated institution and employ ees, only under an appropriate understanding of 
confidentiality  with such board or committee, affiliated institution and employ ees.  Data 
generated b y this trial will be considered confidential by  [CONTACT_093], except to the extent 
that it is included in a publication as provided in the Publications section of this protocol.
Confidentiality of Subject Records 10.1.2
By [CONTACT_12570], the investiga tor agrees that the Sponsor , MSD, or Sponsor or MSD 
representative, IRB/ERC, or regulatory  authority representatives may consult and/or copy 
trial documents in order to verify  worksheet/case report form data.  By [CONTACT_398856], the subject agree s to this process.  If trial documents will be photocopi[INVESTIGATOR_551673]/case report form information, the subject will be identified by  
[CONTACT_398857] y; full names/initials will be masked prio r to transmission .
By [CONTACT_12570], the investigator agrees to treat all subject data used and disclosed in 
connection with this trial in accordance with all applicable privacy laws, rules and 
regulations. 
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 126
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-[ADDRESS_725219] to the investigator, and all subinvestigators and trial site personnel, 
may be used and disclosed for trial management purposes, as part of a regulatory  
submissions, and as r equired b y law.  This information may include:
1.name, address, telephone number and e -mail address;
2.hospi[INVESTIGATOR_26342];
3.curriculum vitae or other summary  of qualifications and credentials; and
4.other professional docu mentation.
Consistent with the purposes described above, this information may be transmitted to the 
Sponsor, MSD, and subsidiaries, affiliates and agents of the Sponsor or MSD , in your 
country  and other countries, including countries that do not have laws protecting such 
information.  Additionally, the investigator’s name [CONTACT_26407] [CONTACT_551732].  By [CONTACT_12570], the investiga tor expressly  consents to these uses and 
disclosures.
If this is a multicenter trial, in order to facilitate contact [CONTACT_26387], an 
investigator’s name [CONTACT_3669] [CONTACT_551733].
Confidentiality of IRB/IEC Information 10.1.4
The name [CONTACT_19525]/IEC that reviews and approves this trial is required to be 
recorded .  There is also a requirement to document that each IRB/IEC meets regulatory  and 
ICH GCP requirements by [CONTACT_551734]/IEC members and to make these records available for regulatory  
agency  review upon request by  [CONTACT_19496].
Compliance with Financial Disclosure Requirements 10.2
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure by [CONTACT_6230] (21 CFR Part 54).  Financial 
Disclosure information may be requested based on these regulations .  It is the 
investigator's/subinvestigator's responsibility to comply with an y such request.  
The investigator/subinvestigator(s) agree, if requested in accordance with 21 CFR Part 54, to 
provide his/her financial interests in and/or arrangements with the Sponsor and M SD to allow 
for the submission of complete and accurate certification and disclosure statements.  The 
investigator/subinvestigator(s) further agree to provide this information on a provided 
Certification/Disclosure Form, commonly  known as a financial discl osure form . The  
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 127
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
Confidentialinvestigator/subinvestigator(s) also consent to the transmission of this information to and 
within the [LOCATION_002] for these purposes.  This may involve the transmission of 
information to countries that do not have laws protecting persona l data.
Compliance with Law, Audit and Debarment 10.[ADDRESS_725220] the trial in an efficient and 
diligent manner and in conformance with this protocol; generall y accepted standards of Good 
Clinical Practice (e.g., International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice: 
Consolidated Guideline and other generally  accepted standards of good clinical practice); and 
all applicable fede ral, state and local laws, rules and regulations relating to the conduct of the 
clinical trial.
The Code of Conduct, a collection of goals and considerations that govern the ethical and 
scientific conduct of clinical investigations, is provided in Section 12.[ADDRESS_725221] for Clinical Trials .
The investigator also agrees to allow monitoring, audits, IRB/ERC review and regulatory  
authority  inspection of trial- related documents and procedures and provide for direct access 
to all trial -related sour ce data and documents.
The investigator agrees not to seek reimbursement from subjects, their insurance providers or 
from government programs for procedures included as part of the trial reimbursed to the 
investigator b y MSD .
The investigator shall prepare and maintain complete and accurate trial documentation in 
compliance with Good Clinical Practice standards and applicable federal, state and local 
laws, rules and regulations; and, for each subject participating in the trial, provide all data, 
and, upon completion or termination of the clinical trial, submit any  other reports as required 
by [CONTACT_551735].
Trial documentation will be promptly  and fully  disclosed by [CONTACT_551736], copy ing, review 
and audit at reasonable times by [CONTACT_551737].  The investigator agrees to promptly  take any reasonable steps that ar e requested 
as a result of an audit to cure deficiencies in the trial documentation and worksheets/case 
report forms.
The investigator must maintain copi[INVESTIGATOR_551674].  This 
documentation includes, but is not limited to, the protocol, worksheets/case report forms, 
advertising for subject participation, adverse event reports, subject source data, 
correspondence with regulatory  author ities and IRBs/ERCs, consent forms, investigator’s 
curricula vitae, monitor visit logs, laboratory  reference ranges, laboratory  certification or 
quality  control procedures and laboratory  director curriculum vitae.  By  [CONTACT_12570],  
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 128
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-[ADDRESS_725222] consult with and obtain 
written approval b y MSD prior to destro ying trial and/or subject files.  
ICH Good Clinical Practice 
guidelines recommend that the investigator inform the subject’s 
primary  physician about the subject’s participation in the trial if the subject has a primary  
physician and if the subject agrees to the primary  physician being informed.
The investigator will promptly  inform MSD of any  regulatory  authorit y inspection conducted 
for this trial.
Persons debarred from conducting or working on clinical trials by [CONTACT_551738].  The investigator will 
immedia tely disclose in writing to MSD if any person who is involved in conducting the trial 
is debarred or if any proceeding for debarment is pending or, to the best of the investigator’s 
knowledge, threatened.
In the event 
a particular trial site is prematurel y terminated, that trial site’s IRB/IEC.
Accordin g to European legislation, a sponsor must designate an overall coordinating 
investigator [INVESTIGATOR_8178] a multi- center trial (including multinational).  When more than one trial site 
is open in an EU country , MSD will designate, per country , a national principal coordinator 
(Protocol CI), responsible for coordinating the work of the principal investigators at the 
different trial sites in that Member State, according to national regulations.  For a single -
center trial, the Protocol CI is the principal investigator.  In addition, MSD must designate a 
principal or coordinating investigator [INVESTIGATOR_537562], to the best of his/her knowledge, the report accurately  describes the 
conduct and results of the trial [Clinical Study  Report (CSR) CI ].  MSD may consider one or 
more factors in the selection of the individual to serve as the Protocol CI and or CSR CI  (e.g., 
availability  of the CI during the anticipated review process, thorough understanding of 
clinical trial methods, appropriate enrollment of subject cohort, timely  achievement of trial 
milestones).  The Protocol CI  must be a participating trial investigator. 
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 129
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-[ADDRESS_725223] (FDAMA) and the 
Food and Drug Administration Amendments Act (FDAAA), the sponsor of the trial is solel y 
responsible for determining whether the trial and its results are subject to the requirements 
for submission to the Clinical Trials Data Bank, http://www.clini caltrials.gov.  The Sponsor
will review this protocol and submit the information necessary  to fulfill these requirements.  
Entries are not limited to FDAMA/FDAAA mandated trials. Information posted will allow 
subjects to identify  potentially  appropriate trials for their disease conditions and pursue 
participation by [CONTACT_3379] a central contact [CONTACT_266222].    
By [CONTACT_12570], the investigator acknowledges that the statutory  obligations under 
FDAMA/FDAAA are that of the Sponsor and agrees not to submit any  information about this 
trial or its results to the Clinical Trials Data Bank.
Quality Management System 10.[ADDRESS_725224] operating procedures (SOPs) to ensure that trials are 
conducted and data are generated, documented, an d reported in compliance with the protocol, 
accepted standards of Good Clinical Practice, and all applicable federal, state, and local laws, 
rules and regulations relating to the conduct of the clinical trial.
Data Management 10.[ADDRESS_725225] data.  By [CONTACT_12570], the investigator acknowledges that his/her 
electronic signature [CONTACT_75412] y binding equivalent of a written signature.  By [CONTACT_75393] g 
his/her electronic signature, the investigator confirms that all recorded data have been 
verified as accurate.
Detailed information regarding Data Management procedures for this protocol will be 
provided separatel y.
Publications 10.7
Study  results will be published in acco rdance with applicable local and national regulations.  
If necessary , the authorities will be notified of the investigator’s name, address, 
qualifications, and extent of involvement.  The terms regarding the publication of study 
results are contained in the agreement signed with the Sponsor and/or MSD.  A  s igned 
agreement will be retained by  [CONTACT_1052]/or MSD . 
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 130
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-[ADDRESS_725226] OF REFERENCES
1.Disis ML . Immune regulation of cancer. J Clin Oncol 2010;28:4531 -4538.
2.Boon T, van der Bruggen P. Human tumor antigens recogn ized by T lymphocy tes. J 
Exp Med 1996;183:725-729.
3.Ercolini AM, Ladle BH, Manning EA, etal. Recruitment of latent pools of high 
avidity  CD8(+) T cells to the antitumor immune response. J Exp Med 2005;201:[ADDRESS_725227] clinical outcome. Science 
2006;313:1960-1964.
5.Talmadge JE, Donkor M, Scholar E. Inflammatory  cell infiltration of tumors: Jekyll 
or Hy de. Cancer Metastasis Rev 2007;26:373 -400.
6.Usubütün A, Ayhan A, Uygur MC, zen H, klu C, Acan S. Prognostic factors in renal 
cell carcinoma. J Exp Clin Cancer Res 1998;17:77 -81.
7.Hiraoka N. Tumor -infiltrating lymphocy tes and hepatocellular carcinoma: molecular
biology . Int J Clin Oncol 2010;15:544 -551.
8.Nobili C, Degrate L, Caprotti R, et al. Prolonged survival of a patient affected by 
[CONTACT_551739] -2 immunotherap y. Report of a case. Tumori 2008;94:426 -430.
9. Hodi FS, Dranoff G. The biologic importance of tumor -infiltrating lymphocy tes. J 
Cutan Pathol 2010;37(suppl 1):48 -53.
10.Kloor M. Lym phocy te infiltration and prognosis in colorectal cancer. Lancet Oncol 
2009;10:840 -841.
11. Hillen F, Baeten CIM, van de Winkel A, et al. Leukocy te infiltration and tumor cell 
plasticity  are parameters of aggressiveness in primary  cutaneous melanoma. Cancer 
Immunol Immunother 2008;57:97 -106.
12.Lee HE, Chae SW, Lee YJ, et al. Prognostic implications of type and density  of 
tumour -infiltrating l ymphocy tes in gastric cancer. Br J Cancer 2008;99:1704 -1711.
13.Leffers N, Gooden MJM, de Jong RA, et al. Prognostic significance of tumor -
infiltrating T-lymphocy tes in primary  and metastatic lesions of advanced stage 
ovarian cancer. Cancer Immunol I mmunother 2009;58:[ADDRESS_725228]:   MK -3475 (SCH 900475), INCB 024360 131
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
Confidential14.Nishimura H, Honjo T, Minato N. Facilitation of β selection and modification of 
positive selection in the thymus of PD-1-deficient mice. J Exp Med 2000;191:891 -
897.
15.Liotta F, Gacci M, Frosali F, et a l. Frequency  of regulatory  T cells in peripheral blood 
and in tumour -infiltrating lymphocy tes correlates with poor prognosis in renal cell 
carcinoma. BJU Int 2010;107:1500-1506.
16.
Godin- Ethier J, Hanafi LA, Pi[INVESTIGATOR_74852], etal. Indoleamine 2,3-dioxy genase 
expression in human cancers: clinical and immunologic perspectives. Clin Can Res 
2011;17:6985
-6991.
17.Mellor AL, Munn DH. IDO expression by [CONTACT_405]: tolerance and tryptophan 
catabolism. Nat Rev Immunol 2004;4:[ADDRESS_725229] 2007;117:1147
-1154.
19.Mellor AL, Baban B, Chandler P, etal. Induced indoleamine 2,3, dioxy genase 
expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol 
2003;171:1652-1655.
20.Frumento G, Rotondo R, Tonetti M, etal.  Tryptophan -derived catabolites are 
responsible for inhibition of T and natural killer cell proliferation induced by 
[CONTACT_165958] 2,3 -dioxy genase. J Exp Med 2002;196:459-468.
21.Fallarino F, Grohmann U, You S, et al. The combined effects of try ptophan starvation 
and tryptophan catabolites down -
regulate T cell receptor zeta-chain and induce a 
regulatory  phenot ype in naive T cells. J I mmunol 2006;176:6752 -6761.
22.Zou W. Regulatory  T cells, tumour immunity  and immunotherapy . Nat Rev Immunol 
2006;6:295-307.
23.Munn DH, Zhou M, Attwood JT, etal. Prevention of allogeneic fetal rejection by 
[CONTACT_551740]. Science 1998;281:1191- 1193.
24.Uyttenhove C, Pi[INVESTIGATOR_165856] L, Théate I, etal. Evidence for a tumoral immune resistance 
mechanis m based on tryptophan degradation by [CONTACT_165958] 2,3-dioxy genase. Nat 
Med 2003;9):[ADDRESS_725230] GC. 
Inhibition of indoleamine 2,3-dioxy genase, an immunoregulatory  target of the cancer 
suppressio n gene Bin1, potentiates cancer chemotherap y. Nat Med 2005;11:312 -
319.
26.Huang L, Baban b, Johnson BA, Mellor AL. Dendritic cells, indoleamine 2,3 
dioxy genase and acquired immune privilege. Int Rev I mmunol 2010;29:[ADDRESS_725231]:   MK -3475 (SCH 900475), INCB 024360 132
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
Confidential27.Weinlich G, Murr C, Richardsen L, W inkler C, Fuchs D. Decreased serum try ptophan 
concentration predicts poor prognosis in malignant melanoma patients. Dermatology 
2007;214:8-14.
28.Okamoto A, Nikaido T, Ochiai K, et al. Indoleamine 2,3-dioxy genase serves as a 
marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. 
Clin Cancer Res 2005;11:6030-6039.
29.Brandacher G, Perathoner A, Ladurner R, etal. Prognostic value of indoleamine 2,3-
dioxy genase expression in colorectal cancer: effect of tumor 
infiltrating T cells. Clin
Cancer Res 2006;12:1144-1151.
30.Ino K, Yoshida N, Kajiy ama H, et al. Indoleamine 2,3-dioxy genase is a novel 
prognostic indicator for endometrial cancer. Br J Cancer 2006;95:1555 -1561.
31.Nakamura T, Shima T, Saeki A, et al. Expression of indoleamine 2, 
3-dioxy genase 
and the recruitment of Foxp3 -expressing regulatory  T cells in the development and 
progression of uterine cervical cancer. Cancer Sci 2007;98:874-881.
32.Witkiewicz A, Williams TK, Cozzitorto J, et al. Expression of indoleamine 2,3-
dioxy genase in metastatic pancreatic ductal adenocarcinoma recruits regulatory  T 
cells to avoid immune detection. J Am Coll Surg 2008;206:849
-854.
33.Robert C, Thomas L , Bondarenko I, et al. Ipi[INVESTIGATOR_80049]. N Engl J Med 2011;364:2517-2526. 
34.Topalian SL, Hodi FS, Brahmer JR, et al. Safety , activity , and immune correlates of 
Anti- PD-1 antibody  in cancer. N Engl J Med 2012;366:2443 -2454.
35. H amid O, Rober C, Daud A, et al. Safety  and tumor responses with lambrolizumab 
(Anti -PD-1) in melanoma. N Engl J Med 2013;369:134-144.
36.Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipi[INVESTIGATOR_195709]. N Engl J Med 2013;369:[ADDRESS_725232] cancer. Br J Cancer 2013;108:1560 -1565.
38.Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA -4 combination 
blockade expands infiltrating T cells and reduces regulatory  T and myeloid cells 
within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010;107:4275 -4280.
39.Selby  M, Engelhardt J, Lu L-S, et al. Antitumor activity  of concurrent blockade of 
immune checkpoint molecules CTLA -4 and PD-1 in preclinical models. J Clin Oncol 
2013;31(suppl):3061 (abstr). 
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 133
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
Confidential40.Postow M, Chesney  J, Pavlick A, et al.  Nivolumab and ipi[INVESTIGATOR_551675]. N Engl J Med 2015;372:[ADDRESS_725233] RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-
dioxy genase is a critical resistance mechanism in antitumor T 
cell immunotherap y 
targeting CTLA -4. J Exp Med 2013;210:1389-1402.
42.Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF. Up-
regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is 
driven by  [CONTACT_398]8(+) T cells. Sci Transl Med 2013;5:200ra116.
43.Ferlay  J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of 
worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 
2010;127:2893-2917.
44.Siegel R, Naishadham MA, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. Jan-
2012;62:10-29.
45.Cancer Facts and Figures 2012. American Cancer Society .Atlanta, GA 2012.
46.American Cancer Society . Melanoma Skin Cancer. Atlanta, GA: American Cancer 
Society (ACS); 2015. http://www.cancer.org/cancer/skincancer -melanoma/index.  
Accessed May  13, 2015.
48.UpToDate. Overview of the management of advanced cutaneous melanoma. 2015. 
http://www.uptodate.com/contents/overview -of-the-management -of-advanced -
cutaneous -
melanoma?topi[INVESTIGATOR_261293] =ONC%2F85841&elapsedTimeMs=4&source=machineLearnin
g&searchTerm=melanoma&selectedTitle=3%7E150&view=print&display edView=fu
ll&anchor=H863137073# .  Accessed [June 15, 2015].
49. Vemurafenib US Prescribing Information. Aug- 2011.
50.Robert C, Schachter J, Long GV, et al.  Pembrolizumab versus ipi[INVESTIGATOR_222104].  N Engl J Med 2015; DOI : 10.1056/NEJMoa1503093.
51.Robert C, Long GV, Brady  B, et al. Nivolumab in previously  untreated melanoma 
without BRAF mutation.  N Engl J Med 2015b; 372:320-30.
52.Gangadhar TC, Hamid O, Smith DC, et al.  Preliminary  Results From a Phase 1/2 
Study  of Epacadostat (INCB024360) in Combination With Pembrolizumab in 
Patient s With Selected Advanced Cancers . Abstract # O7 presented at the 30th 
Annual Meeting of the Society  for Immunotherapy
 of Cancer 2015.
53.Boyer EW, Shannon M. The serotonin syndrome. New Engl J Med 2005;352:1112-
1120. 
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 134
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
Confidential54.Finkelstein, D.  A  p roportional hazards model for Interval -Censored Failure Time 
Data.  Biometrics 1986 Dec; 42:845-[ADDRESS_725234] ratio in quantify ing the between- group difference in survival analy sis. J Clin 
Oncol. 2014 Aug 1;32(22):2380-5.
56.Odell PM, Anderson KM, Kannel WB. New models for predicting cardiovascular 
events. J Clin Epi[INVESTIGATOR_5541]. 1994 Jun;47(6):583 -92.
57.Miettinen OS, Nurminen M. Comparative anal ysis of two rates. Statistics in Medicine 
1985;4:213-226.)
58. Hodi FS, O'Day  SJ, McDermott DF, et al. Improved survival with ipi[INVESTIGATOR_362]. N Engl J Med 2010; 363:711-23.
59.Maurer W, Bretz F. Multiple Testing in Group Sequential Trials Using Graphical 
Approaches. Stat Biopharm Res. 2013 Nov; 5( 4):311-320.
60.Anderson KM, Clark JB. Fitting Spending Functions. Statistics in Medicine 2010; 
29(3):321
-327.
61.Zhang Y, Li Y, Diamond S, Yeleswaram S. Effects of Epacadostat with Co-
Administration of Linezolid on Brain Extracellular Fluid Concentrations of 
Serotonin: An Intracerebral Microdial ysis Study  in Sprague -Dawley  Rats. American 
Association of Pharmaceutical Scientists 2016, abstract/poster 19M0400.  
62.Boyer EW, Shannon M. The Serotonin Syndrome. N Engl J Med 2005; 352:1112-
1120. 
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 135
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-[ADDRESS_725235] for Clinical Trials 12.1
[COMPANY_006] *
Code of Conduct for Clinical Trials
I. Introduction
A. Purpose
[COMPANY_006], through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing and reporting these trials in 
compliance with the highest ethical and scientific standards. Protection of subject safety is the overriding concern in 
the design of clinical trials. In all cases, [COMPANY_006] clinical trials will be conducted in compliance with local and/or 
national regulations and in accordance with the ethical principles that have their origin in the Declaration of Helsinki. 
B. Scope
Such standards shall be endorsed for all clinical interventional investigations sponsored by [CONTACT_75395] (parties) employed for their execution (e. g., contract research organizations, collaborative research efforts). This 
Code is not intended to apply to trials which are observational in nature, or which are retrospective. Further, this Code 
does not apply to investigator -initiated trials which are n ot under the control of [COMPANY_006].
II.Scientific Issues
A. Trial Conduct
1.Trial Design
Except for pi[INVESTIGATOR_19354], clinical trial protocols will be hypothesis -driven to assess safety, efficacy 
and/or pharmacokinetic or pharmacodynamic indices of [COMPANY_006] or comparator products.  Alternatively, [COMPANY_006] may 
conduct outcomes research trials, trials to assess or validate various endpoint measures, or trials to determine 
subject preferences, etc.  
The design (i.e., subject population, duration, statistical power) must be adequate to address the specific purpose 
of the trial.  Research subje cts must meet protocol entry criteria to be enrolled in the trial. 
2.Site Selection
[COMPANY_006] selects investigative sites based on medical expert[INVESTIGATOR_18700], access to appropriate subjects, adequacy of facilities 
and staff, previous performance in [COMPANY_006] trials, as well as budgetary considerations.  Prior to trial initiation, sites 
are evaluated by [CONTACT_75396].
3.Site Monitoring/Scientific Integrity
Trial sites are monitored to assess compliance with the trial protocol and general principles of Good Clinical 
Practice.  [COMPANY_006] reviews clinical data for accuracy, completeness and c onsistency. Data are verified versus source 
documentation according to standard operating procedures.  Per [COMPANY_006] policies and procedu res, if fraud, 
misconduct or serious GCP -non-Compliance are suspected, the issues are promptly investigated. When necessary, 
the clinical site will be closed, the responsible regulatory authorities and ethics review committees notified and 
data disclosed a ccordingly. 
B. Publication and Authorship
To the extent scientifically appropriate, [COMPANY_006] seeks to publish the results of trials it conducts.  Some early phase or 
pi[INVESTIGATOR_26346] -generating rather than hypothesis testing.  In such cases, publication of  
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 136
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
Confidentialresults may not be appropriate since the trial may be underpowered and the analyses complicated by [CONTACT_75397].
[COMPANY_006]’s policy on authorship is consistent with the requirements outlined in the ICH-Good Clinic al Practice 
guidelines. In summary, authorship should reflect significant contribution to the design and conduct of the trial, 
performance or interpretation of the analysis, and/or writing of the manuscript.  All named authors must be able to 
defend the trial results and conclusions.  [COMPANY_006] funding of a trial will be acknowledged in publications. 
III. Subject Protection
A.IRB/ERC review
All clinical trials will be reviewed and approved by [CONTACT_75398]/ERC before being initiated at each site.  
Significant changes or revisions to the protocol will be approved by [CONTACT_1201]/ERC prior to implementation, except that 
changes required urgentl y to protect subject safety and well-being may be enacted in anticipation of IRB/ERC 
approval. For each site, the IRB/ERC and [COMPANY_006] will approve the subject informed consent form. 
B.Safety
The guiding principle in decision -making in clinical trials is that subject welfare is of primary importance.  Potential 
subjects will be informed of the risks and benefits of, as well as alternatives to, trial participation. At a minimum, trial 
designs will take into account the local standard of care.  Subjects are ne ver denied access to appropriate medical care 
based on participation in a [COMPANY_006] clinical trial. 
All participation in [COMPANY_006] clinical trials is voluntary.  Subjects are enrolled only after providing informed consent for 
participation.  Subjects may withdraw from a [COMPANY_006] trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C.Confidentiality
[COMPANY_006] is committed to safeguarding subject confidentiality, to the greatest extent possible. Unless required by [CONTACT_2371], 
only the investigator, sponsor (or representative) and/or regulatory authorities will have access to confidential medical 
records that might identify the research subject by [CONTACT_2300].  
D.Genomic Research
Genomic Research will only beconducted in accordance with informed consent and/or as specifically authorized by 
[CONTACT_75399].
IV.Financial Considerations
A.Payments to Investigators
Clinical trials are time- and labor-intensive.  It is [COMPANY_006]’s policy to compensate investigat ors (or the sponsoring 
institution) in a fair manner for the work performed in support of [COMPANY_006] trials.   [COMPANY_006] does not pay incentives to 
enroll subjects in its trials.  However, when enrollment is particularly challenging, additional payments may be made
to compensate for the time spent in extra recruiting efforts.
[COMPANY_006] does not pay for subject referrals.  However, [COMPANY_006] may compensate referring physicians for time spent on 
chart review to identify potentially eligible subjects.
B.Clinical Research Fund ing 
Informed consent forms will disclose that the trial is sponsored by [CONTACT_44873], and that the investigator or sponsoring 
institution is being paid or provided a grant for performing the trial.  However, the local IRB/ERC may wish to alter 
the wording of thedisclosure statement to be consistent with financial practices at that institution.  As noted above, 
publications resulting from [COMPANY_006] trials will indicate [COMPANY_006] as a source of funding. 
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 137
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-2018
ConfidentialC.Funding for Travel and Other Requests
Funding of travel by [CONTACT_75400] (e.g.,to scientific meetings, investigator meetings, etc.) will be 
consistent with local guidelines and practices including, in the U.S., those established by [CONTACT_75401] (AMA). 
V. Investigator Commit ment
Investigators will be expected to review [COMPANY_006]’s Code of Conduct as an appendix to the trial protocol, and in signing 
the protocol, agree to support these ethical and scientific standards.
* In this document, "[COMPANY_006]" refers to [COMPANY_006] Sharp & Dohme Corp. andSchering Corporation, each of which is a 
subsidiary of [COMPANY_006] & Co., Inc.  [COMPANY_006] is known as MSD outside of the [LOCATION_002] and Canada.  As warranted by 
[CONTACT_74647], [COMPANY_006] also includes affiliates and subsidiaries of [COMPANY_006] & Co., Inc." 
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 138
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-[ADDRESS_725236]:   MK -3475 (SCH 900475), INCB 024360 139
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301-10) Final Protocol 18-May- [ADDRESS_725237]:   MK -3475 (SCH 900475), INCB 024360 140
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301-10) Final Protocol 18-May- [ADDRESS_725238]:   MK -3475 (SCH 900475), INCB 024360 141
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301-10) Final Protocol 18-May- [ADDRESS_725239]:   MK -3475 (SCH 900475), INCB 024360 142
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301-10) Final Protocol 18-May- [ADDRESS_725240]:   MK-3475 (SCH 900475), INCB 024360 143
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-[ADDRESS_725241]:   MK-3475 (SCH 900475), INCB 024360 144
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-[ADDRESS_725242]:   MK-3475 (SCH 900475), INCB 024360 145
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-[ADDRESS_725243]:   MK-3475 (SCH 900475), INCB 024360 146
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-[ADDRESS_725244]:   MK-3475 (SCH 900475), INCB 024360 147
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-[ADDRESS_725245]:   MK-3475 (SCH 900475), INCB 024360 148
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-[ADDRESS_725246]:   MK-3475 (SCH 900475), INCB 024360 149
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-[ADDRESS_725247]:   MK-3475 (SCH 900475), INCB 024360 150
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-[ADDRESS_725248]:   MK-3475 (SCH 900475), INCB 024360 151
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-[ADDRESS_725249]:   MK-3475 (SCH 900475), INCB 024360 152
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
ConfidentialEastern Cooperative Oncology Group Performance Status 12.4
Grade Performance Status
0Normal activity . Fully  active, able to carry  on all pre-disease performance 
without restriction.
1Symptoms, but ambulatory . Restricted in physically  strenuous activity, but 
ambulatory  and able to carry  out work of a light or sedentary  nature (e.g., light 
housework, office work).
2In bed <50% of the time. Ambulatory  and capable of all self-care, but unable to 
carry out an y work activities. Up and about more than 50% of waking hours.
3In bed >50% of the time. Capable of onlylimited self-care, confined to bed or 
chair more than 50% of waking hours.
4100% bedridden. Completely  disabled. Cannot carry  on any self-care. Totally  
confined to bed or chair.
5 Dead 
*As published in Am. J. Clin. Oncol.:  Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., 
McFadden, E.T., Carbone, P.P.: Toxicity And Response Criteria Of The Eastern Cooperative Oncology 
Group. Am J Clin Oncol 5:[ADDRESS_725250]:   MK-3475 (SCH 900475), INCB 024360 153
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
ConfidentialProhibited Monoamine Oxidase Inhibitors and Drugs Associated with Significant 12.5
Monoamine Oxidase Inhibitory A ctivity
NOTE:  As of Amendment 10, this section is no longer applicable.
Monoamine Oxidase InhibitorsDrugs Associated With Significant 
Monoamine Oxidase Inhibitory Activity
Hydrazines (example phenelzine) Meperidine
Caroxazone Linezolid
Echinopsidine Methylene blue
Furazolidone
Tranylcypromine
Brofaromine
Metralindole
Minaprine
Moclobemide
Pi[INVESTIGATOR_551676] 
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 154
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
ConfidentialCommon Terminology Criteria for Adverse Events v4.0 12.6
The descriptions and grading scales found in the revised NCI Common Terminology  Criteria 
for Adverse Events (CTCAE) version 4.0 will be used for adverse event repo rting 
(https://ctep.cancer.gov/ ). 
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 155
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
ConfidentialResponse Evaluation Criteria in Solid Tumors (RECIST ) 1.[ADDRESS_725251] 1.1* will be used in this study  for assessment of tumor response. While either CT or 
MRI  may  be utilized, as per RECI ST 1.1, CT is the preferred imaging technique in this study .
* As published in the European Journal of Cancer 
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 156
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
ConfidentialPublication on Serotonin Syndrome 12.8
NOTE:  As of Amendment 10, this section is no longer applicable.
 
  04XN7M
Product:   MK -3475 (SCH 900475), INCB 024360 157
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-[ADDRESS_725252]:   MK -3475 (SCH 900475), INCB 024360 158
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-[ADDRESS_725253]:   MK -3475 (SCH 900475), INCB 024360 159
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-[ADDRESS_725254]:   MK -3475 (SCH 900475), INCB 024360 160
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-[ADDRESS_725255]:   MK -3475 (SCH 900475), INCB 024360 161
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-[ADDRESS_725256]:   MK -3475 (SCH 900475), INCB 024360 162
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-[ADDRESS_725257]:   MK -3475 (SCH 900475), INCB 024360 163
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-[ADDRESS_725258]:   MK -3475 (SCH 900475), INCB 024360 164
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301- 10)Final Protocol 18-May-[ADDRESS_725259]:   MK-3475 (SCH 900475), INCB 024360 165
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-[ADDRESS_725260] of Abbreviations 12.9
Abbreviation/Term Definition
AACR American Association for Cancer Research
ADA Anti-Drug Antibodies
AE Adverse Event
AJCC American Joint Committee on Cancer
ALT Alanine Aminotransferase
APS Allred proportion score
aPTT Activated Partial Thromboplastin Time
ASaT All Subjects as Treated
AST Aspartate Aminotransferase
BCG Bacillus Calmette –Guérin vaccine
BID twice daily
CBC Com plete Blood Count
CFR Code of Federal Regulations
CI Confidence Interval
CL Clearance
CNS Central Nervous System
CR Com plete Response
CRP C-reactive protein
CrCl Calculated Creatinine Clearance
CSR Clinical Study Report
CT Com puted Tomography
Ctrough serum minimum concentration 
CTCAE Common Toxicity Criteria for Adverse Events
CTFG Clinical Trial Facilitation Group
CTLA -[ADDRESS_725261]:   MK -3475 (SCH 900475), INCB 024360 166
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301-10) Final Protocol 18-May- 2018
ConfidentialAbbreviation/Term Definition
FDAMA Food and Drug Administration Modernization Act
FFPE Form alin-fixed, paraffin -embedded
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GI Gastrointestinal
H&N Head and neck
HBsAg Hepatitis B surface Antigen
HCV Hepatitis C Virus
HIV Human Immunodeficiency Virus
HR Hazard Ratio
IA1 interim analysis 1
IA2 interim analysis 2
IA3 interim analysis 3
IB Investigator’s Brochure
ICF Informed Consent Form
ICH International Conference on Harmonization
IDO1 indoleamine 2,[ADDRESS_725262]
irRECISTImmune related Response Evaluation Criteria in Solid Tum ors 
(Modification of RECIST 1.1)
ITT Intent To Treat
IUD Intrauterine device
IUS Intrauterine hormone -releasing system
IV Intravenous
IVRS Interactive Voice Response System
IWRS Integrated Web Response System
Kg Kilogram
LDH Lactate Dehydrogenase
LFT liver function test
MAOI monoamine oxidase inhibitors
mcL Microliters
MEL Melanoma 
mg Milligram
mg/kg Milligram per Kilogram
mL milliliter
MRI Magnetic Resonance Imaging
MSD [COMPANY_006] Sharp & Dohme Corp., a subsidiary of [COMPANY_006] & Co., Inc.
MSI Microsatellite Instability
MTD maximum tolerated dose
n/aor N/A Not Applicable
NCI National Cancer Institute
NCCN National Comprehensive Cancer Netw ork  
  04XN7M

Product:   MK -3475 (SCH 900475), INCB 024360 167
Protocol/Amendment No.: 252-10 (INCB [ZIP_CODE] -301-10)
MK-3475-252-10 (INCB [ZIP_CODE]-301-10) Final Protocol 18-May- 2018
ConfidentialAbbreviation/Term Definition
NSAID Non-Steroidal Anti -inflammatory Drug
NSCLC Non-Small Cell Lung Cancer
ORR Overall Response Rate
OS Overall Survival
PD pharmacodynamic or progressive disease
PD-[ADDRESS_725263] Restricted Mean Survival Time
RNA Ribonucleic Acid
SAC Scientific Advisory Committee
SAE Serious Adverse Event
SAP Statistical Analysis Plan
SCC squamous cell carcinoma
SCCHN squamous cell carcinoma of the head and neck
SD Stable Disease
SNP single nucleotide polymorphism
SNRI serotonin/norepi[INVESTIGATOR_551677]
T3 Total triiodothyronine
T4 Free thyroxine
TCC transitional cell carcinoma
TNBC Triple negative breast cancer
Treg regulatory T cell
TSH Thyroid Stimulating Hormone
ULN Upper Limit of Normal
US [LOCATION_002]
V Volume of distribution
WHO World Health Organization
  
  04XN7M

Product:   MK-3475 (SCH 900475), INCB 024360 168
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-[ADDRESS_725264] the specified power (~98%) to detect a true hazard ratio (pembrolizumab +epacadostat 
versus pembrolizumab + placebo) for progression -free survival of 0.65:1.00.
As specified in Section 8.9, the statistical considerations assume a 12 month period for the 
600 patient protocol -specified enrollment.  PFS for the patients treated with the 
pembrolizumab + placebo regimen is assumed to follow a distribution with a “cure” rate of 
30%, with PFS for the remaining 70% of patients following an exponential distribution with 
a median of 4.[ADDRESS_725265] ratio under the alternative hypothesis for PFS 
between the pembrolizumab + epacadostat combination and the pembrolizumab + placebo 
regimen is assumed to be 0.65.
Similarly , OS for patients treated with the pembrolizumab + placebo regimen is assumed to 
follow a distribution with a “cure” rate of 35%, with survival for the remaining 65% of 
patients following an exponential distribution with a median of [ADDRESS_725266] 
ratio under the alternative hypothesis for OS between the pembrolizumab + epacadostat 
combination and the pembrolizumab + placebo regimen is assumed to be 0.70.
For the PFS and OS hy potheses , anexponential alpha -spending function with nu=0. 75 
(approximating an O’Brien -Fleming boundary ) will be used.  For PFS the cumulative alpha 
will be 1.25 %; for O S the cumulative alpha will be 1.25% (if PFS superiority is not 
demonstrated) or 2.5% (if PFS superiority  is demonstrated).
The R code generating the monitoring specifications for PFS is specified below.  The R code 
generating the monitoring specifications for OS follows the same approach. 
  04XN7M
Product:   MK-3475 (SCH 900475), INCB 024360 169
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-[ADDRESS_725267]:   MK-3475 (SCH 900475), INCB 024360 170
Protocol/Amendment No.: 252-10(INCB [ZIP_CODE] -301-10)
MK-3475 -252-10(INCB [ZIP_CODE] -301-10)Final Protocol 18-May-2018
Confidential13.0 SIGNATURES
Sponsor's Representative 13.[ADDRESS_725268] this clinical trial in accordance with the design outlined in this protocol 
and to abide by [CONTACT_19373] (including other manuals and documents 
referenced from this protocol).  I  agree to conduct the trial in accordance with generally 
accepted standards of Good Clinical Practice.  I also agree to report all information or data in 
accordance with the protocol and, in particular, I agree to report any serious adverse events 
as defined in Section 7.0–TRIAL PROCEDURES (Assessing and Recording Adverse 
Events ).  I also agree to handle all clinical supplies provided by [CONTACT_551741].  I understand that information that 
identifies me will be used and disclosed as described in the protocol, and that such 
information may be transferred to countries that do not have laws protecting such 
information.  Since the information in this protocol and the referenced Investigator’s 
Brochure is confidential, I understand that its disclosure to any third parties, other than those 
involved in approval, supervision, or conduct of the trial is prohibited.  I will ensure that the 
necessary  precautions are taken to protect such information from loss, inadvertent disclosure 
or access b y third parties.
TYPED NAME
[CONTACT_26410] 
  04XN7M